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Abstract 
 
The molecular mechanisms underlying the dopaminergic neuronal death in 
Parkinson's disease (PD) result still unclear and thus proven strategy to prevent 
the disease also remains unknown and an unmet priority. Several pathogenic 
pathways have been implicated in PD pathogenesis and, among them, 
microtubule (MT) dysfunction is emerging as a contributing factor of the 
disease. MT cytoskeleton is a complex network essential for neuronal 
morphogenesis and its proper regulation is crucial for neuronal survival and 
functions including axonal transport. MTs are common targets for several PD-
inducing toxins and PD-linked proteins including parkin that, beyond its E3 
ubiquitin ligase activity, plays a role in regulating mitochondrial homeostasis 
and trafficking. Some data, derived from murine and human cell cultures, 
provide evidences that parkin mutations, which are responsible for both familial 
and sporadic forms of PD, affect MT system. In this scenario, we analyzed in 
detail the interplay between parkin, MT system and mitochondrial axonal 
transport using gene-based murine models of the disease. 
First, we investigated MT dysfunction in PARK2-Q311X transgenic mice, a 
model that resembles the hallmark characteristic of the disease in age-
dependent way. Our initial analyses showed that mice at 6 and 16 weeks of age 
did not show deficits in striatal innervations and depletion of tyrosine 
hydroxylases (TH), indicating that they could be suitable to study the early 
pathogenic phases that precede neuronal death. Thus, we studied the impact of 
parkin Q311X mutation on MT stability and mitochondrial homeostasis in 6 
and 16 weeks old mice with the aim to pinpoint the involvement of their 
dysfunction as early event in neurodegeneration. We found that Q311X point 
mutation leads to the unbalance of post-translationally modified tubulins 
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(PTMs), which are associated with differences in MT stability, inside 
dopaminergic neurons. On the contrary, none alteration was observed for 
mitochondrial dynamics and distribution in nigrostriatal fibers at these very 
early time points. Notably, we also reported that the unbalance of tubulin PTMs 
occurs in PARK2 knockout (KO) model during aging (2, 7 and 24 months of 
age) and precedes the block of mitochondrial transport within dopaminergic 
fibers. Collectively, our results from PARK2 mouse models support the concept 
that early α-tubulin PTMs alterations might play an important role in PD 
etiopathogenesis.  
Next, we moved to primary neuronal cultures obtained from midbrain of mouse 
embryos as experimental model for investigating in detail the effect of parkin in 
modulating MT dynamics and mitochondria motility. Morphometric analyses, 
performed on primary neurons isolated from PARK2KO and heterozygous mice 
showed that parkin deficiency affects axonal outgrowth. To test whether the 
impact of parkin deficiency on morphology is linked to MT dysfunction, we 
firstly investigated MT dynamics. Beyond the enrichment in the level of Tyr 
tubulin (marker of dynamic MTs), we observed that parkin deficiency increases 
MT dynamics by live cell imaging. Moreover, we assessed MT-based axonal 
transport and our results confirmed that loss of parkin affects mitochondria 
movement. We showed that this alteration depends on MT destabilization as it 
is rescued by MT stabilizer paclitaxel in primary neurons and also in PARK2-
silenced PC12 cells. 
Overall, these data pinpoint parkin as a regulator of tubulin PTMs and MT 
dynamics in neurons and reinforce the idea that MT dysfunction may be crucial 
and represent an early step in the chain of events leading to dopaminergic 
neuron death.  
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State of the Art 
 
1.1 Microtubules 
The cytoskeleton is a complex network of intracellular filaments and regulatory 
proteins that extends throughout the cytosol and provides support for cell shape 
and internal organization. In addition, cytoskeleton is involved in different 
functions, such as motility, chromosome segregation and intracellular transport. 
Many different components work together to form the cytoskeleton of 
eukaryotic cells that consists of three major classes of elements: actin filaments, 
intermediate filaments and microtubules (MTs).  
Here we focus on MTs, which are non-covalent cytoskeletal polymers involved 
in many cellular processes including mitosis, cell motility, intracellular 
transport, secretion and morphogenesis. MTs are polarized and dynamic 
structures built up by α/β tubulin heterodimers, two highly similar proteins 
conserved among all eukaryotic species. Tubulin structure can be divided into 
three domains: the N-terminal part contains the nucleotide binding domain, the 
middle structure is involved in monomers contact and taxol binding, and, 
finally, the C-terminal domain that is implicated in protein interactions 
(Nogales et al. 1998). After the cloning of the first α- and β-tubulin genes, 
(Cleveland et al. 1978), the existence of different genes coding for α- and β-
tubulin, at least 10 in mammals, was revealed. The tubulin isoforms are 
differently expressed during development and are specifically localized in 
certain type of cells and tissues. For instance, neuronal MTs are known to 
depend on some β-tubulin isotypes, whereas most of the other MT functions are 
independent on their composition (Janke and Bulinski 2011). 
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As shown in figure 1, tubulin dimers associate in a head-to-tail fashion to create 
linear protofilaments, which subsequently assemble laterally to form MT, a 25 
nm wide hollow tube. A single MT is formed of 10–15 protofilaments, usually 
13 in mammalian cells (Desai and Mitchison 1997). The head-to-tail 
association of the α/β heterodimers makes MTs polar structures with two 
distinct ends characterized by different polymerization rates: "plus end" and 
"minus end" exposing β and α monomer, respectively.  
The intrinsic MT polarity is due to the different ability of α- and β-tubulin to 
hydrolyze the energy carrier guanosine-5'-triphosphate (GTP). Both α- and β-
tubulin bind the GTP, but the site on α -tubulin is entrapped at the interface 
between the two monomers, avoiding the exchange between GTP and 
guanosine 5' diposphate (GDP) (non-exchangeable site N-site). On the contrary, 
the GTP binding domain on the β-tubulin monomer is exposed and this allows 
the GTP hydrolysis (exchangeable site E-site). The differences in GTP 
hydrolysis result in a fast-growing plus end and slow-growing minus end 
(Carlier et al. 1987). MTs switch between phases of rapid growth and 
shrinkage, process known as dynamic instability. Conversion from growth to 
shrinkage is termed "catastrophe" whereas the switch from shrinkage to growth 
is called "rescue" (Mitchison and Kirschner 1984). The dynamic instability 
depends on the equilibrium between the polymerization velocity and GTP 
hydrolysis on the E-site of β-monomer. After the GTP-tubulin is incorporated 
into MT, it is hydrolyzed into GDP and the energy stored in the subunits is 
released. Furthermore, it is believed that some of this energy goes to deform the 
tubulin subunit, being GDP-tubulin most stable in a curved state, and so MT 
rapidly shrinks (Burbank and Mitchison 2006). If the addition of free subunits 
is faster than the hydrolysis of GTP on incorporated subunits, the formation of 
GTP cap occurs and stabilizes MT. Once the GTP cap is lost, the protofilaments 
State of the Art 
 
   8 
 
splay apart resulting in a rapid MT depolymerization (catastrophe) (Conde and 
Cáceres 2009). The dynamic instability is described by 5 parameters: 
polymerization rate, shrinkage rate, catastrophe (transition from polymerizing 
to depolymerizing phase) frequency, rescue (transition from depolymerizing to 
polymerizing phase), and pause (time spent neither polymerizing nor 
depolymerizing). The polymerization rate of α/β heterodimers into MTs is 
proportional to the concentration of free tubulin and is regulated by temperature 
(370C), presence of Ca2+ at intracellular level (Keith et al. 1986), other than by 
the presence of GTP.  
 
 
Figure 1. Representation of dynamic instability of microtubules.  
(a) Structure of a protofilament and (b) MT. (c) Representative scheme of 
typical dynamic instability of MTs. (Conde and Cáceres 2009). 
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The dynamic instability allows the cell to adapt quickly to environmental 
changes and to respond to cellular needs, through reorganization of MTs. For 
instance, cells rapidly reorganize cytoskeleton throughout mitosis transition or 
during the extension of growth cones from neurons (Burbank and Mitchison 
2006). The proper control of MT dynamic probably results from the sum of 
multiple proteins and post-translational modifications (PTMs) of α- and β-
tubulins associated to MTs (Dubey et al. 2015). MTs interact with different 
proteins within cells, such as motor and non-motor MT-associated proteins 
(MAPs). Motor proteins, which include the family of kinesins (KIFs) and 
dyneins, are able to generate force using the adenosine 5'-triphosphate (ATP) 
hydrolisis and, upon interaction with MTs, are involved in different intracellular 
functions, most obviously intracellular transport (Janke and Bulinski 2011). 
Due to the viscous nature of the cytosol, the movement of cargo and organelles 
requires active transport along MT cytoskeleton by molecular motors inside the 
cells (Luby-Phelps 2000). KIFs are essentially responsible for anterograde 
transport, while the retrograde one is mediated by cytoplasmic dyneins. The 
heterogeneous group of non-motor MAPs includes many proteins that can both 
stabilize or destabilize, by changing the frequencies of transition between 
growing and shrinkage state. The structural MAPs are known to bind and 
stabilize MTs and, among them, tau, MAP1 and MAP2, are found specifically 
in neuronal cells, and MAP4 is expressed in others cell type (Conde and 
Cáceres 2009). One of the mechanisms involved in MAP regulation is the 
phosphorylation, which promotes their detachment from MTs and impairs their 
stabilizing function (Trinczek et al. 1995).  
In addition, a group of intensively studied MAPs is formed by plus end tracking 
proteins (+ TIPs) that specifically accumulate at the plus end of growing MTs. 
The + TIPs control different aspects of cellular architecture through the 
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regulation of MT dynamics, the interaction of cellular structures and signaling 
molecules (Akhmanova and Steinmetz 2008). Some kinesins (e.g. kinesin 13 
MCAK), which belong to that family, regulate MT dynamics and depolymerize 
MTs thus promoting spindle assembly and chromosome segregation 
(KlineSmith and Walczak, 2004). By contrast, EBs (end-binding) proteins, 
crucial among the +TIPs family, usually promote MT polymerization and 
inhibit catastrophe events, increasing MT rescue frequencies and decreasing the 
depolymerization rate (Lansbergen and Akhmanova, 2006). EBs form a comet-
like accumulation on the distal part of MT and, in particular EB3, conjugated to 
fluorescent protein (e.g. EB3-mCherry), is amply used as a tool in live cell 
imaging approach to follow MT growth (Akhmanova and Steinmetz 2008). 
Moreover, a further class of MAP includes MT severing enzymes, such as 
spastin and katanin, which are able to destabilize the MT lattice. In particular, 
these enzymes generate internal break in a MT and are implicated in the 
regulation of neurite outgrowth as well as branching formation (Roll-Mecak 
and McNally 2010). 
Tubulin is prone to a number of post-translational modifications (PTMs), which 
are intrinsic regulators of MT dynamics. The well-studied PTMs include 
tyrosination/deTyrosination, Δ2 and Δ3-tubulin, acetylation, polyglutamylation, 
polyglycilation, polyamilation, and phosphorylation (Figure 2). The generation 
of a specific pattern of PTMs, together with the incorporation of diverse 
isoforms of tubulin, confers a MTs identity namely "tubulin code". These 
modifications, which are differently distributed inside the cell, have the 
potential to generate complex molecular signals on MTs that can be read by 
others proteins. Most of these modifications interest α-tubulin, whereas fewer of 
them are associated with the C-terminal of β-tubulin. The enzymes, which 
catalyze such modifications, can act on tubulin dimers but most of them work 
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preferentially on tubulin already incorporated in MT (Conde and Cáceres 2009). 
Across different species, most α-tubulin genes encode the C-terminal tyrosine 
residue. Furthermore, α-tubulin is tyrosinated (Tyr) in its nascent state, with the 
cyclic addition and removal of tyrosine residue. Thus, the 
tyrosination/deTyrosination cycle starts with the removal of Tyr residue at the 
C-terminal of α-tubulin, which leads to the exposure of penultimate glutamate 
(named Glu residue) (deTyrosination); the subsequent re-addition of the Tyr 
residue serves to recover the nascent form of tubulin (Tyrosination). 
 
 
 
 
Figure 2. Tubulin post-translational modifications (PTMs). 
Representation of different tubulin PTMs distribution on the α/β-tubulin dimer 
with respect to their position in the MT lattice (from Janke, 2014). 
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The tubulin tyrosine ligase (TTL) was the first enzyme, known to be involved 
in PTMs, to be purified (Schroder et al. 1985) and cloned (Ersfeld et al. 1993). 
The cytosolic enzyme carboxipeptidase (CCP), which removes the Tyr group, is 
still unknown. TTL enzyme acts exclusively on soluble tubulin dimers, whereas 
CCP favors the tubulin polymerized into MT and thus, the newly assembled 
MTs are almost formed of Tyr tubulin (Janke and Bulinski 2011). The removal 
of the Glu residue leads to a Δ2 tubulin modification, an irreversible PTM 
catalyzed by deglutamylase enzyme and, the subsequently proteolysis of the C-
terminal tail generates Δ3 tubulin. While tyrosination is associated to dynamic 
MTs, deTyrosination and Δ3 tubulin are linked to MT stability. This latter 
tubulin PTM renders MT less susceptible to depolymerizing action of KIF 13, 
which binds preferentially tyrosinated plus end. Moreover, MT deTyrosination 
increases the affinity for KIF-1, involved in intracellular transport in neurons, 
without affecting its velocity. The second tubulin PTM to be discovered was the 
acetylation of Lys40 (K40) on α-tubulin (L'Hernault and Rosenbaum 1985). 
Recently, has been described also another acetylation event on Lys 252 (K252) 
of β-tubulin (Chu et al. 2011). The first modification was reported to take place 
on MT polymer (Maruta et al. 1986), whereas the second one preferentially on 
non-polymerized tubulin (Chu et al. 2011). Acetylation is enriched on stable 
MTs and, specifically, the K40 modification occurs in the inner face of MTs 
and affects the binding and the traffic of different proteins, such as kinesin 
(Dompierre et al. 2007). The enzyme involved in K40 acetylation is the acetyl 
transferase α-TAT1, whereas the removal of acetyl group is catalyzed by 
HDAC6 (histone deacetylase 6) and Sirt2 (sirtuin type 2) enzymes. How the 
enzyme gains access to K40 site is not clear, but recent studies propose that 
TAT scans MTs bi-directionally within the lumen using surfacing diffusion 
(Song and Brady 2015). Polyglutamylation is the addition of glutamate residues 
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variable in length which occurs on several glutamates sites of α and β tubulin in 
the C terminal domain. This modification was first discovered in the brain as 
well as on axonemal tubulin. The deglutamylase enzyme, involved in glutamate 
side chains removing, belongs to the CCP family. Tubulin polyglicylation or 
glycilation, like polyglutamylation generates side chains of glycine within the C 
terminal tails of  α and β tubulin. Differently, in most organism analyzed so far, 
this modification occurs exclusively on cilia and flagella. The enzymes 
involved in glycilation reaction belong to TTL family and, in mammals, some 
of them can initiate or elongate the side chain. The role of that modification in 
MT function regulation is still unknown (Magiera and Janke 2014). Tubulin 
polyamilation is a recently discovered PTM and consist in the addition of 
amines to glutamine residues of α and β tubulin and, among several glutamine 
residues that can be polyaminated, glutamine 15 (Q15) on β tubulin is the 
primary modification site. The enzyme involved in the reaction is the 
transglutaminase that can act both on free tubulin and MTs and, most likely, 
this modification is associated to MT stabilization (Song et al. 2013). 
Phosphorylation of the serine residue S172 of β-tubulin, catalyzed by cyclin-
dependent kinase 1, has been shown to regulate MT dynamic during cell 
division. It has also been identified another phosphorylation event on the C 
terminal of α tubulin, catalyzed by the tyrosine kinase Syk, that may affect 
MAP binding.   
 
1.1.1 Microtubules in the neuron: a glance at physiological and 
pathological conditions 
Neurons are highly polarized cells with a peculiar morphology that generally 
consists of cell body (soma), from which several shorter dendrites emerge, and 
a long axon. A critical aspect of neuronal function depends on establishing the 
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neuronal polarity between the somatodendritic and axonal compartments (Craig 
and Banker, 1994). Dendrites and axons differ in both morphology and function 
thanks to the diverse patterns of proteins expression and organelles associated. 
The dendrites are specialized to receive signal whereas the axon, transmits it to 
other neurons or muscles, through structures known as synapses. The MT 
organization mainly contributes to the establishment of cell polarization and in 
fact, in the early stages of neuronal differentiation, it navigates the growth cone 
and axon elongation. Furthermore, MTs are essential throughout the life of the 
neuron because they constitute both the architectural strut and the railway, 
required for the support of their peculiar morphology and for shape changes 
during neuroplasticity and intracellular transport, respectively. Neurons have 
different MTs organization between the two compartments: the axonal MTs are 
characterized by uniform orientation, with the plus end facing the axon tip, 
whereas dendritic MTs have mixed orientation, with their plus end facing either 
the cell body or the dendritic tips (Baas et al. 1988). The plus end is crucial site 
for tubulin polymerization, whereas minus end is often anchored to a MT-
organizing center (MTOC) that constitutes the major center of MT nucleation. 
The most important MTOC in the animals is the centrosome, typically 
composed of two centrioles and periocentriolar materials. The nucleating 
structures is called γ-tubulin ring complex (γ-TuRC), where γ-tubulin binds 
specifically β-tubulin to establish the polarity orientation of MT polymerized 
from the complex. Some MTs remains attached to their nucleating structure 
while others MT may be released and transported away from the centrosome 
through the molecular motors (Baas et al. 2005).  
The intrinsic polarity of MT allows the selective trafficking of cargo inside the 
neurons to establish the differences that distinguish the two compartments. 
Disorganization of MT polarity can result in the incorrect localization of cargo 
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(Dubey et al. 2015). For instance, most of neuronal proteins are synthesized in 
the cell body and anterograde axonal transport allows them to reach the distal 
part of the axon. The retrograde axonal transport, enhanced by dynein, conveys 
proteins from axon to the cell body for degradation and recycling.  
Another key feature that contribute to the delivery of different cargo and 
distinguish the neuronal compartment is the different stability of MTs (Baas et 
al. 1991) generated by the expression of tubulin isotypes, MT associated 
proteins and tubulin PTMs (tubulin code) (Janke 2014). The pattern of 
expression of PTMs varies throughout neuron compartments and changes 
during neuronal differentiation (Figure 3). Older MTs are most stable because 
tubulin PTMs accumulate over time, due to the specific enzymes that act 
preferentially on assembled MT; by contrast, newly synthesized one is more 
dynamic. For instance, in developing neurons, where the dendrites and synapses 
are not yet differentiated and the axon is extending, the levels of 
deTyrosination, Δ2 tubulin, glutamylation and polyamilation are relatively low 
in the perikaryon. Acetylation, glutamylation and deTyrosination are high in the 
growing axon and reduced in the growth cone that is conversely enriched in 
tyrosinated tubulin, meaning that MTs are more dynamic for normal 
pathfinding. The minor neurites have a low amount of acetylated MTs but high 
level of deTyrosinated glutamylated/polyglutamileted MTs. In mature neurons, 
where the dendrites and synaptic specializations are formed, the enrichment of 
tubulin PTMs associated to stable MTs occurs. Polyamination of axonal MTs 
increases respect to young neurons and deTyrosinated and Δ2 tubulin remain 
relatively high. Acetylated MTs increase not only in both axon and dendrites 
but also in synaptic region, where dynamic MTs are reduced to form stable 
connections (Song and Brady 2015). 
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Figure 3. Post-translational modifications of tubulin vary in different regions of 
a neuron and change during neuronal differentiation. (from Song and Brady 
2015) 
 
 
In addition, the localization of MAPs differs as well: MAP2 is found 
exclusively in dendrites, where it decorates stable MT, and tau, found in both 
compartment, is mainly enriched in the distal axons (Kapitein and Hoogenraad 
2011).  
The proper functioning and regulation of MT dynamics and assortment of 
regulatory proteins are essential for the health of nervous system. Mounting 
evidence suggests that the alteration of neuronal MT organization constitutes a 
key insult in neurodegenerative disorders pathogenesis. Tubulin PTMs are 
involved, in some way, in regulating most of the processes based on MT 
function, and, interestingly, aberrations in the normal pattern of tubulin PTMs 
could directly or indirectly lead to disease (Janke and Bulinski 2011). 
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The generation of TTL- null mice reveals the importance of tyrosinated tubulin 
during brain development. These mice show a deleterious neuronal 
abnormalities and die after birth, meaning that TTL enzyme have a vital role for 
the nervous system. Cultured TTL-null neurons show anomalies in the 
morphogenesis such as an erratic time course of neurite outgrowth (Erck et al. 
2005). However, these neurons display a mislocalization of CLIP70, a +TIP 
protein that accumulates to the plus end of growing MTs and regulates MT 
dynamics. Konishi et al. (2009) showed that the inhibition of TTL via siRNA 
knockdown in rat hippocampal neurons resulted in a decrease of tyrosinated 
tubulin and the subsequent mislocalization of kinesin-1. Moreover, also 
mutations in tubulin genes have been found to cause neuronal diseases. 
Specifically, mutations in βIII-tubulin, a neuron specific isoform, result in 
severe neurological symptoms, such as peripheral neuropathy and loss of axons 
in many kinds of brain neurons. Some of these mutations affect the binding on 
MTs and the function of a broad range of KIFs in neurons (Niwa et al. 2013).  
Alteration of MT system was shown to be an early event in neurodegenerative 
disorders associated with axonal transport impairment. The proximal cause of 
cell death could be due to the accumulation and mislocalization of different 
organelles within neuron due to the axonal transport damage. For instance, a 
proper intracellular distribution of mitochondria is crucial for neuronal survival 
to fulfill the ATP demand to areas of need. Indeed, defects in mitochondrial 
transport that lead to energy deprivation, have been associated to several 
disease models (Vos et al. 2008). 
Many major human neurodegenerative diseases, including amyotrophic lateral 
sclerosis (ALS), Huntington’s disease (HD), Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) have been shown to display an axonal transport 
impairment.  
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Reduced tubulin acetylation and altered MT-dependent axonal transport have 
been observed in HD model; enhanced MT acetylation leads to the recruitment 
of both molecular motors, kinesin and dynein, to MTs, with subsequent restore 
of brain-derived neurotrophic factor (BDNF) release in HD neurons (Dompierre 
et al. 2007). Misregulation of MAPs, such as the changes in tau expression and 
localization seen in AD, has the potential to alter the steady-state distribution of 
organelles (Perlson et al. 2010). Fanara et al. (2007) reported an increase of MT 
dynamics at very early stages before the axonal transport alteration in a mouse 
model of ALS. The treatment with MT stabilizing agent restores the transport, 
suggesting that the observed defect was due to the increase in MT dynamics. 
Next, striking data showed that MT alteration occurs very early in a toxic model 
of parkinsonism preceding the axonal transport impairment and that the 
treatment with a MT-stabilizer agent, epothilone D, exerts a neuroprotective 
effect (Cartelli et al. 2013). 
Thus, the right balance between stable and dynamic MTs, the correct level of 
tubulin PTMs, and the proper function of motor and non-motor MAPs are the 
prerequisite for neuronal survival, neuronal development and also axonal 
transport. 
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1.2 Parkinson’s disease 
Parkinson’s disease (PD) is the second most common neurodegenerative 
movement disorder affecting 1% of population who are over 65 years old and 
up to 5% of population by the age of 85 (Forman et al. 2004). More commonly, 
patients develop late-onset PD but some cases are characterized by early-onset 
that occurs before the age of 50 (Pellegrini et al. 2016). Clinically, PD is 
characterized by motor deficits including resting tremor, bradykinesia (slowness 
in movements), postural instability and rigidity. Motor impairment is often 
accompanied by non-motor symptoms and signs including mood, sleep and 
cognitive disturbances (Dauer and Przedborski 2003).  
Although the pathological changes occur in different areas of the brain, the 
principle pathological hallmark of the disease, which underlies the 
characteristic motor phenotypes, is the loss of dopaminergic neurons that 
project from the midbrain Substantia nigra pars compacta (SNpc) to the 
Corpus striatum (ST) (Figure 4). Neurons whose cell bodies are located in the 
ventrolateral tier and project to the dorsolateral putamen are specifically 
affected. The loss of midbrain dopaminergic neurons results in striatal 
neurotrasmettitor dopamine (DA) deficiency. Thus, the nigrostriatal system, 
which allows an individual to execute proper and coordinated movements, is 
compromised in PD. A much more modest cell loss occurs in the mesolimbic 
dopaminergic neurons, where the cell bodies in the ventral tegmental area 
(VTA) project their terminals to the caudate. The PD symptoms become evident 
when the loss of dopaminergic neurons in the SNpc reaches the 60% and when 
DA is depleted about 80% (Dauer and Przedborski 2003). The nigral damage is 
always accompanied by extensive extra-nigral pathology, involving different 
neuronal populations in others brain regions such as cortex, thalamus and 
subthalamic nuclei (Braak et al. 2003). Another histopathological hallmark of 
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PD is the presence of fibrillar aggregates referred to as Lewy bodies (LBs), 
intraneuronal proteinacious cytoplasmic inclusions where α-synuclein (α-syn) is 
the major constituent (Spillantini et al. 1997). LBs are also found in the 
neuronal cell processes called intraneuritic LBs or Lewy neurites. LBs affect 
not only the surviving neurons in the SNpc but accumulate in several neuronal 
type in the brain such as, components of the autonomic, limbic and 
somatomotor systems. According to the Braak staging, during presymptomatic 
stages (1-2) LBs are confined to the medulla oblongata, pontine tegmentum and 
olfactory bulb. As disease evolves, the SN and nuclear greys of the midbrain 
and forebrain become to be affected (stages 3-4), and thus the patients start the 
pathological changes and probably have symptomatic phase of the illness. In 
advanced stages (5-6) the inclusion body pathology can be found in the limbic 
structures and neocortex (Braak et al. 2003).  
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Figure 4. Neuropathology of Parkinson’s disease.  
(A) Schematic representation of the normal nigrostriatal pathway (in red). Cell 
bodies of dopaminergic neurons are located in the Substantia nigra pars 
compacta (SNpc). These neurons project to the basal ganglia and synapse in the 
Corpus striatum. Dopaminergic neurons are characterized by the pigmentation 
produced by neuromelanin. (B) Schematic representation of the diseased 
nigrostriatal pathway (in red). It is characterized by the loss of dopaminergic 
neurons that project to the putamen (dashed line) and a much more modest loss 
of those neurons projecting to the caudate (thin red solid line). It is observed 
depigmentation (decrease of pigment neuromelanin; arrows) of the SNpc due to 
the marked loss of dopaminergic neurons. (C) Immunohistochemical labeling of 
Lewy Body intraneuronal inclusions in a SNpc neuron containing α-synuclein 
and ubiquitin (from Dauer and Przedborski 2003). 
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The etiology of PD has yet to be established but the combination of both 
environmental components and genetic predisposition contributes to the 
incidence of the disease, even though ageing is considered the main risk factor. 
Environmental toxins were long thought to be the predominant cause of PD; 
chronic or limited exposure to neurotoxins such as chemical compounds, 
herbicides, pesticides and hydrocarbon solvents promotes the progressive 
dopaminergic neurodegeneration. One of the best studied toxins is the 1-
methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) that was associated to PD. 
In 1982, young drug users, during the illicit synthesis heroin developed a 
progressive parkinsonian syndrome (Langston et al. 1983). In humans, in 
monkeys and in rodents the administration of MPTP leads to a severe 
parkinsonian syndrome displaying all the features that characterize PD. The 
pre-toxin MPTP is converted to the active toxic molecule MPPP by oxidation in 
the glial cells. This is released by an unknown mechanism in the extracellular 
space and than is selectively up-taken by dopaminergic neurons through the 
dopamine transporter (DAT) rendering these neurons particularly vulnerable 
(Dauer and Przedborski 2003). Other compounds such as rotenone and 
paraquat, respectively pesticide and herbicide, are PD-neurotoxins and, among 
the hydrocarbon solvents, 2,5- hexanedione (2,5-HD), the toxic metabolite of n-
hexane, has been shown to induce parkinsonism in animals and humans 
(Spencer and Schaumburg 1985; Pezzoli et al. 1990; Pezzoli et al. 2000). 
Most of the environmental toxins have been demonstrated to be mitochondrial 
poisons that interfere with mitochondrial respiratory chain inhibiting the 
complex I. Thus, mitochondrial dysfunction and the consequent oxidative stress 
was considered the principal culprit in neuron death (Malkus et al. 2009) and 
may also act in part by causing the accumulation of misfolded proteins. Proteins 
aggregation could directly damaged the cells interfering with intracellular 
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trafficking, a MT-dependent process (Dauer and Przedborski 2003). 
Interestingly, some of the PD-toxins, mentioned above, have been shown to 
affect MT cytoskeleton and MT dynamics in vitro and in vivo models 
(Cappelletti et al. 1999; Cappelletti et al. 2005; Ren et al. 2005; Cartelli et al. 
2010; Cartelli et al. 2013).  
On the other hand, significant progress has been made on the understanding of 
PD pathogenesis through the discovery of several monogenic forms of the 
disease and genetic risk factors associated, respectively, with familial and 
apparently sporadic PD. Familial PD is characterized by early-onset with 
autosomal dominant or recessive pattern inheritance and to date, a growing 
number of mutations associated with PD have been discovered; nineteen loci 
that segregate with familial forms of the disease have been reported (Table 1).  
Genetic studies, centered on idiopathic cases, have successfully identified 
genetic risk of the disorder, as well as polymorphisms that enhance disease 
susceptibility (Kumaran and Cookson 2005). Among the different genes 
associated to the disease, SNCA (PARK1; encoding α-synuclein) and LRRK2 
(PARK8; encoding dardarin) are causative of autosomal dominant PD, whereas 
mutations in PINK1 (PARK6-PTEN-induced kinase 1), DJ1 (PARK7), Parkin 
(PARK2), and ATP13A2 (PARK9) cause the autosomal recessive forms of the 
disease. These related PD proteins, such as α-syn, parkin, and PINK1, are 
identified to participate in different process (Figure 5) including mitochondrial 
homeostasis, ubiquitin proteosome pathway and, interestingly, also in the 
regulation of MT system.  
Since PD-related neurotoxins and PD-linked proteins are involved in a complex 
network of interrelated molecular events, an important open issue remains the 
identification of the upstream pathway that leads to dopaminergic-specific 
neuronal cell death.  
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Table 1. PARK loci and identified genes that segregate with familial forms 
of PD (from Kumaran and Cookson, 2015). 
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Figure 5. Molecular processes involved in PD pathogenesis as highlighted 
by genetic findings. Using genes recently nominated as risk factors for 
idiopathic PD along with those responsible for familial PD, it is possible to 
extrapolate a number of cellular processes that may underlie disease 
development. Genes listed in italics represent nominated risk factors for 
idiopathic PD, whereas those in normal font are associated with familial PD. An 
asterisk denotes that the gene is linked to both forms of the disorder. Some 
genes like SNCA and LRRK2 are associated with multiple processes. While the 
majority of cellular pathways contribute to both familial and sporadic forms of 
the disease, neuroinflammation likely plays a more prominent role the latter. 
Conversely, mitochondrial dysfunction shows a greater association with 
familial PD (from Kumaran and Cookson 2015). 
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1.2.1 Microtubules and Parkinson's disease 
The molecular mechanism underlying neuronal death in PD results still 
unknown and current therapies offer just the management of symptoms rather 
than prevention of neuron death and the reversion or block of disease 
progression. Several pathogenic pathways, correlated each others, have been 
implicated in dopaminergic neurons degeneration such as, oxidative stress, 
mitochondrial dysfunctions, accumulation of misfolded proteins due the 
ubiquitin-proteasome system (UPS) and autophagic machinery impairment and 
local inflammation (Kumaran and Cookson 2015). Understanding which 
mechanism might be the primary insult leading to PD is a major challenge to 
deal. Interestingly, the early MT dysfunction is becoming established as a key 
insult in PD pathogenesis.  
Within the context of studies based on PD-neurotoxins, appealing results have 
been shown for MPTP and rotenone. MPP+, the toxic metabolite of MPTP, 
affects MT dynamics in vitro, acting as catastrophe promoter, increasing the 
frequency of transition from MT growth to shrinkage (Cappelletti et al. 2005). 
In addition, alterations of MT stability have been shown to precede 
mitochondria transport defect and neurite degeneration in MPP+-exposed PC12 
cells (Cartelli et al. 2010). The systemic injection of MPTP to mice induces MT 
alteration very early, before TH depletion, neuron degeneration and axonal 
transport impairment suggesting an important role of MT dysfunction in 
triggering neurodegeneration (Cartelli et al. 2013). MPP+ has also been proved 
to decrease anterograde and increase retrograde axonal transport of 
membranous vesicles in squid axoplasm (Morfini 2007). Moreover, rotenone 
depolymerizes purified MTs in vitro, as well as MTs in the cell (Marshall 1978) 
(Ren et al. 2005). Depolymerization of MTs, induced by rotenone, disrupts 
vesicular transport in dopaminergic neurons. When MT alteration occurs, the 
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trafficking of vesicles collapses and their subsequent accumulation becomes 
evident in the cytoplasm. The leakage of DA from the vesicles leads to the 
generation of oxidative stress induced by DA oxidation, and, consequently, to 
neuronal death (Yong Ren, Wenhua Liu, Houbo Jiang 2005) (Choi et al. 2011).  
Several PD-linked proteins, such as α-syn, LRRK2, parkin and DJ1, interact 
and affect MT system. The interaction of α-syn with tubulin promotes its 
aggregation in fibrils in vitro (Alim et al. 2002). Its cytotoxicity is attributed to 
oligomers formation, whose overexpression in cells elicits MT disruption (Prots 
et al. 2013). Recently, it has been proposed α-syn as a novel, foldable, MT-
dynamase, which changes its conformation when binds to α2β2 tetramers and 
regulates MT nucleation and dynamics in vitro and in cell. Furthermore, PD-
related α-syn mutants are much less sensitive than WT-α syn to tubulin-induced 
folding and mainly promote tubulin aggregation. This could leads to an 
impairment of the correct MT organization on the neuronal processes (Cartelli 
et al. 2016). LRRK2 has been shown to interact and phosphorylate β-tubulin 
isoforms in the brain and to modulate MT stability (Law et al. 2014). 
Fibroblasts obtained from PD patients, carrying LRKK2 mutations, showed an 
altered MT stability (Cartelli et al. 2012). Finally, it has been reported also a 
novel role for DJ-1 in MT dynamics regulation (Sheng et al., 2013) and also the 
interplay between parkin and MTs and its involvement in PD pathogenesis has 
been investigated (as discussed in detail in the next paragraph).   
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1.3 Parkin 
Parkin (PARK2) is the first gene associated with the autosomal recessive 
juvenile parkinsonism (AR-JP) (Kitada et al. 1998), one of the monogenic 
forms of PD. It is the second largest human gene (1.3 Mb) with 12 exons and 
maps to chromosome 6q25.2-q27. The high sequence conservation of PARK2 
gene across the species, not only in vertebrates (human, rat, mouse) but also in 
invertebrates (Caenorhabditis elegans and Drosophila melanogaster) (Kahle et 
al., 2000), suggests that parkin plays a common and evolutionary conserved 
role. Mutations in PARK2 gene are responsible for about 50% of familial cases 
and about 70% of sporadic cases with an early onset (age < 20). Across the 
entire gene including all the 12 exons, a large number of PARK2 mutations 
have been identified. Up to now, more than 170 different mutations, including 
missense/nonsense substitutions, exon deletions, multiplications, and point 
mutations, have been reported in AR-JP (Corti et al. 2011). PARK2-linked PD 
is characterized by a recessive inheritance. In recessively inherited disorders, 
two mutations—either the same mutation (homozygous) or two different 
changes in the two alleles (compound heterozygous)—are needed to cause the 
disease phenotype (Klein et al. 2007). Otherwise, the heterozygous subject, 
carrying a single mutation, should be unaffected. Nevertheless, several studies 
identified both diverse cases of late-onset PD with a single mutated allele (West 
et al. 2002) or heterozygous asymptomatic individuals with some nigrostriatal 
abnormalities. These evidences suggest that PARK2 haploinsufficiency might 
be a risk of factor for PD progression (Khan et al., 2005). Moreover, genetic 
studies have revealed the existence of polymorphisms that enhance disease 
susceptibility rather than mutations that cause the disease. 
PARK2 gene encodes for a cytosolic protein of 465 aminoacids (52 kDA), that 
is expressed in most of the tissues including heart, testis and skeletal muscles. 
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Moreover, it is abundantly expressed in the brain and especially in the SN 
(Kitada et al. 1998; Huynh et al. 2001). 
In 2000, Shimura and colleagues showed that parkin is a member of E3 
ubiquitin ligase and is responsible for the transfer of activated ubiquitin to 
protein substrates (Shimura et al. 2000). The ubiquitylation process occurs 
through the covalent attachment of monoubiquitin or polyubiquitin chains to 
lysine residues (most frequently K63, K48, K11 and K6 linkages) of the 
substrate (Hershko and Ciechanover 1998). E3 ligase enzyme, involved in the 
last step of ubiquitination pathway, plays an important role in targeting 
damaged or misfolded proteins that are degraded via the ubiquitin proteasome 
system (UPS). Ubiquitination pathway is carried out by the action of three 
enzymes: E1 ubiquitin activating enzymes, E2 ubiquitin conjugating enzymes 
and E3 ubiquitin ligase. The E1 enzyme uses ATP to activate ubiquitin, forming 
thioester between its catalytic cysteine and the C terminal carboxyl group of the 
ubiquitin. The ubiquitin is then transferred to cysteine active site of E2 by 
transthioestherification. Then, E2-ubiquitin interacts with E3 ligase, which 
mediates the transfer of ubiquitin to substrate protein.  
Parkin belongs to the RBR (RING between RING) class of E3 ubiquitin ligases, 
which combine the structure similarity of RING and the chemistry of HECT 
ligase to transfer the ubiquitin to the substrate (Wenzel et al. 2012; Lazarou et 
al. 2013). Structurally, parkin protein consists of an ubiquitin-like (UBL) 
domain at the N-terminal region and the RBR (Ring-Between-Ring) domain at 
the C-terminal region (Figure 6 A). The UBL is involved in different processes, 
such as proteosome association, substrate recognition and the regulation of 
parkin level and activity. The RBRs comprises a C3CHC4-type RING (really 
interesting new gene) domain RING1, which binds the E2 enzymes but it is not 
involved directly in catalysis and RING2 domain, which contains the catalytic 
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cysteine (cys 431), receives the ubiquitin from the E2. The two RING domains 
are separated by two Cysteine/Histidine (Cys/His)-rich Zn-binding domains in-
between-RING (IBR). Different studies showed the existence of the His 433 
and Glu444 in the proximity of Cys 431, suggesting the presence of catalytic 
dyad or triad (Wauer and Komander 2013; Trempe et al. 2013). Parkin contains 
also two flexible linker domains: the first one (following the UBL domain) is 
poorly conserved with an unknown function and, the second one, located 
between the IBR and RING2 domain is named repressor element of parkin 
(REP), because it is involved in parkin activity regulation. RING0, also known 
as unique parkin domain (UPD) domain, is an atypical RING located at the N-
terminal of RBR domain. 
The activity of parkin within the cell is tightly regulated by multiple 
mechanisms of auto-inhibition (Figure 6 B). Cytosolic parkin exists in the auto-
inhibited conformation and the high resolution crystal structures of RING0-
RBR domains, which lack the UBL domain, revealed multiple interactions that 
regulate parkin activity (Kumar et al. 2015). The catalytic domain in RING2 is 
buried by the hydrofobic interaction with RING0 (Wauer and Komander 2013; 
Trempe et al. 2013); REP domain forms two-turn helix which bounds to RING1 
and, thereby, prevents the interaction between RING1 and ubiquitin charged E2 
(Trempe et al. 2013). The N-terminal UBL uses hydrophobic interaction, 
centered around Ile44, to bind and occlude the RING1 domain. 
Different studies have made progress in understanding the molecular 
mechanisms underlying parkin activation. PINK1, the mitochondrial Ser/Thr 
kinase, is required for parkin activation. These two proteins are involved in 
common pathways that regulate mitophagy of damaged mitochondria (Narendra 
et al. 2012). 
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Figure 6. (A) Schematic structure of parkin shows the different domains of the 
protein and (B) representation of parkin-phosphoubiquitin (phosphoUb) 
complex. The yellow star mark represents the catalytic cysteine in the RING2 
domain (from Zheng and Hunter 2015). 
 
 
Studies derived from mammalian cell lines and human fibroblasts showed that 
the carbonyl cyanide m-chlorophenyl hydrazone (CCC) treatment, which causes 
a mitochondrial depolarization, promotes the recruitment of parkin on 
mitochondria in a PINK1-dependent manner. This leads to a reduction of 
mitochondrial mass and the colocalization of mitochondrial proteins with 
autophagosomal e lysosomal markers (Narendra et al. 2008). 
PINK1 activates parkin through two events of phosphorylation, one occurs on 
Ser 65 of UBL domain and the other one on the equivalent residue in ubiquitin 
molecule (Figure 6 B) (Pickrell and Youle 2015). In 2015, Kumar and 
colleagues have demonstrated that UBL phosphorylation optimizes parkin for 
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phosphoubiquitin recruitment at the interface between RING0 and RING1 
domains, a binding that promotes the displacement of the UBL domain (Kumar 
et al. 2015). Recent studies demonstrate that phosphoubiquitin binding is 
necessary for the translocation of parkin to mitochondria. Wauer and colleagues 
(2015) showed that phosphoubiquitin binding induces a straightening of the 
helix in the RING1 domain, which promotes conformational changes. This 
leads to destabilization of inhibitory interaction between REP and RING2 and 
to the release of UBL from RBR domain. Moreover, the release of UBL 
enhances its phosphorylation by PINK1, leading to open conformational 
changes, which activate parkin. This phosphorylation enables parkin to 
ubiquitinate different substrates within the cells, from cytosolic to outer 
mitochondrial membrane proteins and target them for mitophagy (Pickrell and 
Youle 2015; Chan et al. 2011).  
Parkin, together with PINK1, is involved in the "mitochondrial quality control", 
a term used to describe the coordination of mitochondrial dynamics, mitophagy 
and biogenesis in order to maintain a mitochondrial healthy pool in cell (Scarffe 
et al. 2014). Thus, parkin/PINK1 pathway might control the distribution of 
mitochondria within the cells through the axonal transport regulation. PINK1, 
when is exposed on the surface of dysfunctional mitochondria, phosphorylates 
miro. Miro is a Ca2+ binding GTPase at the outer mitochondrial membrane 
(OMM) necessary for anterograde transport regulation. Its phosphorylation 
mediated by PINK1, in turn, promotes the ubiquitination by parkin and the 
subsequent degradation by proteosome. This process leads to the dissociation of 
kinesin motors from mitochondria. Therefore, PINK1/parkin may stop the 
movement of impaired mitochondria into neurites to quarantine the mitophagy 
(Itho et al. 2013). Mitochondrial dynamics is a term associated to fusion and 
fission events, which are crucial inside cells for mitochondrial number, shape 
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and transport. The fusion event of two mitochondria enables the exchange of 
contents to acquire components from healthy mitochondria. Conversely, fission 
process allows the mitochondrial division into smaller pieces, promoting the 
degradation of damaged components. This process is necessary both to produce 
one functional mitochondria (Youle et al. 2012) and to facilitate mitochondrial 
transport. Parkin deficient Drosophila, which results in reduced lifespan, male 
sterility and severe defect in flight and climbing abilities, show mitochondrial 
alterations (Greene et al. 2003) and flight muscle degeneration. Whitworth and 
colleagues (2005) has observed a mild dopaminergic neuronal loss in parkin 
mutants flies. Loss of parkin or PINK1 promotes in both flight muscle and 
dopaminergic neuron the formation of swollen mitochondria, supporting the 
idea that parkin promotes mitochondrial fission or inhibits mitochondrial 
fusion. These defects are suppressed by increasing the expression of dynamin-
related GTPase (DRP1), or by downregulation of the fusion-promoting 
GTPases, Mitofusin (MFN) and OPA1. In Drosophila parkin induces MFN2 
ubiquitination and its subsequent proteosomal degradation (Ziviani et al. 2010). 
Different studies performed on mammalian cells have complicated this point of 
view because some of the studies demonstrates that PINK1/parkin promotes 
fusion, (Lutz et al. 2009), even though not all are in agreement with each others. 
MFN a protein involved in fusion events, it has been demonstrated to be a 
substrate of both PINK1 and parkin (Ziviani et al. 2010). Interestingly, MFN2 
interacts also with Miro, independently of its role in fusion events (Misko et al. 
2010). DRP1 is a regulator of mitochondrial fission and it is also has been 
proposed to be substrate of parkin (Wang et al. 2011). 
The proper control of mitochondrial dynamics is crucial for neurons to fulfill 
the needs in the different compartments and to reorganize working pieces into 
well functioning machinery (Scarffe et al. 2014). When the organelles is 
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completely damaged, they are removed by the proteosomal degradation and 
mitophagy, and the replenish of new functional mitochondria or the increase in 
cellular demands requires the mitochondrial biogenesis. Parkin plays also a 
functional role in mitochondrial biogenesis by regulating the level of PARIS, a 
zinc finger protein, which mediates repression of a master regulator of 
mitochondrial biogenesisis, the peroxixome proliferator-activated receptor 
gamma (PPARγ) coactivator-1α (PGC1α) (Scarffe et al. 2014).  
Parkin has several others substrates, such as CDC-rel1 (a synaptic vesicles 
associated GTPase), cyclin E, p38 transfer RNA, Paelr1 (parkin associated 
endothelin receptor like receptor), O-glycosylated form of α-syn (named 
αSp22) and synphilin-1 (an α-syn interacting protein), synaptotagmin XI, α- and 
β-tubulin and many others. Moreover, pakin is autoubiquitinated and so it can 
be considered a self-substrate. Pathogenic mutations associated to PD occur 
throughout the domains of parkin protein; these mutations lead to different 
consequences: they could compromise the structural integrity of the protein 
(e.g. C212Y, C289G and C441R affect zinc coordination, while R42P, K211N 
and T351P disrupt protein folding or stability), interfere with substrates binding 
(e.g. R42P, K161N and T2403) or directly affect the enzyme activity (e.g. 
T415N, G430D, C431F, M434K, C418R and C441R). Only these latter 
mutations, that affect RING2 domain, abolish parkin E3 enzymatic activity 
meaning that the RING2 finger motif is the catalytic core of parkin. 
Different studies highlighted the neuroprotective capacity of parkin against 
several insults, preventing cell death under various stress conditions: 
mitochondrial and endoplasmic reticulum (ER), accumulation of toxic and 
misfolded protein, such as α-syn (Feany et al. 2003) and MT destabilization. 
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1.3.1 Parkin and Microtubules 
In 2003, Ren et al. reported the discovery of parkin as a novel tubulin-binding 
protein, as well as a MT-associated protein.  
In rat brain lysates or transfected human embryonic kidney (HEK) 293 cells, α- 
and β-tubulin strongly co-immunoprecipitated with parkin after the treatment 
with colchicine and the incubation at 4°C, conditions that ensure MT 
depolymerization. They showed that parkin tightly binds to MT in taxol-
mediated MT coassembly assays and that it is localized in a puncta manner 
along MTs. The treatment with colchicine, a MT-destabilizing drug, leads 
parkin to be more diffuse on the cytoplasm. Moreover, they also showed that 
the expression of wild-type parkin in cells significantly increased the 
ubiquitination and facilitated the degradation of α- and β-tubulin through its E3 
ligase activity, whereas the parkin AR-JP-linked mutants (K161N, T240R, 
C431F) abolished the activity of parkin towards tubulins and others substrates. 
Next, it has been demonstrated that parkin is able to bind tubulin and MTs 
through three independent domains: Linker, RING1 and RING2. The 
expression of these domains in cells reduced the ability of colchicine to 
depolymerize MTs, suggesting a role of parkin in MT stabilization. PD-linked 
mutations (K161N in the Linker, T240R in RING1, C431F in RING2) did not 
disrupt the binding between parkin and tubulin or MTs as well as its ability to 
attenuate MT depolymerization induced by colchicine, meaning that the ability 
to bind tubulin and stabilize MTs is independent of E3 ligase activity (Yang et 
al. 2005) Therefore, the interaction of parkin with MTs may facilitate its E3 
ligase activity (Feng 2006). The expression of wild-type parkin has been 
demonstrated to protect dopaminergic neurons against MT-depolymerizing PD-
toxins, such as colchicine and rotenone, through MAP kinase pathway 
activation. In contrast the protective effect of parkin was abrogated by its PD-
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linked mutant, that produces a truncated protein lacking any three MT-binding 
domains (Ren et al. 2009). This demonstrated that the integrity of MT network 
is essential for the survival of midbrain neurons (Feng 2006). Midbrain 
dopaminergic neurons are particularly vulnerable to MT depolymerization 
because of their peculiar morphology and neurochemistry. Dopaminergic 
neurons characterized by long and elaborate axon, rely on MTs to transport 
vesicles containing DA (Feng 2006). Recently, it has been demonstrated that 
parkin maintains morphological complexity of human midbrain derived-iPSc 
neurons by its MT-stabilizing effect (Ren et al. 2015). Parkin PD-linked 
mutants reduce the complexity of neuronal process and promote MT 
destabilization; the overexpression of wild-type parkin significantly increases 
MT stability and rescues the morphological defects, the same effect obtained by 
treating the cells with MT-stabilizing taxol. 
Noteworthy, Cartelli et al. (2012) demonstrated that MT stability is 
compromised in human fibroblasts carrying PARK2 mutation. In particular, 
they showed morphological alteration, reduced MT mass, and changes in 
molecular pathways implicated in MT stability. Moreover, PARK2 fibroblasts 
display an enrichment of Tyr tubulin, suggesting that MT system becomes more 
dynamic when parkin is mutated. The pharmacological MT stabilization and the 
transfection of wild type parkin rescue fibroblast phenotype and restore MT 
stability. 
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Aim of the Project 
 
The tightly control of MT system is crucial for neuron survival and many 
evidences support the concept that MT dysfunction could contribute to PD 
pathogenesis. Mutations in PARK2 gene, responsible for the majority of AR-JP, 
cause MT destabilization and reduce the complexity of neuronal process in both 
murine and human dopaminergic neurons (Ren et al., 2009; Ren et al., 2015). 
Moreover, striking data derived from our laboratory showed that PD-patient 
skin fibroblasts, bearing PARK2 mutations, display reduced MT mass and 
morphological defects (Cartelli et al. 2012). Interestingly, besides the well-
known ligase activity, parkin regulates other cellular functions such as 
mitochondria homeostasis, including mitochondrial dynamics and transport 
(Scarffe et al. 2014), and MT stability (Yang et al. 2005). 
To gain more insight into the intracellular roles of parkin, our aim was to 
investigate its influence on MT stability and MT-based neuronal function, 
namely axonal transport, in gene-based models of the pathology and, in 
particular, we wondered whether MT dysfunction could be an early event 
triggering neurodegeneration.  
The first task we faced was to characterize MT system in vivo. We usedPARK2-
Q311X transgenic mice expressing the C-terminal truncated human parkin 
associated with Turkish early-onset PD (Lu et al. 2009) which resembles the 
hallmarks characteristic of the disease in an age-dependent way. We aimed to 
investigate if the point mutation Q311X affects MT and mitochondrial system 
in the nigrostriatal pathway through the analysis of tubulin PTMs, crucial 
controller of MT stability, and of proteins involved in mitochondrial dynamics 
and transport, respectively. To pinpoint the timetable of events in triggering 
neurodegeneration, we performed our experiments in young and adult mice (6 
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and 16 weeks old) before the onset of the previously described defects and 
neuronal loss (Lu et al. 2009). Furthermore, we studied the impact of parkin 
absence on MT and mitochondrial system in PARK2 KO mice (Goldberg et al. 
2003) at different ages, ranging from young adult to old mice (2-24 months). 
Since PARK2 KO mice do not show the pathological hallmarks of the 
pathology, except for some nigrostriatal abnormalities, we used this model both 
to elucidate the physiological role of parkin and to unravel the early events in 
PD pathogenesis. 
Then we moved to cultured neuronal cells. MT stability and mitochondrial 
transport were assessed in PARK2-silenced PC12 cells, extensively studied as a 
model of dopaminergic neurons in culture, and in primary midbrain cultures 
obtained from PARK2 KO and heterozygous mice. In order to verify the 
hypothesis that parkin modulates MT dynamics directly and to investigate in 
detail the interplay between MT system and mitochondrial transport we used a 
live cell imaging approach.  
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Main Results 
 
Our understanding of the mechanisms underlying the initiation and the 
progression of PD began with the study of PARK2-Q311X transgenic mice at 
different ages (6 and 16 weeks old) in the attempt to disclose the time course of 
MT dysfunction and to compare these defects with changes in mitochondrial 
dynamics and transport. The quantification of dopaminergic terminals in the 
Corpus striatum ruled out the occurrence of neurodegeneration in these young 
and adult mice, whereas a modest but significant increase of TH levels within 
the cell body of dopaminergic neurons in the Substantia nigra of PARK2-
Q311X mice, at both 6 and 16 weeks of age, was observed. The 
characterization of MT system has been carried by analysing tubulin PTMs that 
are associated to MTs with different stability. The results showed an unbalance 
in the levels of tubulin PTMs in the early phases of the disease, namely before 
neurodegeneration occurs. Biochemical analysis, performed on total protein 
extract, showed a significant decrease of deTyr tubulin, associated with stable 
MTs, on ventral mesencephalon of 16 weeks old mice. On the contrary, we 
observed an increase of acetylated tubulin, associated with stable MTs, in the 
Corpus striatum at the same time point. Confocal analysis showed that α-
tubulin PTMs changes occur specifically inside dopaminergic cell soma of the 
Substantia nigra and becomes evident already in 6 weeks old mice. In 
particular, the quantification of fluorescence intensity within single TH 
positive-cells in Substantia nigra showed a significant reduction of Tyr tubulin, 
marker of dynamics MTs; the observed changes of Tyr tubulin in 6 weeks old 
mice seems to be transient as older mice do not show any significant alteration 
with respect to controls. Furthermore, our analyses also revealed a concomitant 
enrichment of deTyr tubulin in the Substantia nigra followed by a significant 
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decrease in older mice (16 weeks). On the contrary, western blot analyses of 
proteins involved in mitochondrial fusion and fission (MFN2 and DRP1, 
respectively) did not show any significant alteration in their levels in ventral 
mesencephalon and in Corpus striatumof both 6 and 16 weeks old PARK2-
Q311X mice. The distribution of mitochondria along dopaminergic fibers was 
investigated as it is a useful, even if indirect, approach to assess axonal 
transport but we did not observe any impairment at the same time points (De 
Gregorio et al., to be submitted, PART II).  
The early unbalance of tubulin PTMs was also reported for PARK2 knockout 
mice that showed an increase in dynamic MTs followed by the accumulation of 
stable MT pools, both in the Substantia nigra and Corpus striatum, which 
precedes the block of mitochondrial transport without affecting the levels of 
protein involved in mitochondrial dynamics (Cartelli et al., to be submitted, 
PART II). Collectively, our data coming from two different mouse disease 
models support the relevance of parkin in modulating tubulin PTMs in vivo. 
In the second part of the project, we evaluated the impact of parkin deficiency 
on MT system and on the interplay between MT and mitochondrial transport in 
cultured cells. Live cell imaging analyses carried out in PARK2-silenced PC12 
cells clearly showed that the absence of parkin significantly accelerates MT-
growth, causing MT destabilization. At the same time, parkin-silencing speeds 
up specifically the anterograde transport velocity, with no effects on the 
retrograde one; noteworthy, silenced cells display a higher fraction of 
mitochondria moving towards the soma, meaning that parkin absence causes a 
disorientated mitochondrial trafficking. These axonal transport defects were 
restored by the MT-stabilizing agent paclitaxel, confirming the importance of 
modulation of parkin on MT stability (Cartelli et al., to be submitted, PART II). 
Next, we moved to primary mesencephalic neuronal cultures obtained from 
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PARK2 KO and PARK2 heterozygous mice. Neurons isolated from PARK2 KO 
showed the defective axonal outgrowth at 1 and 2 day in vitro (DIV) of 
differentiation with a concomitantly increase of neuronal sprouting only at 1 
DIV, that to say in cells that are actively involved in neurite emission. In 
agreement with the data obtained in PARK2-silenced PC12 cells, parkin 
deficiency causes MT destabilization, that consequently leads to altered 
mitochondria axonal transport. In primary neurons the absence of parkin 
significantly accelerates MT growth and at the same time slightly speeds up the 
total velocity of mitochondrial axonal transport, with a mild but not significant 
increase in anterograde or retrograde transport specifically. Instead, parkin 
absence did not affect mitochondrial trafficking direction in primary neurons. 
The treatment with paclitaxel decreased mitochondrial velocity compared also 
to the control cells. Probably, the effect could be due to the high concentration 
of paclitaxel that we have used for our experiments. Finally, the effect of parkin 
on MT stability was assessed also by immunofluorescence analysisof tubulin 
PTMs that revealed an enrichment of Tyr tubulin in primary neurons derived 
from PARK2 KOmice respect to PARK2 heterozygous and control mice (De 
Gregorio et al, Manuscript in preparation, PART III). 
In conclusion, these results strongly indicate that parkin is a regulator of MT 
stability in cultured neurons and in vivo and, together with all the striking data 
coming from other gene- and toxins-based models of the disease, reinforce the 
idea that MT dysfunction may be crucial in PD pathogenesis (Pellegrini et al. 
2015; Cappelletti et al. 2015; Cartelli and Cappelletti, 2016). 
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Conclusions and Future Perspectives 
 
Here, we have demonstrated the impact of parkin on the regulation of tubulin 
PTMs and MT dynamics in neurons and in murine gene-based experimental 
models of the disease. Importantly, our data strongly suggest that alterations of 
MT stability accounts for very early event underlying PD pathogenesis and 
likely triggers defects in axonal transport. 
We showed that the absence of parkin, according to its proposed MT-stabilizing 
effect (Yang et al. 2005), alters the equilibrium between stable and dynamic 
pools of MTs making this cytoskeletal system destabilized with respect to the 
controls, in both neuronal cultures and in vivo (Cartelli et al., to be submitted, 
PART II; De Gregorio et al., manuscript in preparation, PART III). 
Interestingly, the early enrichment of dynamic MT pool is followed by the 
accumulation of PTMs associated with stable MTs in late stages and precedes 
the block of mitochondrial axonal transport in PARK2 KO mice (Cartelli et al., 
to be submitted, PART II). 
Furthermore, we showed that the rare pathogenic mutation PARK2-Q311X 
induces the very early unbalance of tubulin PTMs in vivo and becomes 
noticeable before that TH depletion and dopaminergic neuron loss occurs (De 
Gregorio et al., to be submitted, PART II). In detail, Q311X mutation results in 
the early enrichment of tubulin PTMs associated to stable pool. Most likely, the 
over-stabilization effect may be due to a dominant gain of a toxic novel 
function of the mutant protein. This could be view as an attempt of 
dopaminergic neurons to balance or counteract the depolymerizing insult, 
through the accumulation of tubulin PTMs that protect them from the 
collapsing MT system (Cartelli and Cappelletti, 2016). 
Since the transgenic mouse models have their specificities and limitations, the 
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future perspectives of this project involve the analysis of MT stability in the 
context of human neuronal cells taking advantage of iPSC-derived 
dopaminergic neurons obtained from the PD patients bearing different PARK2 
mutations. This allows investigating whether the decrease of MT mass 
described by Ren et al. (2015), due to the effect of parkin mutations, correlates 
with the unbalance of tubulin PTMs.  
An expected consequence of the alteration of MT stability is the dysregulation 
of axonal transport. Indeed, our data demonstrate that parkin regulates 
mitochondrial trafficking in a MT-dependent manner by showing that the 
impairment of mitochondrial transport along axons is rescued by MT stabilizer 
agent paclitaxel. The concept that the stabilization of MT could be an efficient 
strategy for neuroprotection is supported by data coming from others 
experimental models of PD (Ren et al. 2009; Cartelli et al. 2012). Importantly, 
Epothilone D, drug acting as aMT stabilizer agent, exerts neuroprotective 
effects in a toxin-based murine model of PD (Cartelli et al. 2013). Thus, MT 
system could represent a reliable therapeutic target for management of the 
disease (Brunden et al. 2014). These findings will open the way to deeply 
investigate how to control MT stability using different strategies, including the 
modulation of enzymes that specifically regulate PTMs of tubulin, crucial 
controller of MT dynamics and mitochondrial transport. 
Finally, a side research of the lab demonstrated that the PD-related pre-synaptic 
protein α-syn is a novel, foldable, MT-dynamase, which changes its 
conformation when binds to α2β2tetramers and regulates MT nucleation and 
dynamics, enhancing MT growth rate and catastrophe frequency, in vitro and in 
cell. Furthermore, we confirmed interaction of α-syn with β-III tubulin and we 
observed its co-localization with the most dynamic MTs pool (tyrosinated 
tubulin), at pre-synapse of PC12 cells and human neurons. Furthermore, PD-
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related α-syn mutants are much less sensitive than WT α-syn to fold upon 
tubulin binding and cause tubulin aggregation rather than polymerization. This 
could potentially lead to impairment of the proper MT organization in the 
neuronal processes at the pre-synapse. Therefore, these results obtained from 
PD-linked α-syn mutants provide hints for the pathogenesis in PD, which could 
involve MT-dependent processes, such as axonal transport (Cartelli et al. 2016). 
Future work will be necessary to better understand the link between axonal 
transport impairment, α-syn/MT in the context of PD. 
Overall, the data arising from the present work reinforce the idea that MT 
dysfunction may play a crucial role in the chain of events leading to 
neurodegenerative processes underlying PD pathogenesis. Indeed, MT system 
represents a point of converge in the action of neurotoxins and different 
proteins related to PD, including parkin and α-syn, whose mutations we 
reported to cause defects in MT dynamics and/or stability. Furthermore, 
alterations of MT dynamics that become noticeable before any other signs of 
neurodegeneration (Cartelli et al. 2013; Cartelli et al. to be submitted; II parte; 
De Gregorio et al., to be submitted) might result in the failure of the axonal 
transport that is a common defect of many neurodegenerative diseases, 
including PD. Indeed, the morphology of dopaminergic neurons, which have a 
complex neurite arborization, makes them particularly sensitive to axonal 
transport failure. According to this, the primary step in the PD pathogenesis is 
the degeneration of striatal dopaminergic terminals that, in turn, triggers the 
neuron death, the so called "dying back" process (Coleman et al. 2005). This 
could be likely due to axonal transport failure or MTs alteration.  
Importantly, all these evidences make the study of MT dysfunction a challenge 
for a better comprehension of PD pathogenesis and, notably, supply the 
rationale for the development of novel MT-target based therapeutic strategies to 
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treat PD and other disorders of central nervous system (Cartelli and Cappelletti 
2016). 
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ABSTRACT 
 
Parkinson's disease (PD) is a movement disorder due to the progressive loss of 
dopaminergic neurons whose pathogenesis remains still unclear. So far, 
neurodegeneration in PD is likely caused by a combination of multifactorial 
events and involves different pathogenic pathways. Among them, the 
dysfunction of microtubules is emerging as novel contributing factor of the 
disease, and this evidence is supported by several studies on toxin-based 
experimental models of PD. Our goal is to further investigate the role of 
microtubule dysfunction in PD neurodegeneration using a gene-based model of 
the disease, namely PARK2-Q311X transgenic mice which that show age-
dependent loss of dopaminergic neurons, and we investigated whether this point 
mutation Q311X of parkin affects microtubule system in the nigrostriatal 
pathway. In particular, we analyzed microtubule stability and mitochondrial 
system in young mice (6-16 weeks old), before the onset of the previously 
described defects and neuronal loss, with the aim to discover the timetable of 
events in triggering neurodegeneration. In order to reveal the possible 
alterations in microtubule and/or mitochondrial system, respectively, we 
performed different analysis of post-translational modifications of tubulin and 
of proteins involved in mitochondrial fusion and fission. Throughout 
biochemical and confocal analyses, our results highlighted an early microtubule 
dysfunction associated with the unbalance of different α-tubulin post-
translational modifications within dopaminergic neurons in young PARK2-
Q311X transgenic mice. On the contrary, none alteration was observed in 
mitochondrial dynamics and distribution in nigrostriatal fibers, at least at the 
time points we investigated. Finally, the quantification of dopaminergic 
terminals in the Corpus striatum ruled out the occurrence of neurodegeneration 
in these young mice. Taken together, our results suggest that the observed 
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alterations in microtubule stability could be attributable to a very early event 
underlying neurodegeneration in PARK2-Q311X mice. 
 
 
INTRODUCTION  
 
Parkinson's disease (PD) is a progressive and multifactorial neurodegenerative 
disorder characterized by the selective degeneration of dopaminergic neurons 
projecting from the Substantia nigra pars compacta (SN) to the Corpus 
striatum (ST). This leads to a severe striatal dopamine deficiency and, 
consequently, to the typical movement disorders of parkinsonism (Dauer & 
Przedborski 2003). The molecular mechanisms underlying the neuronal loss are 
still unclear, but several pathogenic pathways have been reported causing 
dopaminergic neurons degeneration including oxidative stress, mitochondrial 
dysfunctions, proteolytic stress due the ubiquitin-proteasome system (UPS) 
impairment and local inflammation  (Kumaran & Cookson 2015). Recently, the 
microtubule (MT) dysfunction is becoming established as a promising 
hypothesis in PD pathogenesis. PARK2 gene, whose mutations result in both 
familial and sporadic forms of PD (Shimura et al. 2000), encodes for parkin 
which is a RING-between-RING E3 ligase that catalyses the attachment of 
ubiquitin to specific substrates and, in addition, it has been implicated in many 
other cellular functions, such as mitochondrial homeostasis and MT 
cytoskeleton stabilization. Indeed, a large body of evidence showed the ability 
of parkin to modulate mitochondrial dynamics (fusion and fission), mitophagy 
and transport (Scarffe et al. 2014), but also its capacity to bind α- and β-tubulin 
heterodimers promoting their degradation (Ren et al. 2003) and to stabilize MTs 
through the redundant interaction of three domains (Yang et al. 2005). Further 
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work performed both on murine and human induced pluripotent stem cells 
(iPSC)-derived dopaminergic midbrain neurons showed that parkin protects 
neurons against depolymerizing agents, such as rotenone and colchicine (Ren et 
al. 2009; Ren et al. 2015). Striking data coming from our laboratory showed 
that human fibroblasts, obtained from PD patients carrying PARK2 mutations, 
exhibit an altered MT stability, and the pharmacological MT stabilization and 
the transfection of wild type parkin restores MT stability (Cartelli et al. 2012). 
These evidences strongly support the concept that the interplay between parkin 
and MTs could have a crucial role in PD context. 
Nevertheless, the impact of parkin on MTs in vivo has been poorly investigated 
to date. Mouse transgenic models that are actually available have their own 
specificities but also limitations. The parkin knockout mice developed until 
now do not exhibits dopaminergic neurons loss or motor impairment, except for 
nigrostriatal abnormalities (Goldberg et al. 2003), Locus coeruleus alterations 
(Von Coelln et al. 2004), features of mitochondrial dysfunction and oxidative 
damage (Palacino et al. 2004). On the other hand, transgenic mouse model 
selectively overexpressing a truncated human mutant parkin (Parkin-Q311X) in 
dopaminergic neurons, display age-related neuropathologies of PD (Lu et al. 
2009). Thus, PARK2-Q311X transgenic mouse is a good gene-based 
experimental model of the disease, because it shows dopaminergic neurons 
degeneration in the Substantia nigra at 16 months of age that is preceded by a 
significant loss of their terminals in the Corpus striatum, progressive motor 
deficits, α-synuclein pathology and the reduction of the striatal dopamine levels 
(Lu et al. 2009). Recently, it has also been demonstrated that PARK2-Q311X 
mice display an impairment of the autophagic pathway at the level of lysosomal 
function which, in turn, coincides with defects in mitochondrial quality control 
and increased neurodegenerative and behavioural phenotypes (Siddiqui et al. 
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2015). Thus, this genetic model seems to be appropriate for investigating 
whether the point mutation Q311X affects MT system in the nigrostriatal 
pathway in a context of the neurodegenerative process. 
In this work, we used PARK2-Q311X mice at different ages in the attempt to 
disclose the time course of MT dysfunction and to compare these defects with 
changes in mitochondrial dynamics. A cohort of young PARK2-Q311X and 
wild type control littermate mice were tested at 6 and 16 weeks of age. For this 
purpose, we used different approaches to examine α-tubulin post-translational 
modifications (PTMs), associated to MTs with different stability, and 
mitochondrial dynamics and distribution in nigrostriatal fibers. Our data 
revealed early alterations in MT dynamics in two regions of interest, the 
Substantia nigra and the Corpus striatum, that occur already in 6 weeks old 
transgenic mice. On the other hand, none alteration was observed for 
mitochondrial dynamics and transport. Thus, we suggest that the observed 
changes in MT stability could be attributable to a very early event in a gene-
based model of the disease.  
 
 
RESULTS   
 
PARK2-Q311X mutation does not cause the loss of dopaminergic fibers in 
the Corpus striatum of young mice. 
To evaluate the impact of Q311X mutation on MT and mitochondrial systems 
focusing on early events, we analyzed young mice (6 and 16 weeks old). The 
first approach was the quantitative analysis of tyrosine hydroxylase in 
Substantia nigra and Corpus striatum to point out whether signs of 
dopaminergic neurons loss were detectable in the nigrostriatal  pathway of mice 
at this young age.  
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For this purpose, we first performed immunostaining with anti-TH antibodies 
on coronal sections prepared from Corpus striatum of 16 weeks old mice and 
analyzed the dopaminergic terminals both in the whole region (Figure 1A) and 
in four sub-regions, namely dorsal, dorso-medial, dorso-lateral and ventral 
Corpus striatum (Figure 1B). We found that PARK2-Q311X transgenic mice at 
16 weeks of age did not show any significant difference in the optical density of 
TH-positive fibers when compared to wild type, although a mild but not 
significant decrease was observed in the ventral Corpus striatum (Figure 1C). 
Then we moved to a biochemical approach and we performed western blot and 
densitometric analyses on lysates obtained from ventral mesencephalon, that 
contains the Substantia nigra, and we found no apparent differences between 
PARK2-Q311X and wild type littermate mice (Figure 2A). In addition, the 
analysis of lysates obtained from striatum revealed a modest decrease of TH 
level at 6 weeks while a mild increase was observed in 16 weeks old transgenic 
mice (Figure 2B). Finally, we further confirmed our results by 
immunofluorescence staining with anti-TH antibodies in sagittal sections 
obtained from differently aged PARK2-Q311X mice. Sagittal sections offer the 
advantage to allow analyzing the entire nigrostriatal pathway, from 
dopaminergic cell bodies in Substantia nigra to fibers and, in the end, terminals 
in Corpus striatum. We quantified TH immunofluorescence in these three 
neuronal compartments (Figure 3A). We observed a modest but significant 
increase of TH level within the cell body of dopaminergic neurons in the 
Substantia nigra of PARK2-Q311X mice at both 6 and 16 weeks of age 
compared to the wild type mice (Figure 3 B-C), whereas no differences were 
observed for the others compartments. 
Taken together, these results did not reveal any loss of dopaminergic terminals 
in the striatum of PARK2-Q311X mice, thus suggesting that neuronal 
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degeneration usually associated to PD is not detectable in young mice, at least 
until 16 weeks of age, and that this could be a reliable time point for 
investigating early events in this PD model. The functional role of the increase 
in TH level we observed in cell bodies of neurons located in the Substantia 
nigra remains to be deeply investigated. 
 
PARK2-Q311X mutation impacts on the level of post-translationally 
modified α-tubulin. 
Parkin is involved in different cellular functions and, interestingly, it has also 
been shown to interact with MTs and, in particular, is involved in their 
stabilization (Yang et al. 2005) other than in the ubiquitination of misfolded α/β 
tubulin heterodimers, thus promoting their degradation via UPS (Ren et al. 
2003). Up to now, proof of the association of parkin with tubulin comes from 
cell-based assays whereas their interplay in vivo has been poorly investigated. 
Here, we hypothesized that the MT system could be affected in the early-stage 
of neurodegeneration in vivo. To verify this hypothesis, we looked at α-tubulin 
PTMs in Substantia nigra and striatum of young wild type and PARK2-Q311X 
mice (6 and 16 weeks old). α-Tubulin PTMs are related to MTs with different 
stability, being tyrosinated (Tyr) the most dynamic pool and deTyrosinated 
(deTyr), delta2 (Δ2), acetylated (Ac) the more stable ones (Janke & Kneussel 
2010). Biochemical analysis, performed on total protein extract, showed a 
significant decrease of deTyr tubulin on ventral mesencephalon of 16 weeks old 
mice (Figure 4A) whereas an increase of acetylated tubulin occurs, in the 
striatum at the same time point (Figure 4B). 
Next, to uncover whether the observed changes of α-tubulin PTMs might be 
attributed specifically to dopaminergic neurons or to other cell types resident in 
these brain areas, we moved to confocal microscopy. For this purpose, each 
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sagittal section was concurrently immunostained with anti-TH antibody, to 
identify the dopaminergic neurons, and α-tubulin PTMs antibodies. Confocal 
analysis showed that α-tubulin PTMs changes occur within dopaminergic cell 
soma and becomes evident already in 6 weeks old mice (Figure 5A, 6A). 
Surprisingly, the quantification of fluorescence intensity within single TH 
positive-cells in Substantia nigra showed a significant reduction of Tyr tubulin 
(Figure 5B); the observed changes of Tyr tubulin in 6 weeks old mice seems to 
be transient as older mice do not show any significant alteration with respect to 
controls (Figure 5C). The slight but not significant reduction of Tyr tubulin 
levels observed by biochemical analyses of ventral mesencephalon lysates is 
probably due to the contribution of other cell types, such as glia or non-
dopaminergic neurons. Furthermore, our analyses also revealed a concomitant 
enrichment of deTyr tubulinin Substantia nigra (Figure 6B) followed by a 
significant decrease in older one (16 weeks) (Figure 6C), suggesting that an 
unbalance of tubulin PTMs occurs very early in dopaminergic neurons of 
PARK2-Q311X mice with respect to controls.  
On the other hand, looking a further modified tubulin associated to stable MTs, 
Ac tubulin, any apparent alteration was found in the three brain regions in 
PARK2-Q311X mice versus wild type mice both at 6 and 16 weeks old of age 
(Figure S1).  
The analysis of fluorescence intensity of Tyr, deTyr and Ac tubulin performed 
in TH-positive fibers of the nigrostriatal pathway and terminalsin the striatum 
did not reveal any significant alteration in PARK2-Q311X mice compared to 
wild type mice for both time points.The increase of Ac tubulin levels observed 
by western blotting in Corpus striatum of 16 weeks old PARK2-Q311X mice 
was not confirmed by immunohistochemical analyses. This result could be 
probably due to an alteration occurring in other cell types resident inside the 
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striatum area. Our data revealed that the unbalance of α-tubulin PTMs which 
becomes evident in 6 weeks old PARK2-Q311X mice is likely an early event 
associated with dopaminergic neurons. 
 
PARK2-Q311X mutation does not compromise mitochondrial dynamics. 
Accumulating evidence demonstrates that mutations in PARK2 gene act via the 
formation of insoluble parkin protein and subsequent loss of its E3 ligase 
activity, which, in turn, could result in the inability to govern the 
"mitochondrial quality control" within the cell. Mitochondrial dynamics, which 
consists of fission and fusion events important for the isolation and clearance of 
unhealthy mitochondria (Detmer & Chan 2007), is one of the pathway where 
parkin and (PTEN)-induced Putative Kinase-1 (PINK1) work together to 
control mitochondrial health (Scarffe et al. 2014). The alteration of fusion and 
fission equilibrium has been found in PD (Santos & Cardoso 2012). Thus, to 
assess the status of mitochondria dynamics in PARK2-Q311X mice, we 
performed biochemical analyses on brain lysates and checked for two crucial 
proteins involved in the process. We analyzed the levels of mitofusin-2 (MFN2) 
and dynamin-related protein-1 (DRP1), that are involved in mitochondria fusion 
and fission processes, respectively.The level of MFN2 and DRP1 were 
normalized on voltage-dependent anion channel (VDAC)/porin, a structural 
protein of the mitochondrial pore. Western blot and densitometric analysis did 
not show any significant alteration in the levels of the two proteins in ventral 
mesencephalon (Figure 7A) and in Corpus striatum (Figure 7B) of both 6 and 
16 weeks old PARK2-Q311X mice. 
Therefore, we hypothesized that execution of mitochondrial fusion and fission 
processes is not impaired by Q311X mutation in parkin in vivo, at least in 
young mice. 
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Mitochondria distribution is not altered in the nigrostriatal pathway of 
PARK2-Q311X mice. 
Axonal transport impairment is involved in many neurodegenerative disease 
and it has been shown that axon degeneration could depend mainly on this 
defect (Burke & O’Malley 2013). Moreover, studies performed on hippocampal 
neurons demonstrated that PINK1/parkin pathway arrests the movement of 
damage mitochondria (Wang et al. 2011). On the ground that axonal transport is 
a MT-dependent process, we wondered if the defects in MT system we 
observed in young PARK2-Q311X mice could be related to any impairment of 
axonal transport. 
To assess the status of axonal transport, we evaluated the distribution of 
mitochondria along fibers as it is a useful, even if indirect, approach. For this 
purpose, we performed a double immunostaining of TH and VDAC/porin in 
sagittal sections including the nigrostriatal pathway from 16 weeks old PARK2-
Q311X and control mice.We observed dopaminergic fibers with a 
homogeneous distribution and fibers with scattered mitochondria, being the last 
a typical feature of transport impairment (Figure 8A). We scored the two 
different fibers in the nigrostriatal pathway and we did not found any difference 
in mitochondria distribution in PARK2-Q311X (Figure 8B). In addition, 
fluorescence intensity analysis of VDAC inside the Substantia nigra cell bodies 
and Corpus striatum terminals did not reveal mitochondrial accumulation 
within the two cellular compartments (Figure 8C). 
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DISCUSSION 
 
The concept that neuronal cytoskeletal dysfunction is involved in several 
disorders of the central nervous system is emerging and, nowadays, it is unclear 
whether this alteration could be crucial, even the primary cause, in the 
neurodegenerative process. In particular, MT alteration has been reported in 
many gene and toxic-based experimental model of parkinsonisms (Cappelletti 
et al. 2015; Cartelli & Cappelletti 2016; Pellegrini et al. 2016).  Here, we 
investigated whether MT dysfunction could be considered a culprit in triggering 
neurodegeneration in a transgenic mouse genetic model of PD, PARK2-Q311X 
mice, which resembles the characteristic hallmarks of the disease in age-
dependent way. We demonstrated, that the over-expression of truncated Q311X 
mutant parkin, a rare mutation found in Turkish early-onset PD patient (Hattori 
et al. 1998), impacts on the MT system in mice and becomes noticeable at 6 
weeks of age before that TH depletion and dopaminergic neuron loss occurs (16 
months of age). Importantly, no alterations were observed in the mitochondria 
dynamics and mitochondria transport in the nigrostriatal fibers at the same time 
points. Thus, we speculate that the observed changes in MT stability could be 
attributable to a very early event in neurodegeneration, at least in this genetic 
model of PD. 
Up to now, several pathogenic pathways correlated each other, have been 
implicated in PD pathogenesis. Understanding which mechanism might be the 
primary insult leading to dopaminergic neuron degeneration is a major 
challenge to deal for uncovering suitable therapeutic targets of the disease. In 
order to reveal whether MT dysfunction could be a key event involved PD 
progression, we had to investigate MT system in the early phases of the disease, 
before that neurodegeneration occurs. Since the primary target of the 
degenerative process in PD is the striatal dopaminergic terminals (the so called 
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"dying back" process) (Dauer & Przedborski 2003) and asymptomatic 
heterozygous mice bearing PARK2 mutation display a pre-synaptic 
dopaminergic dysfunction in the Corpus striatum (Binkofski et al. 2007), we  
analyzed the possible dopaminergic terminal deficit in the Corpus striatum of 
PARK2-Q311X transgenic mice. Thus, the analysis of dopaminergic axonal 
innervations and the quantification of fluorescence intensity of TH in the 
nigrostriatal pathway, confirmed that young PARK2-Q311X transgenic mice 
did not show striatal denervation and TH depletion. This result fits with the 
late-onset of dopaminergic neurodegeneration,16 months of age, as reported by 
Lu et al. (Lu et al. 2009). Therefore, young PARK2-Q311X mice we employed 
in the present work, namely 6 and 16 weeks old mice, might be considered a 
suitable model to study the early pathogenic phases that precede neuronal death. 
Tubulin PTMs have been linked to neurodegenerative processes (Rogowski et 
al. 2010) and in particular, their alteration has been reported in the gene and 
toxic-based model of PD (Cartelli et al. 2012; Cartelli et al. 2013). We 
characterized the impact of mutant parkin on MT cytoskeleton in the 
nigrostriatal system and, from our results the occurrence of α-tubulin PTMs 
unbalance emerges. Biochemical analysis showed the specific unbalance of 
modified forms of α-tubulin in the ventral mesencephalon and on Corpus 
striatum of 16 weeks old PARK2-Q311X mice; on the other hand, 
immunofluorescence microscopy of α-tubulin PTMs, performed selectively 
within dopaminergic neurons, revealed earlier alteration on MT system 
(6weeks). Probably, we do not observe the reduction of Tyr tubulin by Western 
blotting because of the presence of other cell type in ventral mesencephalon 
region. Consistent with these results, we can speculate that dopaminergic 
neurons, involved in the neurodegeneration process, are likely earlier altered 
and more sensitive to MT alteration in respect to other cell type. The proper 
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control of MT system is crucial for neuronal survival and function and in 
particular, dopaminergic neurons appear to be highly vulnerable to any insults 
that could damage MT cytoskeleton because of their peculiar morphology 
characterized by long axons that project from the Substantia nigra to Corpus 
striatum which that made these complex neurons strongly dependent on 
intracellular trafficking (Feng et al. 2006; Hunn et al. 2015). According to the 
proposed MT-stabilizing effect of parkin (Yang et al. 2005), its mutations are 
expected to impact on MT system. Recently, it has been shown that MT 
destabilization and unbalance of the α-tubulin PTMs occur in human fibroblast 
derived from PD patients carrying PARK2 mutations (Cartelli et al. 2012). 
Moreover, further evidence comes from a very recent work by Ren et al. (Ren 
et al. 2015) that has been performed in iPSC-derived dopaminergic neurons 
which were generated from PARK2-linked PD patients, and that reported the 
significant reduction in MT stability and neuronal processes complexity. The 
genetic manipulation via over-expression of wild type parkin or 
pharmacological treatment with taxol rescued the control phenotype in both 
human fibroblast and iPSC-derived dopaminergic neurons. This process seems 
to be mediated by MAP kinase signaling pathway (Ren et al. 2009) which, in 
turn regulates MT stability through the modulation of α-tubulin PTMs. 
Here, we demonstrated that Q311X mutation induced an enrichment of deTyr 
tubulin and a concomitant decrease of Tyr tubulin, which are associated with 
stable and dynamic MTs pool, respectively, within dopaminergic neurons of 6 
weeks old mice. Most likely, this over-stabilization effect could be due to a 
dominant gain of a toxic novel function of the mutant protein. An alternative 
explanation is that dopaminergic neurons attempt to balance or counteract the 
depolymerizing insult, through the accumulation of tubulin PTMs that protect 
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MTs from depolymerization, such as deTyrosination or acetylation (Cartelli & 
Cappelletti 2016). 
Looking at the multiple cellular culprits involved in neurodegeneration, 
autophagy and mitochondria dysfunction are intensively investigated. In 
contrast to other PARK2 mutations, recently, Q311X it has been recently 
reported to impact the autophagic pathway at the level of lysosomal function 
(Siddiqui et al. 2015). Several studies suggest that impaired mitochondria 
underpin PD pathology (Yao and Wood 2009; Malkus et al. 2009); parkin is 
linked to PINK1 and acts in the same pathway to remove damaged 
mitochondria, via mitophagy (Narendra et al. 2008). The same pathway is also 
implicated in mitochondrial dynamics that includes fusion and fission 
processes. Loss of parkin protein in Drosophila results in swollen mitochondria 
in flight muscles and dopaminergic neurons; this phenotype suggests that the 
balance of fission to fusion is pushed towards the fusion (Clark et al. 2006; Park 
et al. 2006). In contrast, in mammalian cells PINK1/parkin pathway results to 
be pro-fusion, even if its role is still controversial (Yu et al. 2011). Recently, it 
has been demonstrated also a functional interplay between parkin and DRP1 in 
mitochondrial fission and clearance (Buhlman et al. 2014). Because of these 
evidences, we checked for defect in mitochondrial dynamics in PARK2-Q311X 
mice. Biochemical analysis of protein involved in fusion and fission (MFN2 
and DRP1) did not show any change. Our data suggest that Q311X mutation in 
parkin did not affect the correct execution of mitochondrial fusion and fission 
processes, at least in young mice. 
It is commonly assumed that impairment in axonal transport is a key 
pathological event in neurodegeneration (Millecamps & Julien 2013). The 
accumulation of specific proteins, which characterizes many neurodegenerative 
diseases, impacts on axonal transport, but is still subject of debate whether such 
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accumulation could be the cause or a byproduct in the pathogenic pathways. 
Since axonal transport is a MT-dependent process, it is crucial to understand 
whether the dysfunction of MT system could drive the transport impairment in 
disease models. Among the neurodegenerative disorders, intracellular 
trafficking is altered in PD through the dysfunction of dopaminergic pathway 
(Hunn et al. 2015). PINK1/parkin pathway regulates mitochondria transport, 
promoting the degradation of Miro, a protein that allows mitochondria 
interaction with MT. Thus, this pathway leads to the dissociation of kinesin 
motors from mitochondria and the subsequently block of anterograde transport 
(Itoh, et al. 2013). Interestingly, the unbalance in α-tubulin PTMs precedes the 
impairment of the mitochondrial axonal transport in PC12 cells and in MPTP-
treated mice (Cartelli et al. 2010; Cartelli et al. 2013). Based on these 
evidences, we supposed that a similar scenario could occur in PARK2-Q311X 
mice. Indeed, 16 weeks old PARK2-Q311X mice, which displayed the 
significant reduction in deTyr tubulin, did not show any impairment in the 
mitochondrial axonal transport. Indeed, we cannot exclude that older mice 
might display this phenotype before any sign of dopaminergic cell loss occurs. 
However, the earlier increase of TH (Figure 3) in the cell bodies observed in the 
Substantia nigra, could be due to the block of anterograde transport of TH-
positive vesicles along the axons, other than to the increase of TH synthesis as a 
compensative mechanism of dopaminergic neurons implicated in 
neurodegeneration (16 months of age). Further work will be certainly needed to 
deeper investigate the axonal transport in PARK2-Q311X mice, looking, for 
example, at the motor protein kinesin-1, which is highly expressed in neuronal 
cells and whose recruitment to MTs sustains axonal transport and is regulated 
by tubulin PTMs (Reed et al. 2006; Konishi & Setou 2009). 
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Collectively, our results show that parkin modulates tubulin PTMs in rodent 
experimental model of PD and, interestingly, that MT dysfunction occurs very 
early thus suggesting the pivotal role of this cytoskeletal element in PD 
pathogenesis. 
Future work will be focused on our understanding of signalling pathways 
involved in MT dysfunction in PD neurodegeneration, and also the molecular 
mechanisms underlying the interplay between parkin and MTs system. 
 
 
MATERIALS AND METHODS 
 
Animals  
Female wild type and PARK2-Q311X (Lu et al. 2009) were kindly gifted by Dr. 
Fasano S. (Institute of Experimental Neurology, division of Neuroscience, 
IRCSS-San Raffaele Scientific Institute, Milano) and used for all experiments. 
Mice were generated by interbreeding Q311X mutant FVB with wild type C57 
Black mice to obtain heterozygous offspring with respect to the PARK2-Q311X 
transgene and, non transgenic littermates were used as controls. 
Their genotype was screened through PCR-based genotyping using the 
following primers: Transgene Forward 5'-ATG GAC TAC AAA GAC GAT 
GAC GAC AAG-3', Transgene Reverse 5'-ATT CTG CAC AGT CCA GTC 
ATT CCT C-3', Internal Positive Control Forward 5'- CTA GGC CAC AGA 
ATT GAA AGA TCT-3' and Internal Positive Control Reverse 5'- GTA GGT 
GGA AAT TCT AGC ATC ATC C-3'.Mice were host under environmentally 
controlled conditions (room temperature = 22°C, humidity = 40%) on a 12-h 
light/dark cycle with food and water ad libitum and in pathogen-free conditions. 
All procedures were conformed to Italian law (D. Lgs n° 2014/26, 
implementation of the 2010/63/UE) and approved by the Animal Welfare Body 
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of the University of Milan and by the Italian Minister of Health.  All efforts 
were made to minimize suffering. Female mice, 6 and 16 weeks of age at the 
time of the experiment and were killed by decapitation or by transcardiac 
perfusion to perform biochemical or immunohistochemical analyses, 
respectively. 
 
Western blot analysis 
Western blot analyses were performed on protein extracts obtained from mouse 
brain tissues. To get protein samples, Corpus striatum and ventral 
mesencephalon were immediately dissected out on ice, mechanically 
homogenized and, subsequently, sonicated in SDS-PAGE sample buffer. 
Western blots were made as previously described (Cartelli et al. 2013) using the 
following antibodies: anti-Tyrosin hydroxylase (TH) rabbit IgG (ab152, 
Millipore, Darmstadt, Germany)1:600; anti-Actin rabbit IgG (A2066, Sigma-
Aldrich, Saint Louis, MO) 1:200,anti-α-tubulin mouse IgG (clone B-5-1-2, 
Sigma-Aldrich) 1:2000; anti-Tyr tubulin rat IgG (clone YL 1/2, Abcam, 
Cambridge, UK) 1:5000; anti-deTyr tubulin rabbit IgG (ab 48389, Abcam) 
1:1000; anti-Ac tubulin mouse IgG (clone 6-11B-1, Sigma-Aldrich) 1:10000; 
anti-Δ2-tubulina rabbit IgG (Millipore) 1:5000; anti-DRP1 rabbit IgG (clone 
D6C7, Cell Signaling, Danvers, MA,USA) 1:1000; anti-MFN2 rabbit IgG 
(clone D2D10, Cell Signaling) 1:2000; anti-porin rabbit IgG 
(VDAC1/porinab15895, Abcam) 1:2000.Membranes were washed for 30 min 
and incubated for 1 h at room temperature with the appropriate secondary 
antibodies: HRP donkey anti-mouse IgG (Pierce, Rockford, IL), HRP goat anti-
rat IgG (Sigma-Aldrich), or HRP goat anti-rabbit IgG (Pierce). 
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To determine protein concentration of total brain lysate the bicinchinonic agent 
reagent assay (Micro BCA, Pierce) was used and compared with a standard 
curve of bovine serum albumine. 
Immunostaining was revealed by enhanced chemiluminescence (Super-Signal 
West Pico Chemiluminescent, Pierce). Acquisition and quantification were 
performed by ChemiDoc and Image Lab software (Bio-Rad, Hercules,CA). 
 
Immunohistochemistry and confocal analysis 
A cohort of PARK2-Q311X and wild type controls littermates, were 
anesthetized with chloralium hydrate (320 mg/kg, i.p.) via intraperitoneal 
injection and transcardially perfused with 4% paraformaldheyde (PFA) in 0.1 
M phosphate buffer, pH 7.4. Mouse brains were removed and post-fixed for 3 h 
in 4%PFA in agitation at room temperature. Brains were stored in 0.1 M PB 
plus sodium azide (NaN3) at 4°C and were cut with a Vibratome (VT1000S, 
Leica). Sagittal sections (50 μm thick) were washed once in 0.1 M PB plus 
NaN3 and incubated with 0.05 M NH4Cl in 0.01 M PBS pH 7.4 (0.15 M NaCl, 
2mM KH2PO4, 8mM Na2PO4) for 30 min at room temperature to block the 
aldehydic groups. After three 5 min washes in 0.01 M PBS, the sections were 
incubated with 1% bovine serum albumin, 0.2% Triton X-100 in 0.1 M PBS for 
30 min. The sections were stained with the following antibodies previously 
used for immmunoblotting: anti-deTyr tubulin rabbit IgG (1:300); anti-Tyr 
tubulin rat IgG (1: 500); anti-Ac tubulin mouse IgG (1: 500); anti-
VDAC1/porin rabbit IgG (1:300). Each sagittal section was concurrently 
immunostained with anti-TH antibody to identify the dopaminergic neurons. 
For staining of dopaminergic neurons, we used anti-TH mouseIgG (clone 
LNC1, Millipore, Darmstadt, Germany) 1:200 or anti-TH rabbits IgG1:200 
(Millipore) antibodyas appropriate. As secondary antibodies we used 
19 
 
AlexaFluorTM 568 donkey anti-mouse IgG (1:200), Alexa FluorTM488 goat anti-
rabbit IgG (1:200) and AlexaFluorTM 568 donkey anti-rat IgG (1:200) (abcam). 
Coverslips were mounted in Mowiol®-DABCO and examined with a confocal 
laser scan microscope imaging system (TCS SP5, Leica Microsystem, 
Heidelberg, Germany). Parameters were kept constant for all acquisitions to 
compare the fluorescence intensity between the two groups.  
Quantification of the fluorescence intensity for TH, tubulin PTMs and VDAC 
staining was performed within cell body of the dopaminergic neurons in the 
Substantia nigra, within their terminals in the Corpus striatum and in the fibers, 
using the appropriate module of NIH ImageJ software. 
 
Immunohistochemical analysis of tyrosine hydroxylase-positive terminals 
in the Corpus striatum with DAB. 
For quantification of TH in the Corpus striatum, coronal brain sections were cut 
with a Vibratome (VT1000S, Leica) (50 μm thick) and stained with anti-TH 
rabbit IgG(Millipore).  Sections were rinsed in 0.01 M PBS containing 0.05 M 
NH4Cl and NaN3 and incubated for 30 min at room temperature. After 15 min 
wash in 0.01 M PBS, sections were treated with 1% H2O2 for 10 min to block 
endogenous peroxidase activity. After three 10 min washes in 0.01 M PBS, the 
sections were incubated in 0.01 M PBS containing normal goat serum (NGS 
1:20) and 0.2% Triton X-100 for 30 min at room temperature and, successively, 
incubated at 40C overnight with primary anti-TH antibody (1:200). After three 
10 min washes in 0.01 M PBS, sections were incubated with a secondary 
antibody anti-rabbit (DAKO EnVision 1:2). After two 10 min washes in 0.01 M 
PBS and 5 min wash with 0.05 M Tris-HCl buffer, pH 7.2, the staining was 
visualized by incubation with 3,3' diaminobenzidinetetrahydrovhloride (DAB) 
and H2O2in 0.05 M Tris-HCl buffer, pH 7.2. Sections were rinsed in 0.05 M 
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Tris-HCl buffer, pH 7.2,for 5 min and washed twice with 0.01 M PBS for 10 
min. Sections were subsequently dehydrated and mounted on slides. 
The intensity of TH fibers (expressed in optical density) in the striatum was 
measured in four slices per animal using ImageJ software. Measurements were 
performed on the total Corpus striatum or on the following four areas: dorsal, 
dorso-lateral, dorso-medial and ventral striatum (Figure 1 B). To minimize 
background noise, the intensity of the corpus callosum was subtracted to the 
intensity of the TH of the region under investigation. 
To evaluate the mitochondria distribution, the VDAC/porin signal was 
superimposed on dopaminergic fibers, using the mask tool of the Leica 
Confocal Software (Leica). We considered dopaminergic fibers any TH positive 
signal longer than 5 μm and as two distinct fibers signals separated by more 
than 10 μm. 
 
Statistical analysis and data management 
All data were expressed as mean ± S.E.M. (standard error of measurement). 
The statistical significance was assessed by Student’s t-test between the two 
groups. χ2 test was used to analyze qualitative variables.  
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LEGENDS 
 
Figure 1. PARK2-Q311X mutation does not cause the loss of dopaminergic 
fibers in the Corpus striatum. 
(A) Overview of representative micrographs of the Corpus striatum used for 
quantitative immunohistochemical analysis. The analysis was performed with 
ImageJ software in different regions of the Corpus striatum (B). The yellow 
outlines define the area of the Corpus striatum analyzed: total (a,b,c), dorsal (a 
and b) dorso-lateral (a), dorso-medial (b) and ventral (c) striatum. (C) 
Densitometric analyses of TH-positive fibers in total, dorso-lateral, dorso-
medial and ventral Corpus striatum of WT and PARK2-Q311X16weeks old 
mice. The number of mice in the experimental groups was the following: WT (n 
= 4), PARK2-Q311X (n=3). n= 4 sections for each animal. All the values are 
expressed as mean ± SEM. No significant differences were observed between 
the genotypes.  
 
Figure 2. The levels of tyrosine hydroxylase do not change in ventral 
mesencephalon and in Corpus striatum of PARK2-Q311X mice. 
Representative western blot and densitometric analysis of tyrosine hydroxylase 
(TH) and actin on ventral mesencephalon (A) and Corpus striatum (B) protein 
extracts of wild type (WT, grey bars) and PARK2-Q311X mice (black bars) of 
different ages (6 and 16 weeks). The level of TH was normalized on the level of 
actin, in the respective sample, and is expresses as fold change on WT level. All 
the values are expressed as mean ± SEM. The number of mice in the 
experimental groups was the following: WT (n=8) and PARK2-Q311X (n=6) 
for the 6 weeks old mice; WT (n=5) e PARK2-Q311X (n=5) for the 16 weeks 
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old mice. No significant differences were observed between the genotypes in 
both brain regions at the two different time points. 
 
Figure 3. The levels of tyrosine hydroxylase increase within dopaminergic 
neurons in PARK2-Q311X mice. 
(A) Representative confocal images of sagittal sections showing dopaminergic 
neurons in the Substantia nigra, Corpus striatum and nigrostriatal pathway of 
PARK2-Q311X and wild type (WT) littermates of different ages (6 and 16 
weeks old).  Immunostaining represents tyrosine hydroxylase (TH). Scale bar, 
20 μm. Analysis of fluorescence intensity of TH staining in the Substantia nigra 
(SN), Corpus striatum (ST) and nigrostriatal pathway (NP) of 6 (B) and 16 
weeks old mice (C). The number of mice in the experimental groups was the 
following: WT (n=4) and PARK2-Q311X (n=4) for the 6 weeks old mice; WT 
(n=4) and PARK2-Q311X (n=3) for the 16 weeks old mice. n= 2 sections for 
each animals. *p<0.05 according to Student’s t-Test. All the values are 
expressed as mean ± SEM. 
 
Figure 4. PARK2-Q311X mutation affects the levels post-translational 
modifications of tubulin (PTMs) in ventral mesencephalon.  
Representative western blot and densitometric analysis of Acetylated (Ac Tub), 
Tyrosinated (Tyr Tub), deTyrosinated (deTyr Tub) and delta 2 (Δ2 Tub) tubulin 
in ventral mesencephalon (A) and Corpus striatum (B) protein lysates of wild 
type (WT, grey bars) and PARK2-Q311X (black bars) at different ages (6 and 
16 weeks). The levels of α-tubulin PTMs were normalized on the level of total 
α-tubulin (α Tub) in the respective sample. The number of mice in the 
experimental groups was the following: WT (n=8) and PARK2-Q311X (n=6) 
for the 6 weeks old mice; WT (n=5) e PARK2-Q311X (n=5) for the 16 weeks 
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old mice. *p<0.05 according to Student’s t-Test. All the values are expressed as 
fold change on wild type level (mean ± SEM). 
 
Figure 5. PARK2-Q311X mutation affects the level of Tyr tubulin in the 
dopaminergic neurons of Substantia nigra. 
(A) Representative confocal images of sagittal sections showing dopaminergic 
neurons in the Substantia nigra (SN), Corpus striatum (ST) and nigrostriatal 
pathway (NP) of PARK2-Q311X and wild type (WT) littermates of different 
ages (6 and 16 weeks old). Green signal represents tyrosine hydroxylase (TH) 
immunostaining and the blue signal Tyr tubulin. Scale bar, 20 μm. Analysis of 
fluorescence intensity of Tyr tubulin staining inside dopaminergic neuron in all 
the brain areas of 6 (B) and 16 weeks old mice (C). *p<0.05 according to 
Student’s t-Test performed on rough data. All the values are expressed as mean 
± SEM (n = 2 sections for each mouse from 3-4 mice per group). 
 
Figure 6. PARK2-Q311X mutation affects the level of deTyr tubulin in the 
dopaminergic neurons of Substantia nigra. 
(A) Representative confocal images of sagittal sections showing dopaminergic 
neurons in the Substantia nigra (SN) and Corpus striatum (ST) of PARK2-
Q311X and wild type (WT) littermates of different ages (6 and 16 weeks old). 
Red signal represents tyrosine hydroxylase (TH) immunostaining and the green 
signal deTyr tubulin. Scale bar, 20 μm. Analysis of fluorescence intensity of 
deTyr tubulin staining inside dopaminergic neurons in all the brain areas of 6 
(B) and 16 weeks old mice (C). *p<0.05 according to Student’s t-Test 
performed on rough data. All the values are expressed as mean ± SEM. (n = 2 
sections for each mouse from 3-4 mice per group). 
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Figure 7. PARK2-Q311X mutation does not alter mitochondrial dynamics. 
Representative western blot and densitometric analysis of dynamin related 
protein 1 (DRP1) and mitofusin 2 (MFN2) on lysates of ventral mesencephalon 
(A) and Corpus striatum (B) of wild type (WT, grey bars) and PARK2-Q311X 
(black bars) mice of different ages (6 and 16 months). The level of total proteins 
was normalized on the level of voltage dependent anion channel (VDAC) in the 
respective sample. The number of mice in the experimental groups was the 
following: WT (n=8) and PARK2-Q311X (n=6) for 6 weeks old mice; WT 
(n=5) and PARK2-Q311X (n=5) for 16 weeks old mice. Data are expressed as 
fold change of wild type (mean ± SEM). 
 
Figure 8. The axonal mitochondrial transport is not altered in PARK2-
Q311X mice. 
(A) Representative confocal images showing the different distribution of 
mitochondria (VDAC/porin, white signal) within dopaminergic fibers (TH, red 
signal). Arrowhead indicates a fibre with a homogeneous distribution of 
mitochondria (left image), whereas arrow indicates a fibre with a scattered 
distribution of mitochondria (right image). Scale bar, 5 µm. (B) Histogram 
representing the percentage of dopaminergic fibers displaying a homogeneous 
distribution of mitochondria or fibers with scattered distribution in wild type 
(WT, grey bars) and PARK2-Q311X (black bars) mice of 16 weeks of age. (C) 
Analysis of fluorescence intensity of VDAC/porin inside the Substantia nigra 
(SN) and Corpus striatum (ST) of wild type (WT) and PARK2-Q311X of 16 
weeks of age (n = 2 sections for each mouse from 3-4 mice per group). 
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Figure S1. Ac tubulin is not altered in dopaminergic neurons of 
nigrostriatal pathway in PARK2-Q311X mice. 
(A) Representative confocal images of sagittal sections showing dopaminergic 
neurons in the Substantia nigra (SN), Corpus striatum (ST) and nigrostriatal 
pathway (NP) of PARK2-Q311X and wild type (WT) littermates of different 
ages (6 and 16 weeks old). Green signal represents tyrosine hydroxylase (TH) 
immunostaining and the red signal Ac tubulin. Scale bar, 20 μm. Analysis of 
fluorescence intensity of TH staining in all the brain areas of 6 (B) and 16 
weeks old mice (C). *p<0.05 according to Student’s t-Test. All the values are 
expressed as mean ± SEM (n = 2 sections for each mouse from 3-4 mice per 
group). 
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ABSTRACT 
Loss of function mutations in the parkin gene (PARK2) lead to familial forms of 
Parkinson’s disease.Besides the well-known ligase activity, parkin seems to 
regulate other cellular functions including mitochondria homeostasis and 
microtubule stability, although the latter one has been largely neglected during 
the past years. We investigated here the role of parkin in modulating 
microtubule stabilityand mitochondria motility. We found that loss of parkin 
function leads to the imbalance of post-translationally modified tubulins, that 
are associated with differences in microtubule stability, during aging in PARK2 
knockout mice. In particular, acetylated tubulin accumulates over time both in 
dopaminergic neurons and fibers, which are localized in the substantia nigra 
and corpus striatum, respectively. These changes, in vivo, precede the alteration 
of mitochondria transport as assessed by mitochondria accumulation inside 
dopaminergic fibres. In vitro experiments confirmed that loss of parkin function 
affects mitochondria movement and showed that this abnormality depends on 
microtubule stability as it is rescued by paclitaxel, that is a well known 
microtubule stabilizer. Therefore, our work pinpoints parkin as a regulator of 
tubulin post-translational modifications and, thus, microtubule systemin 
neurons, reinforcing the hypothesis that microtubule dysfunction may be crucial  
in the pathogenesis of Parkinson’s disease. 
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INTRODUCTION 
Mutations in the parkin gene (PARK2) are tightly associated with 
neurodegeneration and lead tofamilial forms of Parkinson’s disease (PD) 
known as Autosomal Recessive Juvenile Parkinsonism (ARJP, OMIM 
#600116; Lesage and Brice, 2009).Parkin is an ubiquitin E3-ligase involved in 
the maintenance of cellular health (Shimura et al., 2000): its enzymatic activity 
promotes the degradation of misfolded and damaged proteins through the 
ubiquitin-proteasome system (UPS). In addition to its ligase activity, parkin 
seems to participate in other cellular functions (Alves da Costa and Checler, 
2012) and is able to interact with two targets involved in the pathogenesis of 
PD: mitochondria and microtubules (MTs).  
The ability of parkin to regulate mitochondrial dynamics, through the 
modulation of fusion and fission processes (Scarffe et al., 2014), is largely 
accepted. The phosphatase and tensin homolog (PTEN)-induced putative kinase 
1 (PINK1)/parkin pathway acts upstream of mitofusininducing mitochondrial 
fusion. The same pathway regulates the transport of mitochondria, promoting 
the docking of damaged ones prior to their degradation (Wang et al., 2011). 
Nevertheless, the direct involvement of PINK1/parkin in the regulation of 
mitophagy is somewhat controversial. Supportingobservations came mainly 
from cultured mammalian cells overexpressing parkin, but in induced-
pluripotent stem cell (iPSC)-derived human neurons the endogenous parkin is 
not sufficient to initiate mitophagy (Rakovic et al., 2013). Therefore, it is 
unclear whether parkininvolvementin this process really is relevant in neurons 
orduring PD pathogenesis or not (Grenier et al., 2013). 
Notably, parkin not only interacts with tubulin, the building block of MTs, 
promoting its ubiquitination and degradation via UPS (Ren et al., 2003), but it 
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is also able to directly bind and stabilize MTs (Yang et al., 2005). Therefore, it 
is not surprising that PARK2 mutations or exons’ deletion destabilize MTs and 
abolish the ability of parkin to counteract theMT depolymerization induced by 
rotenone and colchicine in both murine and human midbrain dopaminergic 
neurons (Ren et al., 2009 and 2015). This process seems to be mediated by the 
regulation of MAP kinase pathway (Ren et al., 2009) which, interestingly, has 
been suggested as a possible regulator of MT system,via the modulation of 
tubulin post-translational modifications (PTMs). In agreement with these 
observations, we recently reported that PD-patient skin fibroblasts bearing 
PARK2 mutations display altered tubulin PTM patterns and reduced MT mass, 
and either MT-targeted pharmacological treatment or the overexpression of 
wild-type (WT) parkin rescues control phenotype (Cartelli et al., 2012).  
In order to clarify the effects of parkin on the MT system and MT-dependent 
functions in neurons, we look at PARK2 knock out (KO) mice and show that, in 
the absence of parkin,the equilibrium between stable and dynamic MTs is 
altered, a shift which preceeds mitochondria accumulaton, a well-accepted sign 
of axonal transport block. Afterward, using live cell imaging, we demonstrate 
that parkin-silencing accelerates MT growth and, consequently, impairs 
mitochondrial trafficking in a neuronal cell model.  
 
MATERIALS  METHODS 
Animals 
Wild type and PARK2 knock out (16) C57 Black mice (male and female)were 
purchased from Charles River (Calco, Italy) and used for all experiments. Mice 
were kept under environmentally controlled conditions (ambient temperature = 
 4 
22°C, humidity = 40%) on a 12-h light/dark cycle with food and water ad 
libitum. Mice were kept in pathogen-free conditions and all procedures 
complied with Italian law (D. Lgs n° 2014/26, implementation of the 
2010/63/EU) and were approved by the University of Milan Animal Welfare 
Body and by the Italian Minister of Health. All efforts were made to minimize 
suffering. Miceat different ages (2, 7 and 24 months) were sacrificed by 
decapitation or by transcardiac perfusion to perform biochemical or 
immunohistochemical analysis, respectively. 
Western blot analysis 
Western blot analysis was performed on protein extracts obtained from PC12 
cells or mouse brain regions, accordingly to the previously reported protocols 
(Cartelli et al., 2010; Cartelli et al., 2013). Western blots were made as 
previously described using the following antibodies: α tubulin mouse IgG 
(clone B-5-1-2, Sigma-Aldrich,Saint Louis, MO); deTyrosinated(deTyr) tubulin 
rabbit IgG (Chemicon, Temecula, CA); Tyrosinated(Tyr) tubulin rat IgG (clone 
YL 1/2, Abcam, Cambridge, UK); Acetylated(Ac) tubulin mouse IgG (clone 6-
11B-1, Sigma-Aldrich); mitofusin-2 (MFN2) rabbit IgG (clone D2D10, Cell 
Signaling Technology, Beverly, MA); dynamin-related protein-1 (DRP-1) 
rabbit IgG (clone D6C7, Cell Signaling Technology); phospho-DRP-1 (S616) 
rabbit IgG (clone D9A1, Cell Signaling Technology); VDAC1-porin rabbit IgG 
(Abcam). Membranes were washed for 30 min and incubated for 1 h at room 
temperature with HRP donkey anti-mouse IgG (Pierce, Rockford, IL), HRP 
goat anti-rat IgG (Sigma-Aldrich), or HRP goat anti-rabbit IgG (Pierce). 
Immunostaining was revealed by enhanced chemiluminescence (Super-Signal 
West Pico Chemiluminescent, Pierce). Acquisition and quantification were 
performed by ChemiDoc and Image Lab software (Bio-Rad, Hercules, CA).  
 5 
Confocal analysis  
Mice were anesthetized with chloralium hydrate (320 mg/kg, i.p.) and 
transcardially perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate 
buffer (PB), pH 7.4. Brains were removed, post-fixed 3 h in 4% PFA. Sagittal 
sections (50 µm thick) were cut with a Vibratome (VT1000S, 
LeicaMicrosystems, Heidelberg, Germany), and part of them werecryoprotected 
for long-term conservation at -20°C. Sections were stained with the following 
antibodies:deTyrtubulin rabbit IgG (Chemicon); Tyr tubulin rat IgG (clone YL 
1/2, Abcam); Ac tubulin mouse IgG and with VDAC1/porin rabbit IgG 
(Abcam). To identify dopaminergic neurons and fibres, each section was 
concurrently stained with anti-tyrosine hydroxylase (TH) antibody, made in 
mice (clone LCN1, Millipore,Darmstadt, Germany) or rabbits (Millipore) as 
appropriate. As secondary antibodies we used Alexa Fluor
TM 
568 donkey anti-
mouse IgG, Alexa Fluor
TM 
488 goat anti-rabbit IgG and Alexa Fluor
TM 
568 
donkey anti-rat IgG (Invitrogen, Waltham, MA). Samples were examined with 
a confocal laser scan microscope imaging system (TCS SP2 AOBS, Leica 
Microsystems, Heidelberg, Germany) equipped with an Ar/Ar-Kr 488 nm, 561 
nm and 405 nm diode lasers. Photomultiplier gain for each channel was 
adjusted to minimize background noise and saturated pixels and, once defined 
for control conditions, parameters were kept constant for all acquisitions. To 
estimate the overlapping area between red and green signals, analyses were 
carried out on single-plane raw images and Manders’ coefficients were 
calculated applying the JACoP plug-in (developed and reviewed by Bolte and 
Cordelieres, 2006) for ImageJ software. Quantification of the fluorescence 
inside dopaminergic neurons was performed using the appropriate module of 
the NIH ImageJ software. As previously described (Cartelli et al., 2013), to 
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evaluate the mitochondria distribution, the porin signal was superimposed on 
dopaminergic fibres, using the Mask tool of the Leica Confocal Software 
(Leica); mitochondria accumulations were identified as white pixel-containing 
areas, as thick as long, clearly separated from other white pixels. A TH-positive 
signal longer than 5 µm was considered as dopaminergic fibre, and signals 
separated by more than 10 µm were counted as two distinct fibres. 
Immuno-electron microscopy 
Mice were perfused with 4% PFA and 0.5% glutaraldehyde in PB 0.1 M as 
described for confocal analysis. Vibratome sagittal sections were incubated 
sequentially with anti-TH rabbit IgG (Millipore), biotinylated goat anti-rabbit 
IgG (Vector Laboratories, Burlingame, CA) and with avidin biotinylated 
peroxidase complex (ABC method, Vector Laboratories). After completion of 
the immunoenzymatic procedure, the visualization of reaction was performed 
using a solution of 0.075% 3-3’-diaminobenzidine tetrahydrochloride (DAB; 
Sigma-Aldrich) and 0.002% H2O2 in 0.05 M Tris-HCl buffer, pH 7.6, as 
chromogen. Next, the sections were washed in PB, osmicated, dehydrated and 
flat embedded in Epon-Spurr resin between acetate foils (Aclar, Ted Pella, 
Redding, CA). Selected areas of the embedded sections were then cut with a 
razor blade and glued to blank blocks of resin for further sectioning. Thin 
sections (70 nm) were obtained withan ultramicrotome (Reichert Ultracut E, 
Leica Microsystems)and were observed with a Philips CM10 transmission 
electron microscope at 80 kv; images were acquired using a Morada Olympus 
digital camera.  
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Live cell imaging 
PC12 cells were maintained in cultures and differentiated for 3 days with NGF, 
as previously described (Cartelli et al., 2010). PC12 cells were transiently 
transfected using Lipofectamine 2000 (Invitrogen) (1:3 DNA to Lipofectamine 
ratio), with the shRNA previously reported (Helton et al., 2008; Maraschi et al., 
2014) and together with EB3-mCherry construct(Komarova et al., 2009) or 
Mito-dsRed (Cartelli et al., 2010). 3 days after transfection, cultures were 
transferred to a live cell imaging workstation composed of an inverted 
microscope (Axiovert 200M, Zeiss), a heated (37°C) chamber (Okolab, Naple, 
Italy), and a Plan neofluar 63x/1.25 numerical aperture oil-immersion objective 
(Zeiss). Images were collected with a cooled camera (Axiocam HRM Rev. 2; 
Zeiss, Oberkochen, Germany), every 6 s for the analyses of MT growth and 
every 10-15 s for mitochondrial trafficking; single movie duration was set at 1-
3 min and the total recording time did not exceed 60 min for each dish. For 
rescue experiments, cells were incubated for 2 h with 1 µM paclitaxel (Sigma-
Aldrich) dissolved in methanol. MT growth dynamics were analyzed from EB3 
time-lapse movies using plusTipTracker software (Applegate et al., 2011), 
whereas mitochondrial movement was analyzed by the Imaris software, kindly 
provided by Immagini & Computer (Bareggio, Italy).  
 
Statistical analysis and data management 
The statistical significance of genetic background or treatment was assessed by 
Student’s t-test, one-way ANOVA with Fischer LSD post-hoc testing or 2test 
when appropriate. Analyses were performed using STATISTICA software 
(StatSoft Inc., Tulsa, OK). 
 8 
RESULTS 
Loss of parkin function leads to the unbalance of α tubulinPTMs in 
knockout mice 
The majority ofpathological PARK2 mutations are loss-of-function and result in 
the absence or, at least, in an inactive form of parkin. PARK2 KO mouse is 
mouse model extensively used to investigate the effects of loss of parkin 
function (Goldberg et al., 2003; Itier et al., 2003; Oliveras-Salvàet al., 2011). 
We evaluated MT stability in Corpus striatum and Substantia nigra of WT and 
PARK2KO mice at different ages, ranging from young adult to old mice (2-24 
months). Biochemical analyses of αtubulin PTMs,which are markers of MTs 
with different stability (Janke, 2014), showed that these modifications change 
over time in PARK2 KO mice both in theCorpus striatumand in Ventral 
mesencephalon (Figure S1). Nevertheless, we observed a huge variability that 
could be due to the contribution of multiple cell types (i.e. glial cells or 
different neuronal subpopulations) which can be influenced in different ways by 
the absence of parkin. In order to get more punctual informations about the 
changes in the nigrostriatal system, we moved to immunohistochemistry and 
confocal microscopy.We analysed the distribution ofαtubulin PTMsin the 
Corpus striatum of PARK2 KO mice (Figures1a, red signals) and,to uncover 
whetherthe observablechanges of tubulin PTMscan be attributedto 
dopaminergic terminals (Figure 1a, green signal), we measured theManders’ 
parameters (Figure 1b) which are a reliable tool for the analyses of signal 
distribution and colocalization (Bolte and Cordelieres, 2006). Dopaminergic 
terminals of PARK2 KO mice showed an early decrease of Tyrosinate (Tyr) 
tubulin, the most dynamic MT pool, which isexacerbatedover time. On the 
other hand, we observed the accumulation of PTMs associated to stable MTs, as 
 9 
deTyrosination (deTyr) and Acetylation (Ac), which is highlighted by the 
increased colocalization between deTyr or Ac tubulin and tyrosine hydroxylase 
(TH) signal.This is intriguing as it suggests that th eMT cytoskeleton inside 
dopaminergic terminals of PARK2KO mice specifically loses itsdynamic 
component and accumulates stable MTs,making terminals less prone to rapidly 
reorganize. 
We then moved to the analyses of Substantia nigra and we observed a similar 
scenario (Figure 2a and 2b).Confocal analyses, and the quantification of 
fluorescence intensity inside dopaminergic neurons, showed an early 
accumulation andalater decreaseof Tyr tubulin whichoccurred specifically in 
dopaminergic neurons. Although we observed a time-dependent decrease of 
deTyr tubulin, the time course of Ac MTs is the opposite; indeed, in young 
aninal Ac tubulin is reduced in dopaminergic neurons of PARK2 KO mice but it 
is doubled at 24 months of age (Figure 2a and 2b).Taken together, our data 
uncover the ability of parkin to modulateαtubulin PTMs in vivo,which well 
agrees with aputative direct regulation of MT dynamics as we will investigate 
short after. 
Loss of parkin function impacts mitochondrial transport in knock out mice 
Axonal transport is a process which is strictly dependent on the MT system. It 
has been shown that the PINK1/parkin pathwayarrests mitochondrial movement 
to quarantine damaged mitochondria in hippocampal neurons (Wang et al., 
2011). Thus, we analysed mitochondrial transport in PARK2 KO mice, 
evaluatingthe distribution of mitochondria inside dopaminergic fibres,as 
previously described (Cartelli et al., 2013). We observed dopaminergic fibres 
with a homogeneous distribution of mitochondria as well as fibres showing 
mitochondriathat are sparse or clusteredinto varicosities (Figure 3a), a typical 
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sign of axonal transport impairment (De Vos et al., 2008).We quantified the 
different types of fibres (Figure 3b) and found no differences in mitochondria 
distribution in 2-months old mice, whereas fibres with mitochondria clustering 
significantly increased in PARK2 KO mice, starting from 7 months of age.We 
also performed qualitative ultrastructural analysis of TH-positive fibres by pre-
embedding immunocytochemistry, and observed dopaminergic axons engulfed 
by several clustered mitochondria (arrows) or withouth mitochondrial 
accumulation (arrowheads). In agreement with previous evidence (Palacino et 
al., 2004), the mitochondria of both WT and PARK2 KO mice display a normal 
gross morphology (Figure3c). To exclude that the differences in mitochondrial 
distribution were due to alteration of mitochondrial dynamics, we investigated 
well-known regulators of mitochondrial fusion and fission (Knott et al., 2008), 
namely mitofusin-2 (MFN2), dynamin-related protein-1 (DRP1) and its fission-
promoting phosphorylation on serine 616 (Figure S2). Since we did not observe 
any significant change in the levels of these proteins between WT and PARK2 
KO mice at any age studied, we concluded that parkin absencedoes not impair 
mitochondrial fusion and fission processes, at least in our in vivo model. 
Therefore, showing mitochondria clusters our data reveal a possible failure of 
axonal transport in PARK2 KO old mice. According to the evidence we thus far 
accumulated, we could hypothesize that the mitochondria accumulation 
observed in PARK2 KO mice may be directly caused by the imbalance in post-
translational regulation of tubulin, which is already noticeable in 2-months old 
PARK2 KOmice. 
Parkin regulates mitochondrial trafficking through MT dynamics  
In order to verify the hypothesis that parkin modulates MT dynamics directly 
and to investigate the interplay between MT system and mitochondrial transport 
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in depth, we carried out live cell imaginganalysis. We used parkin-silenced 
NGF-differentiated PC12 cells (Figure S3) expressing either EB3-mCherry, a 
fluorescent protein that specifically binds growing MT plus-end (Komarova et 
al., 2009), or Mito-DsRed, which enables us to follow mitochondrial movement 
(Cartelli et al., 2010). We show that parkin absence significantly accelerates 
MTgrowth (Figure 4a); furthermore, since it has no effects on the frequency of 
MT catastrophes (Figure 4b), parkin-silencing also increases the MT growing 
distance (Figure 4c). At the same time, parkin absence speeds up the 
anterograde velocity of mitochondrial transport (Figure4d), with no effects on 
the retrograde one (Figure 4e); noteworthy, silenced cells display a higher 
fraction of mitochondria moving towards the soma (Figure 4f), meaning that 
parkin absence causes a disorientated mitochondrial trafficking. Therefore, to 
ascertain whether the mitochondrial motility defects were strictly related to 
alterations in the MT system, we performed rescue experiments using the MT-
stabilizing agent paclitaxel, which is able to reduce dynamics at MT plus-ends 
(Ganguly et al., 2010). As shown in Figure 4, paclitaxel restores the 
physiological MT-growth rate and, very interestingly, rescues mitochondria 
transport defects, reverting the direction of mitochondria movement and 
slowing down its velocity. Altogether, our data pinpoint that parkin directly 
regulates MT dynamics and, in turn, modulates mitochondrial trafficking in 
cells.  
 
DISCUSSION 
As for other PD-related proteins, the functional role of parkin is somewhat 
controversial. It is clearly related to the protein degradation system, via its 
ubiquitin-ligase activity (Shimura et al., 2000), and to mitochondrial 
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homeostasis (Scarffe et al., 2014).On the other hand, although the ability of 
parkin to modulate the MT system was proposed many years ago (Feng et al., 
2006), it remained largely neglected. Here, we have first demonstrated that 
parkin is involved in the regulation of MT system and precedes mitochondrial 
accumulation during mouse aging. Using a parkin-silenced cell system, we have 
next demonstrated that parkin modulates MT dynamics speeding up MT growth 
and causes the impairment of mitochondrial transport. 
We have shown that parkin balances tubulin post-translational modifications 
and directly modulates MT growth. In accordance with the proposed MT-
stabilizing effect of parkin (Yang et al., 2005), its absence results in a faster MT 
growth rate (Figure4). This is consistent with the enrichment of the most 
dynamic MT pool, i.e. Tyr-MTs, we have previously shownin human 
fibroblasts (Cartelli et al., 2012) and with the increase of free tubulin recently 
observed in iPSC-derived neurons (Ren et al., 2015). As a whole, these data 
strongly suggest that parkin may be a MT stability modulator in humans, both 
in physiological and in PD contexts. Moreover, in PARK2 KO mice we 
observed an early increase in dynamic MTs followed by the specific 
accumulation of AcMT pools, whichisconsistent withour previous findings in 
MPTP-treated mice (Cartelli et al., 2013). Therefore, our data unmask parkin as 
a novel regulator of MT stability/dynamics, via the modulation of tubulin 
PTMs, which could be achived also by the regulation of tubulin modifying 
enzymes, even though a deeper investigation of that system will be necessary. 
We also demonstrated defective mitochondria distribution and transport in the 
absence of parkin, which is a possible and expected consequence of the 
alteration of MT stability. Indeed, proteins and organelles run along MT tracks 
and we have already reported that mitochondrial transport block can be the 
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result of MT dysfunctionin toxin-induced parkinsonism (Cartelli et al., 2010; 
2013). Our work adds on to the previous accrued evidence on the role of parkin, 
and reveals that parkin, a PD-related protein, physiologically modulates 
mitochondrial trafficking in a MT-dependent manner. Indeed, the analyses 
performed on brain slices and overall live cell imaging experiments on cultured 
cells revealed that the transport defects observed in the absence of parkin are 
dependent on MT dynamics,asthey are rescued by MT stabilization. It has been 
already reported that parkin regulates the trafficking of mitochondria in 
hippocampal neurons, especially of those which are damaged and have to be 
degraded, and that this process is dependent on Miro phosphorylation (Wang et 
al., 2011). In the present work, we provide further details on this physiological 
event showing that parkin is able to regulate mitochondrial mobility in vivo 
(Figure 3). Nevertheless, our results are not necessarily in contrast with those of 
Wang and colleagues (2011); indeed, Schwarz’s lab had already demonstrated 
that the Miro/Milton complex acts as an adaptor recruiting the heavy chain of 
conventional kinesin-1 (Glater et al., 2006). Kinesin-1, which is highly 
expressed in neuronal cells, is sensitive to tubulin PTMs, which modulate its 
axonal recruitment (Konishi and Setou, 2009), its preferential binding to 
specific MT subsets (Dunn et al., 2008) and the velocity of its movement (Reed 
et al., 2006). Furthermore, MT acetylation regulates the binding of WT or 
mutant forms of Leucine-Rich Repeat Kinase 2 (LRRK2) (Law et al., 
2014;Godena et al., 2014), a common cause of genetic PD, and increased level 
of Ac MTs rescues axonal transport and locomotor deficits caused by mutations 
of LRRK2 (Godena et al., 2014). Hence, the changes in tubulin PTMs and MT 
dynamics reported here could be a neuronal attempt aimed at restoring the 
correct mitochondrial trafficking in the absence of parkin. It is intriguing that 
the two proteins which are responsible of the vast majority of genetic PD, 
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parkin and LRRK2, regulate axonal transport and converge their action on Ac 
MTs. The same story is also true for MPTP which increases Ac tubulin both in 
cells and in mice (Cartelli et al., 2010; 2013) and leads to Ac MTs 
fragmentation (Kin-Han et al., 2011). Therefore, under a terapheutical light, in 
order to rescue a physiological axonal transport it could be possible the 
(re)balancing of MT acetylation, through the modulation of enzymes that 
specifically acetylate (αTAT1) or deacetylate (HDAC6) MTs (Akella et al., 
2010; Hubbert et al., 2002). 
Another important aspect to be consideredabout parkin biology is the regulation 
of mitochondrial homeostasis. The direct involvement of parkin in mitophagy is 
debated (Grenier et al., 2013; Rakovic et al., 2013), although the 
PINK1/parkinpathway has been very recently implicated in the initiation of 
local mitophagy in the distal axon (Ashrafi et al., 2014). Nevertheless, parkin is 
crucial for the maintenance of mitochondrial dynamics (Scarffe et al., 2014). It 
has also been reported that MTs participate in the regulation of this process 
(Bowes and Gupta, 2008), which isessential for modulating mitochondrial 
function and movement. In concordance with the evidence that PARK2 KO 
mice do not accumulate mitochondria with an abnormal morphology (Palacino 
et al., 2004), our qualitative ultrastructural analysis showed mitochondria with a 
conventional gross morphology (Figure 3) and the biochemical approach did 
not reveal alteration of mitochondria fusion and fission (Figure S2). 
Nevertheless, this mouse strain shows early respiratory defects in striatal 
mitochondria (Palacino et al., 2004; Damiano et al., 2014) and MT alterations 
(present data). The fact that these problems do not worsen over time can be 
explained in two ways. First, there are many pathways converging on the 
regulation of either mitochondria or MTs; therefore the early defects, due to 
parkin absence, can likely be buffered overtime. Second, mouse models have a 
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shorter lifespans than humans and this does not allow the full unmasking of this 
particular phenotype and the accumulation of sufficient defects overcoming a 
hypothetical pathological threshold. The difficulties in developing animal 
models that exhibit all the key features of human PD are further exacerbated by 
the different scales of human and rodent nigral dopaminergic neurons, whose 
axons reach an average arborization of 460 and 46 cm,respectively (Pissadaki 
and Bolam, 2013; Matsuda et al., 2009). This particular morphology gives rise 
to the selective vulnerability of these neuronal subtypes, and the different time- 
and space-scale could explain why in many animal models those neurons do not 
degenerate.Nevertheless, since MT destabilization and energy failure are 
associated with the latency period of axonal degeneration (Park et al., 2013), all 
data emerging from PARK2 KO mice, as the ones presented here, can be used 
for the analyses of the earlier eventsoccurring in degenerating dopaminergic 
neurons, eventually leading to PD. 
Altogether, our data indicatethat parkin balances stable and dynamic MTs 
through the regulation of tubulin PTMs. When this equilibrium deviates from 
physiological conditions, as we have demonstrated here in the absence of 
parkin, it results in the alteration of mitochondrial transport and, likely, in 
mitochondrial damage and axonal degeneration, mirroring the pathological 
chain of events we reported in toxin-induced parkinsonism (Cartelli et al., 
2013). 
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LEGENDS 
Figure 1. Loss of parkin function leads to the unbalance in tubulin PTMs in the 
Corpus striatum.(a) Confocal images of striatum of wild type (WT) and PARK2 
knockout (PARK2) mice of different ages (2, 7 and 24 months). Green 
represents TH staining and red signals tubulin PTMs. Scale bar, 50 µm. 
(b)Analysis of M1 parameter (Tubulins vs. TH) in striatal sections. Data are 
expressed as mean ± SEM, n= 2-3 sections for each mouse from 3-4 mice per 
group. *p<0.05 according to Student’s t-Test.Actual pvalues are: Tyr Tub, 2 
months= 0.017 and 24 months= 0.0047; deTyr Tub, 2 months= 0.034 and 7 
months= 0.001; Ac Tub, 2 months= 0.021 and 7 months= 0.04. 
 
Figure 2. Loss of parkin functionleads to the unbalance in tubulin PTMsin the 
Substantia nigra.(a)Confocal images of Substantia nigra of wild type (WT) and 
PARK2 knock out (PARK2) mice of different ages (2, 7 and 24 months). Green 
represents TH staining and red signals tubulin PTMs. Scale bar, 50 µm. (b) 
Quantification of fluorescence of Tyrosinated (Tyr Tub), deTyrosinated (deTyr 
Tub) and Acetylated (Ac Tub) tubulin inside dopaminergic neurons in the 
Substantia nigra. Data are expressed as fold change on wild type level (mean ± 
SEM, n= 2-3 sections for each mouse from 3-4 mice per group). *p<0.05 
according to Student’s t-Test, performed on rough data.Actual pvalues are: Tyr 
Tub, 2 months=0.000068 and 7 months=0.000026; deTyr Tub, 2 months= 
0.00000018, 7 months= 0.000055 and 24 months= 0.0001; Ac Tub, 2 months= 
0.000024, 7 months= 0.000026 and 24 months= 0.00006. 
 
Figure 3. Loss of parkin function impacts mitochondrial transport in vivo. (a) 
Representative confocal images showing the different distribution of 
mitochondria (Porin, red signal) inside dopaminergic fibres (TH, green signal). 
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Arrowhead indicates a fibre with an homogeneous distribution of mitochondria 
whereas arrow highlights acluster. Scale bar, 20 µm. (b) Percentage of 
dopaminergic fibres displaying an homogeneous distribution of mitochondria 
(homogeneous, white) or mitochondria accumulation (clustered, black) in wild 
type (WT) and PARK2 knockout (PARK2) mice of different ages (2, 7 and 24 
months). n= 3 sections for each mouse from 3-4 mice per group. ns= not 
significant and *p<0.05 according to 2 test. The actual p values are 7 months = 
0.000005 and 24 months = 0.0000005. (c) Electron micrographs of TH-positive 
fibres. Arrowheads indicate fibres with an homogeneous distribution of 
mitochondria whereas arrows highlight mitochondrial clusteringin both 
longitudinal (left) and trasversal (right) sectioned dopaminergic axons. Scale 
bar, 500nm. 
 
Figure 4. Parkin modulates mitochondrial trafficking via the regulation of MT 
dynamics. Box plots of the MT growth rate (a), histograms showing the 
catastrophe frequency (fCAT, b) andbox plots of the MT growth displacement (c) 
in parkin-silenced (shPARK2) and scramble-treated (shSCR) NGF-
differentiated PC12 cells, in basal conditions (CONT) or after 2 h of treatment 
with 1 µM paclitaxel (PTX). n ≥ 1500 MTs deriving from at least 10-15 cells 
per experimental group. *p<0.05 vs shSCR/CONT, #p<0.05 vs 
shPARK2/CONT according to ANOVA, Fischer LSD post hoc test. The actual 
statistical values correspond to: a) F = 40.74, p = 0.00000001, and the indivualp 
value are shSCR/PTX vs shSCR/CONT = 0.000004, shPARK2/CONT vs 
shSCR/CONT = 0.0000005 and shPARK2/PTX vs shPARK2/CONT = 
0.000002; c) F = 65.15, p = 0.00000001, and the indivual p value are 
shSCR/PTX vs shSCR/CONT = 0.008576, shPARK2/CONT vs shSCR/CONT 
= 0.000008 and shPARK2/PTX vs shPARK2/CONT = 0.000008, 
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shPARK2/PTX vsshSCR/CONT = 0.008516. Box plots of anterograde velocity 
(d) and retrograde velocity (e) of mitochondrial transport in parkin-silenced 
(shPARK2) and scramble-treated (shSCR) NGF-differentiated PC12 cells, in 
basal conditions (CONT) or after 2 h of treatment with 1 µM paclitaxel (PTX). 
n ≥ 200 mitochondria tracks per condition, deriving from at least 10-15 cells per 
experimental group. *p<0.05 vs shSCR/CONT, #p<0.05 vs shPARK2/CONT 
according to ANOVA, Fischer LSD post hoc test. The actual statistical values 
correspond to: d) F = 4.64, p = 0.00033, and the indivualp value are 
shPARK2/CONT vs shSCR/CONT = 0.0014 and shPARK2/PTX vs 
shPARK2/CONT = 0.00018.f) Histogram showing the percentage of immobile 
mitochondria (Stop, black), mitochondria forward (FWD, light grey) or 
backward (BWD, dark grey) moving and vibrating mitochondria (Vibr, white) 
in the same conditions reported in dand e. *p<0.05 vs shSCR/CONT (p value = 
0.00025), #p<0.05 vs shPARK2/CONT (p value = 0.0013) according to 2 test. 
 
Figure S1. Representative western blot (a and c) and densitometric analyses (b 
and d) of Tyrosinated (Tyr Tub), deTyrosinated (deTyr Tub) and Acetylated 
(Ac Tub) tubulin on lysates of corpus striatum(A and B) or ventral 
mesencephalon (C and D) of wild type (WT) and PARK2knockout (PARK2) 
mice of different ages (2, 7 and 24 months). The level of tubulin PTMs were 
normalized on the level of total α tubulin (α Tub) in the respective sample and 
are expressed as fold chance on wild type level (mean ± SEM, n= 3-5 
individuals per group). *p<0.05 according to Student’s t-Test, performed on the 
rough data. Actual pvaluesin b are: Tyr Tub, 2 months= 0.035 and 7 months= 
0.0099; Ac Tub, 7 months= 0.0124.Actual pvaluesin dare: Tyr Tub, 2 
months=0.039; Ac Tub, 7 months= 0.02. 
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Figure S2.Representative western blot (a and c) and densitometric analyses (b 
and d) of phospho-dynamin related protein 1 (pDRP1), dynamin related protein 
1 (DRP1), mitofusin 2 (MFN2) on lysates of corpus striatum and ventral 
mesencephalon of wild type (WT) and PARK2 knockout (PARK2) mice of 
different ages (2, 7 and 24 months). The level of total proteins was normalized 
on the level of voltage dependent anion channel (VDAC) and the level of 
pDRP1 on total DRP1 in the respective sample. Data are expressed as fold 
chance of wild type (mean ± SEM, n= 3-5 individuals per group). 
 
Figure S3. Representative Western blot (a) and relative quantification of parkin 
(b), in PARK2-silenced (shPARK2) and scramble-treated (shSCR) NGF-
differentiated PC12 cells. The level of parkin has been normalized on the total 
amount of loaded proteins (as revealed by Comassie Blue staining).*p<0.05 
according to Student’s t-Test (p value = 0.026).  
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ABSTRACT 
Microtubule (MT) cytoskeleton is a complex network essential for neuronal 
morphogenesis and function, including neuronal plasticity and axonal transport. 
The tightly control of MT system is crucial for neuron survival and its alteration 
has been proved to be involved in many neurodegenerative diseases, such as 
Parkinson’s disease (PD). PARK2gene, whose mutation is responsible for the 
majority of Autosomal Recessive Juvenile Parkinsonism, encodes for parkin, an 
ubiquitin E3-ligase known to play multiple roles including the regulation of 
mitophagy and MT system. Here, we investigated the impact of parkin 
deficiency on neuronal differentiation, MT system and axonal transport in 
murine neurons. Morphometric analyses on primary midbrain cultures from 
PARK2 knockout (KO) and heterozygous mice showed that parkin deficiency 
interferes with the complexity of neuronal processes. To test whether this effect 
was dependent on MT dysfunction, we investigated MT dynamics using live 
cell imaging in neurons expressing mCherry-EB3, a fluorescent protein that 
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specifically binds to growing MT plus-ends. Our results showed that parkin 
absence induces a faster MT growth, making MTs more dynamic. The further 
analysis of post-translational modifications of tubulin by immunofluorescence 
showed that the level of tyrosinated tubulin, that is associated to dynamic MT 
pool, increases in neuronal cells derived from PARK2 KO mice. Finally, we 
investigated the axonal transport of mitochondria by live cell imaging. We 
found that the absence of parkin slightly increases mitochondrial velocity and 
that this effect is rescued by treating with paclitaxel, a MT-stabilizer agent. 
Collectively, these results suggest that parkin interferes with neuronal 
differentiation and impairs the axonal transport of mitochondria through the 
modulation of MT dynamics. Moreover, these data reinforce the concept that 
MT dysfunction could play a crucial role in PD progression. 
 
INTRODUCTION 
Recessive mutations in parkin gene (PARK2) are responsible for Autosomal 
Recessive Juvenile Parkinsonism, characterized by early-onset. Parkin loss of 
function is a recognized genetic mechanism in the early-onset of Parkinson’s 
disease (PD) pathogenesis, whereas the role of heterozygous parkin mutation as 
a risk factor for PD remains still controversial (Klein et al. 2007; Houlden et al. 
2012). Sometimes, asymptomatic individuals bearing PARK2 mutations in 
heterozygosis present nigrostriatal abnormalities, making the heterozygosity for 
this gene a possible risk factor for developing late-onset PD. Thus, deciphering 
the role of parkin haploinsufficiency in parkinsonism is important for a better 
understanding of disease pathogenesis progression (Klein et al. 2007).  
PARK2 gene encodes for parkin, an ubiquitin E3-ligase known to be involved 
in different pathways, including the regulation of mitochondrial homeostasis 
and MT behavior. Interestingly, it has been shown that parkin interacts with 
3 
 
MTs and, in particular, is involved in their stabilization against depolymerizing 
agents (Yang et al. 2005), other than in the ubiquitination of misfolded α/β 
tubulin heterodimers (Ren et al. 2003). MTs are dynamic components of the 
cytoskeleton and their coordinated organization and regulation are essential for 
neuronal function and morphology. Furthermore, the involvement of MT 
system impairment has been clearly proved in the context of many 
neurodegenerative diseases, such as PD (Dubey et al. 2015). Recently, it has 
been demonstrated that parkin maintains the morphological complexity of 
human midbrain derived-iPSc neurons from PD patients through its MT-
stabilizing effect (Ren et al. 2015). Noteworthy, parkin PD-linked mutants 
reduce the complexity of neuronal processes and promote MT destabilization 
whereas the overexpression of wild-type parkin significantly increases MT 
stability and rescues the morphological defects due to mutant parkin, the same 
effect obtained by treating the cells with MT-stabilizing taxol. According to this 
study, Cartelli and colleagues (2012) previously demonstrated that skin 
fibroblasts derived from PD patients, bearing PARK2 mutations, displayed an 
altered MT stability. Notably, MT-stabilizing taxol treatment or the transfection 
of wild-type parkin rescued control phenotype of PD fibroblasts (Cartelli et al. 
2012). 
Consistent with these evidences, we aimed to investigate the interplay between 
parkin and MT system in murine primary neurons. Thus, we have characterized 
MT and mitochondrial system in primary neurons obtained from PARK2-
heterozygous and PARK2 KO mice (Goldberg et al. 2003). Although the 
current PARK2-KO model does not exhibits dopaminergic neurodegeneration, 
the cardinal feature of PD pathology, and shows only some abnormalities in the 
nigrostriatal pathway, it represents a good model to investigate the earliest 
changes that might occur due to parkin deficiency (Martin et al. 2011), other 
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than an useful tool to study the biological role of parkin protein, and in 
particular for our purpose, its interplay with MT cytoskeleton.  
The dysregulation of axonal transport could be a reliable consequence of the 
alteration of MT stability (Cartelli et al. 2013). Mitochondrial transport is 
fundamental for neuron and defects in this process has been linked to energy 
failure and, consequently, implicated in the pathogenesis of neurodegenerative 
diseases (Itoh et al. 2013). Moreover, parkin together with phosphatase and 
tensin homolog (PTEN)-induced putative kinase 1 (PINK1), arrest 
mitochondrial transport via degradation of Miro protein (Wang et al. 2011). 
Here we found that parkin interferes with neuronal differentiation and controls 
MT stability, through the modulation of tubulin PTMs and MT dynamics, in 
neurons. In addition, we revealed that mitochondrial axonal transport is altered 
in neurons derived from PARK2 KO mice and, specifically, parkin absence 
speeds up mitochondrial axonal transport. On the ground that the treatment with 
a stabilizer-MT agent (taxol) speeds down the mitochondrial velocity to the 
control level, we state that parkin regulates axonal transport of mitochondria in 
a MT-dependent way. Collectively, these data reinforce the concept that MT 
dysfunction could play a crucial role in PD progression. 
 
 
RESULTS 
 
Parkin deficiency interferes with neuronal differentiation  
The complexity of neuronal processes is a prerequisite for neurons to form 
connections among them and, interestingly, parkin maintains morphological 
complexity of human neurons by stabilizing MTs (Ren et al. 2015).We looked 
at the impact of parkin deficiency on the neuron morphology using primary 
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midbrain neurons from PARK2 KO (PARK2-/-), heterozygous (PARK2+/-) and 
wild-type (PARK2+/+) mouse embryos at E12.5. Their genotype was screened 
using PCR-based technique. Midbrain cultures were daily observed by phase-
contrast microscope and morphometric analyses were performed in selected 
randomly fields, in order to calculate different parameters of neuritogenesis in 
the early phase of cell differentiation. We checked whether parkin deficiency 
could impact neuronal differentiation after 1 and 2 days of differentiation in 
vitro (DIV). Cultures obtained from PARK2-/- embryos are less differentiated 
than those isolated from wild-type embryos, at both time points (Figure 1A-
2A). The percentage of cells displaying axon outgrowth decreased in PARK2-/-
compared to wild-type cells at 1 DIV (Figure 1B) and 2 DIV (Figure 1B), 
whereas we observed a mild increase of differentiated cells in PARK2+/- cultures 
at 2 DIV (Figure 1B). This surprising difference between control andPARK2+/- 
cells could be due to the potential of the cells to compensate for the deficiency 
of parkin. Furthermore, we have measured the neurite sprouting, namely the 
emission of dynamic processes that might be followed by neurite stabilization 
and outgrowth in developing neurons. Interestingly, our analysis showed that 
the number of sprouting increased in undifferentiated cells obtained from 
PARK2-/- and PARK2+/- mice compared to the control cultures at 1 DIV (Figure 
1C), that to say in cells that are actively involved in neurite emission. As 
expected, the sprouting process is not affected at 2 DIV when the most of cells 
are differentiated (Figure 2C). Moreover, we have investigated the impact of 
parkin deficiency on the complexity of neuronal processes as measured by total 
neurite length and number of branch points. Our analysis showed that the 
average neurite length (Figure 1D-2D) and the average number of branch 
points (Figure 2E) were not significantly affected in our cultures. Based on 
these observations, we conclude that parkin deficiency affects axonal outgrowth 
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and, according to its proposed MT-stabilizing effect, increases the sprouting of 
the undifferentiated cells, a process that involved the dynamic behavior of MTs. 
 
Parkin deficiency increases microtubule dynamics in primary neurons. 
Since MTs are strictly involved in neuronal development and the proper control 
of their dynamics plays an active role in the different phases of neuritogenesis, 
we wondered whether the absence of parkin, which has been reported to 
stabilize MTs (Yang et al. 2005; Ren et al. 2009), could impact differentiation 
of primary neuronal cultures by regulating MT dynamics. To address this issue, 
we transfected primary neurons taking advantage of end-binding protein 3 
(EB3)-mCherry (Wauer and Komander 2013), a fluorescent protein that 
specifically binds to growing MT plus-ends. We visualized the neurons after 3 
days of differentiation in vitro and MT growth dynamics were analyzed from 
time-lapse movies, using plusTipTracker software, following the movement of 
the EB3 comets (Figure 3A).Our results showed that PARK2+/- and PARK2-/- 
neurons displayed an increased MT growth speed (Figure 3B) compared to 
wild-type cells (PARK2+/+). Furthermore, parkin deficiency has no effect on the 
lifetime of the comets (Figure 3D), whereas it increases the MT growing 
distance (Figure3 C). Collectively, our data pinpoint that parkin deficiency 
speeds up MT-growth, making MT more dynamic. 
 
Parkin deficiency impacts MT stability. 
Previous data indicate that, once bound to MTs, parkin reduces the efficiency of 
MT-depolyimerizing PD-toxins, such as colchicine and nocodazole, and 
protects midbrain dopaminergic neurons (Ren et al. 2009). This process seems 
to be mediated by the regulation of mitogen-activated protein (MAP) kinases 
7 
 
signaling pathway, which in turn regulates MT stability through the modulation 
of tubulin post translational-modifications (PTMs). 
Thus, to further investigate in such details MTs, we analyzed the level of 
tyrosinated tubulin(Tyr-tub), which is a PTM associated with the native form of 
α tubulin and, in particular, found in the non-assembled pool of tubulin and in 
highly labile MTs (Bulinski and Gundersen 1991). The midbrain cultures were 
fixed at 7 DIV and concurrently stained with anti-Tyr-tub and anti-tyrosine 
hydroxylases (TH) antibodies, in order to examine MT stability in whole 
midbrain cultures and specifically in dopaminergic TH-positive neurons 
(Figure 4 A). Noteworthy, the quantification of fluorescence intensity revealed 
an enrichment of Tyr-tub in PARK2-/- neurons compared to the PARK2+/- and 
PARK2+/+ genotypes in whole mesencephalic culture (Figure 4 B). Next, we 
analysed in detail dopaminergic neurons and showed that TH+ neurons display 
the same trend observed in the entire culture for Tyr-tub level although the 
limited number of neurons suitable for quantification of fluorescence made the 
sample too small for reaching a statistical significance (Figure 4C). However, 
these cultures allowed us to examine selectively the complexity of TH+ 
neurons. Thus, we performed morphometric analyses and found that the total 
neurite length, the average number of branch points and the average number of 
terminals in dopaminergic neurons at 7 DIV were not significantly different 
from the control (data not shown). Our results suggest that the absence of 
parkin leads to an increased level of Tyr-tub, likely related to more dynamic 
MTs, but does not interfere with length and complexity of neuronal processes in 
murine midbrain neurons at late stages of differentiation. 
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Parkin modulates mitochondrial axonal transport via the regulation of 
microtubule dynamics  
In order to evaluate the impact of parkin absence on intracellular transport, we 
visualized the dynamics of mitochondria and hence axonal transport using live 
cell imaging. This approach was performed on primary midbrain neurons in 5 
DIV cultures over-expressing the N-terminal mitochondrial signal sequence of 
cas2 fused to DsRed plasmid pMitoDsRed (Cartelli et al. 2010), a suitable tool 
to follow mitochondria movement along axons. We analyzed exclusively 
neuronal axons and excluded cell body and the growth cone for assessing the 
velocity of mitochondrial transport. Axonal mitochondria could be subdivided 
into four categories: immobile, vibrant, anterograde and retrograde moving. In 
neurons, mobile mitochondria (anterograde or retrograde) can become 
stationary or pause in areas that have a high energy demand and can move again 
quickly in response to physiological changes (Sheng and Cai 2016). Our results 
show that parkin absence (PARK2-/-) speeds up the velocity of mitochondrial 
axonal transport (Figure 5 A) compared to the control cells (PAR2K+/+), with a 
mild but not significant increase in anterograde or retrograde transport 
specifically (Figure 5B). Therefore, to investigate the interplay between MT 
system and mitochondrial transport in deep, we performed rescue experiments 
using a MT stabilizer agent paclitaxel (PTX). As shown in Figure 5 C, after the 
treatment with 1 µM paclitaxel for 2 hours the total velocity of mitochondria in 
PARK2-/-  (PTX) cells decreased compared to the PARK2-/- (-PTX) and to the 
control cells PARK2+/+ (-PTX). Specifically, looking at anterograde or 
retrograde transport, both the velocities speed down in PARK2-/- cells after the 
treatment with paclitaxel (Figure 5 D). Actually, the treatment decreases 
mitochondrial velocity of PARK2-/- compared also to the control cells 
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(PARK2+/+ -PTX). Probably, the effect could be due to the high concentration of 
paclitaxel that we have used for our experiments. 
Interestingly, parkin-silencing of PC12 cells speeds up the anterograde velocity 
of mitochondrial transport (Cartelli et al., to be submitted), and silenced cells 
display a higher fraction of backword mitochondria moving, meaning that 
parkin absence leads to a disorientated mitochondrial trafficking. Thus, we 
evaluate din primary neurons the percentage of vibrant, immobile and mobile 
mitochondria moving backwards or towards the soma at basal condition (PTX-) 
and after the treatment with 1µM paclitaxel for 2 hours (PTX)and, as reported 
in Figure 5 E, the results show that parkin does not cause a mitochondrial 
disorientated trafficking, at least in this cell model. Collectively, our results 
showed that parkin absence increases the mitochondrial transport velocity and 
the treatment with a MT-stabilizer agent speeds down the velocity to the control 
level, allowing us to suggest that parkin regulates axonal transport of 
mitochondria in a MT-dependent way. 
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FIGURE 5 
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MATERIALS & METHODS 
 
Animals  
Male and female wild-type and PARK2 knockout (Goldberg et al. 2003) C57 
Black mice were purchased from Charles River (Calco, Italy). Mice colony was 
obtained interbreeding heterozygous mice and gave rise to wild-type, 
heterozygous, and homozygous knockout mice at the expected Mendelian ratio. 
Their genotype was screened using PCR-based genotyping with the following 
primers: PARK2+/+ reverse: 5’-CCT ACA CAG AAC TGT GAC CTG G-3’; 
PARK2+/+forward: 5’-GCA GAA TTA CAG CAG TTA CCT GG-3’; PARK2-/-: 
5’-ATG TTG CCG TCC TCC TTG AAG TCG-3’. Mice were host under 
environmentally controlled conditions (ambient temperature = 22°C, humidity 
= 40%) on a 12-h light/dark cycle with food and water ad libitum. Animals 
were kept in pathogen-free conditions and all procedures and the study were 
carried out in accordance with Italian law (D. Lgs n° 2014/26, implementation 
of the 2010/63/EU) and were approved by the University of Milan Animal 
Welfare Body and by the Italian Minister of Health. All efforts were made to 
minimize animal suffering. Mice were killed by decapitation to perform our 
experiments. 
 
Primary mesencephalic cultures 
Primary cultures of mesencephalic neurons from C57 Black mice were prepared 
according to described protocols (Studer 2001) with some modifications. 
Ventral mesencephalon tissues were dissected from E12.5 mouse embryos and 
kept on ice in cold Phosphate-Buffered Saline (PBS) with1% of penicillin-
streptomycin,1% of gentamicin and 1μg/ml amphotericin B (EuroClone). The 
dissected parts were collected in PBS containing 0,6% glucose. 
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Tissues were incubated in Accumax (Millipore) at room temperature and after 
30 min were mechanically dissociated. The cells were resuspended in MACS 
Neuro Medium containing 1% L-glutamine, 1% penicillin-streptomycin and 2% 
of MACS NeuroBrew-21 and plated on poly-D-lysine (Millipore)/laminin 
(Sigma Aldrich) pre-coated coverslip. The cells were seeded in one drop and 
placed in a humidified 37°C, 5% CO2 incubator for 3 h to allow the attachment 
of the cells in the droplets to the coverslip. Afterwards, the culture medium is 
added. The cells were cultured in vitro and the fifty percent of the medium was 
changed every two days. 
 
Morphometric analysis 
The morphology of living cells has been evaluated by phase contrast 
microscopy at 1 and 2 days of differentiation in vitro (DIV). Random fields (at 
least 3 images for each embryo) were acquired for each well using S100 
microscope (Zeiss, Oberkochen, Germany) equipped with AxiocamHR (Zeiss) 
and then analyzed using digital image processing software (Interactive 
measurement module, Axiovision Release 4.8, Zeiss). For the analysis, the 
following four principal features of neuritogenesis were considered: the 
percentage of differentiated and undifferentiated cells, the number of neuronal 
sprouting of both undifferentiated and differentiated cells, the length and the 
number of branch points of the longest neurite for each differentiated cell. In 
detail, one cell was considered differentiated when the neurite length measured 
at least twice of the cell body diameter.  
 
Immunofluorescence and labeling 
The cells were fixed with cold methanol (-20°C) at 7 DIV for 7 min and 
incubated with the following primary antibodies: anti-Tyr tubulin rat IgG (clone 
17 
 
YL 1/2, Abcam, Cambridge, UK) 1: 500 to detect dynamic MTs, anti-tyrosine 
hydroxylase (TH) rabbit IgG (Millipore) 1:200 to identify dopaminergic 
neurons. As secondary antibodies we used AlexaFluorTM 488 goat anti-rabbit 
IgG 1:1000 and AlexaFluorTM 568 donkey anti-rat IgG (Invitrogen) 1:1000. 
The coverslips were mounted in Mowiol® (Calbiochem, San Diego, CA)–
DABCO (Sigma-Aldrich) and samples were examined with the Axiovert 200M 
microscope (Zeiss). 
 
Live cell imaging  
Primary mesencephalic cultures were transiently transfected using 
Lipofectamine 3000 (Invitrogen) (1:3 DNA to Lipofectamine ratio), with EB3-
mCherry construct (Komarova et al. 2009) or Mito-dsRed (Cartelli et al. 2010). 
According to the experimental protocols, at different days after transfection, 
cultures were transferred to a live cell imaging workstation composed of an 
inverted microscope (Axiovert 200M, Zeiss), a heated (37°C) chamber (Okolab, 
Naple, Italy), and a Plan neofluar 63x/1.25 numerical aperture oil-immersion 
objective (Zeiss). Images were collected with a cooled camera (Axiocam HRM 
Rev. 2; Zeiss), every 6 s for the analyses of MT growth and every 10-15 s for 
mitochondrial trafficking; single movie duration was set at 1-3 min and the total 
recording time did not exceed 60 min for each dish. Next, cells were incubated 
for 2 h with 1 μM paclitaxel (Sigma-Aldrich) dissolved in methanol. MT 
dynamics were analyzed from EB3 time-lapse movies using plusTipTracker 
software (Applegate et al. 2011) whether mitochondrial movement by the 
Imaris software. For the analyses of mitochondrial transport in the axons, we 
defined a ROI (region of interest) excluding the cell bodies and the growth 
cone. We have also classified the mitochondria as follows: mobile (with 
anterograde and retrograde movement), vibrant and immobile. 
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Statistical analysis and data management 
All data were expressed as mean ± SEM (standard error of measurement). 
Statistical analyses were performed using STATISTICA software (StatSoft Inc., 
Tulsa, OK). The statistical significance was assessed by Student’s t test, one-
way ANOVA with Tukey HSD, Fischer LSD post-hoc testing or χ2 test when 
appropriate.  
 
 
 
LEGENDS 
 
Figure 1. Parkin deficiency interferes with neuronal differentiation at 1 
day of differentiation in vitro. 
Morphometric analysis showed alteration of neuronal differentiation and 
increase of neuronal sprouting on primary mesencephalic cultures isolated from 
PARK2 knockout (PARK2-/-) and heterozygous (PARK2+/-) mice at 1 DIV. (A) 
Representative phase-contrast micrographs of mesencephalic cultures at 1 DIV. 
Scale bar, 50µm. Three principal features of neuritogenesis were considered for 
morphometric analysis. (B) The percentage of differentiated cells (black bars) 
and undifferentiated cells (white bars) are shown; *p<0.05 vs PARK2+/+ and 
#p<0.001 vs PARK2+/- according to χ2 test, (PARK2+/+, n>1000; PARK2+/-, 
n>1100; PARK2-/-, n>550). (C) The sprouting of undifferentiated cells is 
shown, *p<0.05 and **p<0.005 vs PARK2+/+ according to ANOVA, Fischer 
LSD post hoc test. The actual statistical values correspond to: F = 6,523, p = 
0,013551, and the individual p value are PARK2+/- vs PARK2+/+ = 0,004875, 
PARK2-/-vsPARK2+/+ = 0,035069 according to ANOVAFisher LSD post hoc 
test. (D) The length of the longest neurite for each differentiated cellis shown. 
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Figure 2. Parkin deficiency interferes with neuronal differentiation at 2 
days of differentiation in vitro. 
Morphometric analysis showed alterations of neuronal differentiation on 
primary mesencephalic cultures isolated from PARK2 knockout (PARK2-/-) and 
heterozygous (PARK2+/-) mice at 2 DIV. (A) Representative phase-contrast 
micrographs of mesencephalic cultures at 2 DIV. Scale bar, 50µm. Four 
principal features of neuritogenesis were considered for morphometric analysis. 
(B) The percentage of differentiated cells (black bars) and undifferentiated cells 
(white bars) are shown, *p<0.025 PARK2+/+ vs PARK2+/-, *p<0.05 PARK2-/-vs 
PARK2+/+ and #p<0.05 vs PARK2+/- according to χ2 test (PARK2+/+, n>3800; 
PARK2+/-, n>1500; PARK+/-, n>5200 cells). In addition, the sprouting of 
undifferentiated cells (C), the length of the longest neurite for each 
differentiated cell (D), and the number of the branch points of the longest 
neurite (E) are shown. 
 
Figure 3. Parkin deficiency increases MT dynamics in primary neurons.  
(A) Representative micrographs of midbrain neurons axons, showing the EB3 
comets (EB3-mCherry). On the left is represented the axon of one transfected 
neuron (red, mCherry). Scale bar, 10 µm. The yellow arrows indicate the 
movement of the EB3 comets towards the plus end of MTs within the different 
frame (right panel, elapsed time is shown). Scale bar, 5 µm. Box plots of MT 
growth rate (B), MT growth (C), lifetime of MT (D) in primary mesencephalic 
cultures obtained from n=13/1448 tracks (PARK2+/+), n=10 cells/819 tracks 
(PARK2+/-) and n=8 cells/504 tracks (PARK2-/-) mice. B) *p< 0.05 according to 
ANOVA Tukey HSD post hoc test. C) *p< 0.05 according to ANOVA, Fisher 
LSD post hoc test. All values are expressed as mean ± SEM. 
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Figure 4. Parkin deficiency impacts MT stability. 
(A) Primary mesencephalic cultures were concomitantly stained for tyrosinated 
tubulin (Tyr-tub) and for tyrosine hydroxylase (TH), to investigate MT stability 
in whole culture and inside the dopaminergic neuron at 7 DIV. All cells were 
stained with DAPI (blue), to visualize the nucleus. Scale bar, 20 μm. (B) 
Analyses of immunofluorescence intensity performed in whole mesencephalic 
cultures: n=2 embryos (PARK2+/+); n=3 embryos (PARK2+/-); n=2 embryos 
(PARK2-/-) and selectively in the dopaminergic neurons (C). **p< 0.005 
according to ANOVATukey HSD post hoc test. All values are expressed as 
mean ± SEM. 
 
Figure 6. Parkin deficiency increases mitochondrial transport velocity in 
axon. 
(A) Mitochondria transport in the axons of PARK2-/- and control cells 
(PARK2+/+).  n=7 cells/669tracks (PARK2+/+); n=12 cells/767 tracks (PARK2+/-); 
n=13 cells/1021 tracks (PARK2+/-). *p<0.05 according to Student’s t-Test. (B) 
Anterograde velocity and retrograde velocity of mitochondrial transport in 
PARK2-/-and PARK2+/+ axons. (C) Axonal transport of mobile mitochondria, at 
basal conditions (-PTX) or after 2 h of treatment with 1 μM paclitaxel (PTX). 
*p< 0.05 vs PARK2-/- (-PTX)/ PARK2 +/+ (-PTX); **p< 0.0001 vs PARK2-/- 
(PTX)/PARK2+/+ (-PTX); #p<0.0001 PARK2-/- (PTX) vs PARK2-/- (-PTX) 
according to ANOVA, Tukey HSD post hoc test. (D) Anterograde and 
retrograde mitochondrial velocities in the axons, at basal condition (-PTX) or 
after 2h of treatment with 1 μM paclitaxel (PTX). **p<0.01 vs PARK2-/- 
(PTX)/PARK2-/- (-PTX) and #p<0.0001 for anterograde and retrograde 
movement according to ANOVA Tukey HSD post hoc test. (E) Histogram 
representing the percentage of immobile, vibrant and anterograde or  retrograde 
moving mitochondria before (PTX-) and after 2 h of treatment with 1 μM 
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paclitaxel (PTX), while the table (right) reports the percentage values for the 
different categories. 
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Abstract
Microtubules (MTs) are dynamic polymers consisting of α/β tubulin dimers and playing a plethora of roles
in eukaryotic cells. Looking at neurons, they are key determinants of neuronal polarity, axonal transport
and synaptic plasticity. The concept that MT dysfunction can participate in, and perhaps lead to, Parkinson’s
disease (PD) progression has been suggested by studies using toxin-based and genetic experimental models
of the disease. Here, we ﬁrst learn lessons from MPTP and rotenone as well as from the PD related genes,
including SNCA and LRRK2, and then look at old and new evidence regarding the interplay between parkin
and MTs. Data from experimental models and human cells point out that parkin regulates MT stability and
strengthen the link between MTs and PD paving the way to a viable strategy for the management of the
disease.
Introduction
Themolecular pathways implicated in neurodegenerative dis-
orders are gradually being elucidated and several contributing
factors have been identified. To date, aetiopathogenic mech-
anisms in Parkinson’s disease (PD) converge on accumulation
of aberrant or misfolded proteins, mitochondrial injury,
and oxidative/nitrosative stress, making PD a multifactorial
disease [1,2]. However, the primary degenerative events
remain unclear, thus making it really hard to develop an
efficient therapy for this devastating disorder.
PD is a progressive neurodegenerative disorder that is
characterized by tremor, muscular rigidity and bradykinesia,
with a prevalence of 2–5% in the population aged 60 years,
worldwide. PD can be defined in biochemical terms as a
dopamine-deficiency state resulting from loss of dopamine
neurons in the substantia nigra pars compacta accompanied
by characteristic intraneuronal protein inclusions, termed
Lewy bodies. On these grounds, starting in the 1950s, the
strategy for treating PD has been to restore the dopamine
concentrations in the brain by administering pharmacological
treatment. However, thanks to a huge amount of clinical and
basic research work, a redefinition of PD as a multiorgan
disease has been proposed recently and novel therapeutic
strategies are emerging [3].
In recent years, growing attention has been dedicated to
neuronal cytoskeleton dysfunction and increasing evidence
suggests a role for the microtubule (MT) system in the
pathogenesis of neurodegenerative disorders. Mutations in
tubulin, the major constituent of MTs, have been found
Key words: microtubules, microtubule stability, microtubule-dependent functions, neurodegen-
eration, parkin, Parkinson’s disease.
Abbreviations: iPSC, induced-pluripotent stem cells; MPP+ , 1-methyl-4-phenylpyridinium;
MPTP, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MT, microtubule; PD, Parkinson’s disease.
1To whom correspondence should be addressed (email graziella.cappelletti@unimi.it).
to induce severe neurological disorders, such as peripheral
neuropathy and loss of axons in many kinds of brain
neurons [4] and, very recently, to be associated with familial
amyotrophic lateral sclerosis [5]. Moreover, defects in the
proper regulation of MT organization and stability are
tightly linked to neuronal damages. Indeed, significant
impairment in MT-associated proteins has been extensively
reported in Alzheimer’s disease, frontotemporal dementia
and other tauopathies [6] and, notably, the failure in
polyglutamilation of tubulin can dramatically lead to a rapid
neuronal cell death in an ataxia mouse model [7]. Besides
MTorganization and stability,MT-dependent functions, such
as overall axonal transport, are increasingly investigated in
the field of neurodegeneration. The intracellular transport
of organelles along an axon is a complex and crucial
process for the maintenance and function of a neuron.
Several different mechanisms including defects in the proper
organization of MTs, mutations in MT-associated proteins
andmolecularmotors, and activation ofMT-targeting kinases
act in concert and produce deficits in axonal transport
underlying several neurodegenerative diseases, as extensively
reviewed by Millecamps and Julien [8]. In addition, recent
evidence suggests that axon degeneration underlying PD
could depend mainly on the failure of axonal transport
[9].
The question arises as to whether we can reasonably
include MT dysfunction among the culprits triggering
neurodegeneration in PD or not. Here, we bear in mind
such a key question and move from a brief insight into the
basis of MT functions in neurons to the evidence that MT
dysfunction occurs in experimental parkinsonism and, finally,
to the critical discussion on the interplay between parkin
and MT system in cellular and animal models and in human
tissues.
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Microtubules and microtubule-dependent
functions in neurons
MTs are non-covalent cytoskeletal filaments, which occur in
all eukaryotic cell types from fungi tomammals. They consist
of α/β tubulin heterodimers that assemble in a head-to-tail
fashion into linear protofilaments whose lateral association
forms polarized 25 nm wide hollow cylindrical polymers.
MTs are heterogeneous in length and highly dynamic in vivo
and in vitro, undergoing cycles of polymerization and rapid
depolymerization. This ‘dynamic instability’ property was
first described in 1984 [10] as a feature that is crucial to many
MT functions. The tight regulation of their organization and
dynamics depends on the incorporation of alternative tubulin
isotypes, a highly complex and diverse set of MT-interacting
proteins, and posttranslational modifications occurring on
MTs [11].
MTs play several essential roles in cell shape acquisition
and in the performance of many intracellular processes.
Neurons are a striking example of cells in which MTs
are essential to achieve a high degree of morphological
and functional complexity. Neuronal MTs display different
orientation and dynamics in axons and dendrites, and
interact with specific associated proteins [12]. In addition,
the incorporation of tubulin isotypes and posttranslational
modifications of tubulin are selectively combined and
distributed among different subcellular compartments, thus
generating a tubulin code, that might regulate basic as well
as higher-order neuronal functions. Highly dynamic MTs
are enriched in tyrosinated tubulin and accumulate a set
of factors known as MT plus-end tracking proteins; they
are essential for rapid remodelling and reorganization in the
growth cone underlying axonal elongation during neuronal
differentiation [12] and synaptic plasticity in mature neurons
[13]. On the contrary, a high stability is favoured for MT
functions in the shaft of axons and for the preferential
binding of MT-based motors transporting membrane-bound
organelles and regulatory macromolecular complexes [12].
Neuronal MT stability is related to the accumulation of
several posttranslational modifications of tubulin including
acetylation, detyrosination, 2-tubulin, polyglutamylation
and the very recently described polyamination [14], and to
spatial gradient of tau [15].
Beyond their known conventional roles for supporting
neuronal architecture, organelle transport and synaptic
plasticity, a novel function as ‘information carriers’ has been
attributed to neuronal MTs [16]. This amazing theory posits
that both the short, stable and mobile MTs and the highly
dynamic ends of longer MTs can act as information carriers
in the neuron thanks to their ability to interact with a vast
array of proteins. Short MTs, which appear to be unusually
stable, move rapidly along axons and presumably in dendrites
as well. It is reasonable to assume that they may convey
information and signalling molecules with them. In addition,
highly dynamic regions would act as scaffolds concentrating
MT plus end tracking proteins, which, in turn, interact
with many other proteins and structures contributing to
the plasticity of the neuron, including kinases and small G
proteins that impact the actin cytoskeleton and proteins that
reside at the cell cortex [17].
Microtubule dysfunction in experimental
models of Parkinson’s disease
The concept that MT dysfunctions can participate in, and
perhaps lead to, PD progression has been suggested by
studies on toxin-based and genetic experimental models of
the disease.
Within the context of studies on PD-inducing neurotoxins,
intriguing results have been reported with N-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin
widely used as a tool for studies on sporadic PD [1],
and the herbicide rotenone. We showed that 1-methyl-4-
phenylpyridinium (MPP+ ), the toxic metabolite of MPTP,
reduces MT polymerization and interferes with dynamic
instability of MTs in vitro acting as a destabilizing factor [18].
Then, we confirmed and extended these results reporting that
MPP+ leads to MT alteration in neuronal cell and, in turn,
to mitochondrial trafficking impairment [19]. Finally, we
showed that systemic injection of MPTP to mice induces MT
dysfunction that occurs very early, before axonal transport
deficit, depletion of tyrosine hydroxylase and, ultimately,
dopaminergic neuron degeneration [20]. Moving to the
herbicide rotenone, old studies demonstrated its ability to
induce MT depolymerization in vitro [21], whereas more
recent data suggest that MT disruption may be an alternative
mechanism underlying rotenone-induced dopamine neuron
death in cellular models [22,23].
We can find further signs ofMT involvement inPD looking
at PD-linked genes. Interestingly, several independentGWAS
and meta-analysis studies have shown a genome-wide
significant association of single nucleotide polymorphisms
in the gene coding for α-synuclein (SNCA) and the MT-
associated protein tau [24]. α-Synuclein, the first protein
associated to familial form of PD [25], interacts with tubulin
with crucial consequences: the promotion of its aggregation
in fibrils [26], the interference with tubulin assembly [27] and
the recycling of monoamine transporter [28]. More recently,
MT disruption has been reported in cells overexpressing
α-synuclein [29] or following incubation with extracellular
α-synuclein [30]. In addition, the kinase LRRK2 has been
shown to interact with and to phosphorylate β-tubulin
[31,32] and tubulin-associated tau, whereas a novel role of
DJ-1 in the regulation of MT dynamics has been proposed
[33].
Although these studies provide evidences that the MT
cytoskeleton could be involved in neuronal damage caused
by PD-related proteins or toxins, very little is known about
MT dysfunction in patients. Using cybrid cell lines generated
from idiopathic PD patients, Esteves et al. [34] showed
significant alterations in MT integrity as compared with
healthy subjects. Notably, we have recently analysed primary
fibroblasts deriving from patients with idiopathic or genetic
C©The Authors Journal compilation C©2015 Biochemical Society
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PD and disclosed reduction in MT mass and significant
changes in signalling pathways related to MT stability [35].
We believe that it is not a coincidence that tubulin and
MTs represent a point of convergence in so many different
PD experimental models, thus making the study of MT
dysfunction a challenge leading to a better comprehension
of PD pathogenesis.
The interplay between parkin and
microtubules
Exonic deletions in the Parkin gene were first reported in
Japanese families with autosomal recessive juvenile-onset
parkinsonism with onset frequently occurring before the age
of 20 [36]. The Parkin gene encodes for a member of the
E3 ligase family that catalyses the addition of ubiquitin to
numerous target proteins [37]. The molecular understanding
of the regulation of parkin E3 ligase activity is emerging
[38]. However, it has been suggested that parkin, in addition
to its ligase activity, has a number of other roles including
the regulation of mitochondria dynamics and quality control
designed to preserve mitochondria integrity [39]. Most of
the supporting observations derive from mammalian cell
lines overexpressing parkin, but endogenous parkin does not
induce mitophagy in induced-pluripotent stem cell (iPSC)-
derived human neurons [40]. This raises the issue of whether
parkin involvement in this process is actually relevant in
neurons or in PD pathogenesis [41]. Very recently, it has also
been reported that parkin interacts with the kainate receptor
GluK2 subunit and regulates the receptor function in vitro
and in vivo [42].
Parkin interaction with tubulin and MTs has been
proposed many years ago and remained largely neglected
for a long time. Interestingly, parkin binds and increases
the ubiquitination and degradation of both α- and β-
tubulin [43], whose complex folding reactions are prone to
produce misfolded intermediates. In addition to its E3 ligase
activity on tubulin, however, Yang et al. [44] proposed that
parkin strongly binds tubulin/MTs through three redundant
interaction domains resulting in MT stabilization. At the
moment, we can simply speculate that the anchorage of
parkin to MTs could provide an important environment for
its E3 ligase activity on misfolded substrates that are usually
transported on MTs themselves. Further work demonstrates
that parkin protects midbrain dopaminergic neurons against
PD-causing substances, as rotenone and colchicine, by
stabilizingMTs [45]. This process seems to bemediated by the
regulation of the MAP kinase pathway, which, interestingly,
is a direct regulator of MT stability via the modulation of
tubulin posttranslational modifications.
Bringing into focus the impact of parkin on MT-
dependent functions, a reliable consequence of the alteration
of MT stability could be the dysregulation of axonal
transport. Indeed, previously, parkin has proved to regulate
the trafficking of mitochondria in hippocampal neurons,
especially when they are damaged and have to be degraded.
This process was found to be dependent on the Miro
phosphorylation [46].
Striking data coming from human cells have recently
contributed to our understanding of the interplay between
parkin and MTs strengthening interest in this aspect. We
reported that PD-patient skin fibroblasts bearing Parkin
mutations display reduced MT mass and imbalance in the
pattern of tubulin posttranslational modifications, and that
MT pharmacological stabilization or the overexpression of
wild-type parkin rescue control phenotype [39]. This is
not restricted to skin cells from patients but, interestingly,
has been confirmed in iPSC-derived neurons. Ren et al.
[47] found that the complexity of neuronal processes was
greatly reduced in both dopaminergic and non-dopaminergic
neurons from PD patients with parkin mutations and that
MT stability was significantly decreased as demonstrated by
the reduction in MTmass. Overexpression of parkin, but not
its PD-linked mutants, restored the complexity of neuronal
processes and MT mass. Notably, the MT depolymerizing
agent colchicine mirrored the effect of parkin mutations
by decreasing neurite complexity in control neurons while
the MT stabilizing drug taxol mimicked the effect of
parkin overexpression. These results strongly support the
concept that the interaction of parkin with MTs in neurons
may have an important physiological role. Thus, although
the hypothesis of the interaction of parkin with MTs is
supported mainly by studies in cellular models, it seems
to be a promising theory, which provides a mechanistic
explanation for the multiple intracellular functions and,
possibly, dysfunctions of parkin. Indeed, we are currently
undergoing the analyses of brain samples from Parkin
knockout mice; our preliminary results have shown an early
alteration of MT stability, thus confirming and expanding the
importance of parkin in modulating the MT system.
Concluding remarks
A growing body of evidence from experimental models and
human cells indicates that parkin regulates MT stability and
strengthens the link between MTs and PD. Indeed, the MT
cytoskeleton represents a point of convergence in the action
of various proteins mutated in PD and of PD-inducing
neurotoxins, suggesting that it has a major role in the onset of
the disease and providing the rationale for novel therapeutic
interventions. Thus, MT stabilizing strategies may offer an
opportunity for treating neurodegenerative diseases [48–50].
Importantly, we have recently demonstrated that this may be
true also in PD showing that Epothilone D, a MT stabilizer
drug, exerts neuroprotective effects in a toxin-based murine
model of PD [20].
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α-Synuclein is a Novel Microtubule 
Dynamase
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α-Synuclein is a presynaptic protein associated to Parkinson’s disease, which is unstructured when free 
in the cytoplasm and adopts α helical conformation when bound to vesicles. After decades of intense 
studies, α-Synuclein physiology is still difficult to clear up due to its interaction with multiple partners 
and its involvement in a pletora of neuronal functions. Here, we looked at the remarkably neglected 
interplay between α-Synuclein and microtubules, which potentially impacts on synaptic functionality. 
In order to identify the mechanisms underlying these actions, we investigated the interaction between 
purified α-Synuclein and tubulin. We demonstrated that α-Synuclein binds to microtubules and tubulin 
α2β2 tetramer; the latter interaction inducing the formation of helical segment(s) in the α-Synuclein 
polypeptide. This structural change seems to enable α-Synuclein to promote microtubule nucleation 
and to enhance microtubule growth rate and catastrophe frequency, both in vitro and in cell. We also 
showed that Parkinson’s disease-linked α-Synuclein variants do not undergo tubulin-induced folding 
and cause tubulin aggregation rather than polymerization. Our data enable us to propose α-Synuclein 
as a novel, foldable, microtubule-dynamase, which influences microtubule organisation through its 
binding to tubulin and its regulating effects on microtubule nucleation and dynamics.
Microtubules (MTs) are dynamic polymers consisting of α β tubulin dimers, which play an essential role in cell 
shape acquisition and many intracellular processes1. In large cells, such as neurons, little is known about how 
MTs can nucleate in the axonal compartment, far away from the MT-organizing center in the cell body. Further, 
to date, the regulation of the MT dynamics underlying synaptic functions is still elusive. Many MT-interacting 
proteins are believed to regulate these phenomena; for example, dispersed γ tubulin complexes are reliable nucle-
ating structures in the axon2.
Nowadays, there is increasing evidence for a direct interplay between MTs and α -Synuclein (Syn), a presynap-
tic unfolded protein widely expressed in brain tissues3. Despite the controversial issues on its physiology, Syn has 
been clearly associated with neurodegeneration. Indeed, Syn overproduction due to multiplications of the SNCA 
locus encoding for Syn and point mutations in the gene itself cause familial forms of Parkinson’s disease (PD)3. 
The underlying pathogenic mechanism is still unclear. Cytotoxicity is currently attributed to Syn oligomers4, 
whose overexpression induces MT disruption in cells5. Furthermore, tubulin is known to promote Syn fibrillation 
in vitro6, although it is not clear whether destabilization of the MT cytoskeleton potentiates7 or prevents8 Syn 
aggregation in vivo.
Even though many efforts have been devoted to the identification of a link between tubulin and Syn in patho-
logical contexts, their physiological interaction has been largely ignored. Alim and colleagues9 have revealed that 
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wild type (WT) Syn promotes MT assembly, whereas Chen and colleagues have claimed that neither monomeric 
nor oligomeric Syn influences MT polymerization in vitro10. Co-immunoprecipitation studies as well as affinity 
chromatography have also revealed a direct interaction between Syn and free tubulin11, but it is still unclear 
whether Syn forms a complex with tubulin dimers or with higher-order assemblies.
Here we analyse the interaction between Syn and tubulin and we clear up the physiological relevance of the 
interaction between Syn and MTs. We found that WT Syn undergoes a structural change upon tubulin binding, 
promoting both microtubule nucleation and dynamics. Furthermore, our data obtained with PD-related Syn 
mutants provide hints for the pathogenic mechanism in PD.
Results
Syn binds to MTs and folds upon interaction with the tubulin α2β2 tetramer. In order to investi-
gate the mechanism by which Syn regulates MT cytoskeleton and to determine whether Syn interacts with tubulin 
dimer or with higher-order assemblies, we studied the interaction between purified Syn and tubulin in vitro. First 
of all, we performed co-sedimentation assay (Fig. 1a,b, and Supplementary Fig. S1), an approach which allows 
investigating the capability of a protein to bind polymerized and stabilized MTs12, showing that Syn interacts with 
preformed MTs (Fig. 1a). The plot of [Syn]bound versus [Syn]free (Fig. 1b), which was fitted by nonlinear regression 
to a standard binding equation, enabled us to calculate an apparent Kd of 7.48 ± 1.38 μ M, which is indicative 
of loose binding between Syn and MTs. In addition, differential interference contrast (DIC) and fluorescence 
microscopy analyses confirmed that WT Syn co-polymerizes with MTs (Supplementary Fig. S2), as revealed by 
Syn staining along conventional MTs polymerized in the presence of Syn. We also verified the ability of Syn to 
co-purify with brain tubulin9; two purification batches of tubulin were analysed by western blotting using anti-
Syn antibodies and resulted to be positive for Syn staining, thus confirming that Syn co-purifies with tubulin 
(Supplementary Fig. S2). As the tubulin purification involves cycles of polymerization and depolymerization in 
conditions that should remove the majority of the MT-associated proteins13, this result reinforces the idea that 
Figure 1. WT Syn interacts with preformed MTs and tubulin α2β2 tetramer. (a) Representative Western 
blotting of Syn (0–32 μ M) recovered in the supernatant (S) or pellet (P) fraction from co-sedimentation assays 
without (Syn) or after (Syn + MTs) incubation with preformed MTs (Tub) at constant total MT concentration 
(4 μ M tubulin dimers). (b) Bound Syn plotted versus free Syn (r2 = 0.94). The data reported in the plot derive 
from at least three different replicates. (c) Nano-ESI-MS spectra of 14 μ M tubulin: the peak distributions relative 
to the tubulin dimer and the α 2β 2 tetramer are grouped by brackets, with the indication of the measured mass. 
(d) Overlay of spectra of 14 μ M tubulin (black), and a mixture of 14 μ M tubulin and 14 μ M Syn (red), in the m/z 
range 4000–5200 (α β dimer) or (e) in the m/z range 5600–7000 (α 2β 2 tetramer). The peaks corresponding to 
the α 2β 2/Syn complex are labelled by asterisks. (f) Magnification of panel e, in the m/z range 6100–6500. The 
arrows point to the peaks of the α 2β 2/Syn complex, labelled by the corresponding charge state. The measured 
mass of the complex is also indicated. In each panel, the most intense peak of each distribution is labelled by the 
corresponding charge state.
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Syn can interact also with unpolymerized tubulin11. Thus, we investigated the direct interaction between Syn 
and free tubulin dimers by using native mass spectrometry (MS) and nano-electrospray ionization (nano-ESI). 
The spectra of 14 μ M tubulin and a mixture of 14 μ M tubulin and 14 μ M Syn (black and red spectra, respectively, 
in Fig. 1c–f) reveal that Syn forms a specific complex with the tubulin α 2β 2 tetramer. The measured mass of this 
complex (217.8 kDa) was in agreement with the calculated one for a complex of two tubulin dimers (α 2β 2) and 
one Syn molecule. Moreover, the average charge (34.5+ ) of the complex is close to the expected value for a globu-
lar protein of the same mass (36.1+ )14, suggesting that the complex itself has a compact conformation. However, 
bound Syn does not necessarily have a globular conformation but it can wrap around the tubulin tetramer in an 
ordered, but extended conformation. To address this issue, we studied potential conformational changes resulting 
from tubulin/Syn interaction by far UV circular dichroism (CD). Our data confirmed that Syn is unfolded in the 
absence of the ligand, whereas an equimolar Syn/tubulin mixture gives an overall secondary structure CD signal, 
which is more intense than the sum of the signals of the two individual proteins (Fig. 2a). Moreover, the CD signal 
originating in the mixture shows a gain of signal at 220 nm, which is typical of α -helix structures. Considering 
that (i) the interaction of tubulin with ligands is widely studied and an increase in its α -helix content has never 
been observed, and (ii) Syn is a soluble, intrinsically unfolded protein which is able to adopt α -helix structure in 
adequate conditions15–17, we hypothesize that, upon its interaction with tubulin, Syn folds into a structure which 
is rich in α -helix content. Such a secondary structural transition is reminiscent of the conformational changes 
associated with the RB3-stathmin like domain (RB3-SLD) upon interaction with tubulin18 (Fig. 2b). According 
to the hypothesis that Syn/tubulin interaction induces α -helical structures in Syn, the CD spectra of Syn com-
plexed with tubulin has been extrapolated (Fig. 2a, solid black line, differential spectrum obtained by subtracting 
the tubulin spectrum from the one of the complex) and the related α -helix content estimated to 35%. It is worth 
remembering that such helical content should not reflect the amount of α -helix in a single folded molecule, but 
rather the average content of α -helix in the whole sample, taking into account both the Syn folded molecules 
which interact with tubulin and the unfolded ones remaining free in solution. The formation of a Syn/tubulin 
complex in solution, at neutral pH, has been also investigated by 1H-NMR diffusion measurements approach 
(Fig. 2c). Tubulin alone had a diffusion coefficient (D = 0.37 × 10−10 m2sec−1) consistent with the presence of α 
β dimers in solution, whereas Syn showed a value (D = 0.83 × 10−10 m2sec−1) smaller than the one expected for a 
globular ~14 kDa protein and consistent with the presence of unfolded species19. In the presence of tubulin, the 
diffusion coefficient measured for Syn significantly decreased from 0.83 × 10−10 m2sec−1 to 0.59 × 10−10 m2sec−1. 
This clearly indicates the formation of a complex between these proteins. However, since the measured value is 
actually less than that one expected for a stable 1:1 complex, it should be concluded that, at least in our conditions, 
a certain fraction of Syn still remains in its free state in solution and that the Syn molecules exchange between the 
free and bound states at a rate which is fast compared to both the NMR chemical shift and diffusion measurement 
time scales (fast exchange limit, kex < 100 sec−1). The fraction of free Syn has been estimated within the 45–55% 
range, leading to a Syn/tubulin dissociation constant between 10 and 20 μ M, which is in agreement with the data 
obtained by the co-sedimentation assay (Fig. 1).
Figure 2. WT Syn interacts with tubulin and acquires secondary structure. (a) Far UV CD spectra of 
isolated 14 μ M WT Syn (dashed black line, Syn alone), isolated 14 μ M tubulin (dashed grey line, Tub alone),  
14 μ M WT Syn in the presence of equimolar tubulin (solid grey line, Tub + Syn) and differential spectra (solid 
black line, differential spectrum, [Tub + Syn] – Tub Alone). (b) Far UV CD spectra of isolated RB3-SLD 
(dashed line, RB3 alone) and differential spectra of 7 μ M RB3-SLD in the presence of 14 μ M tubulin (solid line, 
differential spectrum, [Tub + RB3] – Tub Alone). (c) 1H-NMR diffusion coefficient measurements at 25 °C 
from 2D-DOSY projections of 27 μ M Syn (Syn), Syn/tubulin equimolar mixture ([Syn]/[TUB] = 1) and 27 μ M 
tubulin (TUB).
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Altogether, our data provide a relatively detailed insight into the binding of Syn to tubulin and MTs, demon-
strating, for the first time, the formation of a complex between Syn and the tubulin α 2β 2 tetramer, and enabling 
us to posit a Syn folding step.
Folded Syn promotes MT nucleation and increases MT dynamics. Until now, the effects of Syn on 
MT polymerization have been studied without pre-incubating Syn and tubulin dimers9,10. On the other hand, 
our CD results (Fig. 2) indicate that during the period of the analyses (performed on a time scale of 5–10 min 
at 20 °C) Syn folds. Thus, we incubated Syn for 10 min at 20 °C with tubulin in order to allow Syn conforma-
tional rearrangement prior to carefully analyse tubulin assembly kinetics using a standard tubulin:protein ratio 
of 8:1 (Fig. 3a,b). We found that Syn molecules that have not been pre-incubated with tubulin did not influence 
Figure 3. Folded Syn promotes MT nucleation in vitro. (a) Tubulin assembly was recorded over time 
by measuring the increase in absorbance variation (Δ A) at 350 nm. Tubulin (40 μ M) was polymerized in 
the absence (CONT) and in the presence of 5 μ M of naïve (Syn w/o preincubation) or preincubated (Syn 
preincubated with tubulin) WT Syn. (b) Parameters describing nucleation (P, *p = 0.031 vs CONT and 
#p = 0.002 vs Syn w/o preincubation), initial velocity (Vi, *p = 0.018 vs CONT and #p = 0.033 vs Syn w/o 
preincubation) and absorbance variation (Δ A, *p = 0.0016 vs CONT and #p = 0.028 vs Syn w/o preincubation) 
were calculated from polymerisation kinetics analysis. Values are expressed as mean ± SEM (at least five 
independent experiments). *p < 0.05 vs CONT, according to ANOVA, Fischer post hoc test. (c) Final Δ A, 
obtained at various initial tubulin concentrations, were plotted against tubulin concentration. The tubulin 
critical concentration (arrows, x-intercept of fitting lines) was calculated in the absence (CONT, black) and 
in the presence of 5 μ M WT Syn (Syn, blue). Plotted values are mean ± SEM (at least three independent 
experiments). (d) Electron microscope images of MTs assembled (40 μ M Tubulin) in the absence (CONT) or 
in the presence of 5 μ M WT Syn (Syn). Scale bar, 200 (left) and 100 nm (right). (e) MT length measurements 
during the initial phase of tubulin polymerization (40 μ M) in the absence (CONT, black) and in the presence 
of 5 μ M of WT Syn (Syn, blue). Actual p values are 5.1 × 10−14 (240 sec), 2.4 × 10−17 (360 sec) and 2.3 × 10−7 
(480 sec). (f) MT length measurements in similar conditions at steady state (*p= 3.12 × 10−13). MT number is 
at least 600 for each condition, obtained from two independent experiments. *p < 0.05 vs CONT, according 
to Student’s t-test. (g) Quantification over time of the number of MT assembled with WT Syn. Values 
(mean ± SEM) are expressed as a percentage of the control experiment (without Syn). At least 15 fields obtained 
from two independent experiments were analysed for each condition (see Supplementary Fig. S2). *p < 0.05 vs 
CONT, according to Student’s t-test, performed on the raw data. Actual p are 0.024 (6 min), 0.002 (8 min), 0.042 
(64 min).
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tubulin kinetics. By contrast, pre-incubated Syn strongly impacts MT assembly (Fig. 3a) by reducing by half the 
initial velocity of polymerization (Vi) and the MT assembly at the plateau (Δ A), as shown in Fig. 3b. Next, by 
plotting log(A(t)/A∞ ) against log(t) we extrapolated the parameter P, which is indicative of the successive steps 
during the nucleation phase20, and is significantly decreased compared to tubulin alone (Fig. 3b). The effect of 
pre-incubated Syn on P value and its concomitant ability in significantly reducing tubulin critical concentration 
(Fig. 3c), underscored the ability of folded Syn to nucleate MTs. We confirmed the presence of MTs in these 
conditions by electron microscopy and negative staining analysis (Fig. 3d). We next estimated the length and the 
number of MTs assembled in the presence of folded Syn, which revealed that Syn induces the formation of shorter 
and more abundant MTs with respect to controls (Fig. 3e–g, see also Supplementary Fig. S3). The significant 
increase of MT number perfectly agrees with the induction of MT nucleation. However, the significant reduction 
of the MT mean length also suggests that, besides stimulating MT nucleation, Syn should reduce MT elongation, 
either by slowing down MT growth rate or increasing catastrophe frequency, as strongly supported by the reduc-
tion in the initial velocity of polymerization. Notably, this would explain the decrease in total polymer mass (Δ A 
in Fig. 3a,b and Supplementary Fig. S3), which is in contrast to the expected effect of a nucleation inducer.
Thus, we used video-enhanced differential interference contrast (VE-DIC) light microscopy to clear up the 
effects of WT Syn on MT dynamics (Table 1). Tubulin (10 and 15 μ M) was assembled from purified axonemes, in 
the absence or in the presence of increasing concentrations of Syn (0–15 μ M). These protein to protein ratios are 
comparable to those observed in vivo, since the actual cellular concentration of tubulin is up to 40 μ M21 and the 
estimated presynaptic Syn concentration varies between 30 and 60 μ M in neurons22. At low tubulin concentration 
(10 μ M), Syn enhanced catastrophe frequency, 4 to 6.5-fold in comparison to the control. A similar, albeit smaller, 
effect was observed at the highest tubulin concentration (15 μ M), with a 3-fold increase in the catastrophe fre-
quency in the presence of Syn compared to tubulin alone. With the two highest Syn concentrations (10 and 15 μ M), 
we also noticed a significant increase in the MT growth rate in the presence of 15 μ M tubulin. These results would 
indicate that Syn increases MT dynamics by speeding up the growth rate and promoting catastrophe events. In 
order to confirm these data in a neuronal cell line we used differentiated rat PC12 cells, which naturally express 
rat Syn starting from 7th day of NGF treatment23. We transfected PC12 cells with a construct coding for human 
Syn and treated them with NGF for three days. As shown in Fig. 4a, parental PC12 cells lack of endogenous Syn 
whereas transfected ones express human WT Syn. First of all, we confirmed the well-known interaction of Syn 
with β III-tubulin5, either in PC12 cells overexpressing human Syn (Supplementary Fig. S4) or in human neu-
rons derived from embryonic stem cells expressing the endogenous Syn (Supplementary Fig. S5). In addition, 
we highlighted a high degree of co-localization with tyrosinated α -tubulin, which is associated with the most 
dynamic MTs. Thus, to directly investigate MT dynamics in cells, we performed live cell imaging taking advantage 
of end-binding protein 3 (EB3)-mCherry24, a fluorescent protein that specifically binds growing MT plus-ends. 
We visualized MT dynamics under basal conditions (cells kept at 37 °C) or during the MT recovering phase 
(rewarming at 37 °C), which follows a cold-treatment (30 min at 4 °C), in differentiated PC12 cells co-expressing 
EB3-mCherry and GFP-Syn or GFP alone (Fig.4). This approach shows that Syn increases the number of detecta-
ble growing MTs per neurite (Fig. 4c), even though the analysed surfaces do not change (Supplementary Fig. S6), 
and thus demonstrates that Syn favours MT (re)nucleation in cell. Moreover, Syn accelerates MT growth (Fig. 4d) 
and reduces MT lifetime (Fig. 4e). The latter observation is consistent with the enhancement of the catastrophe 
frequency reported by VE-DIC microscopy (Table 1). Altogether, our data demonstrate that, upon interaction 
Tub 10 μM Tub 15 μM
Syn 0 μM Syn 5 μM Syn 10 μM Syn 0 μM Syn 5 μM Syn 10 μM Syn 15 μM
Vgrowth (μ m/min)
1.2 ± 0.1 1.38 ± 0.5 1.08 ± 0.18 1.1 ± 0.086 1.17 ± 0.14 1.38 ± 0.14* 1.32 ± 0.24*
n = 1097 n = 362 n = 395 n = 1420 n = 663 n = 695 n = 973
Vshrinkage (μ m/min)
8.7 ± 2.24 7.35 ± 2.1 7.5 ± 1.65 11 ± 1.77 8.6 ± 2 11.7 ± 2.6 8.5 ± 2.24
n = 357 n = 209 n = 309 n = 287 n = 216 n = 298 n = 336
Fcatastrophe (min−1)
0.16 ± 0.05 1.04 ± 0.3 0.69 ± 0.17 0.09 ± 0.03 0.27 ± 0.07 0.26 ± 0.07 0.22 ± 0.06
n = 9 n = 12 n = 15 n = 9 n = 14 n = 12 n = 11
Frescue (min−1)
0.15 0.67 ± 0.33 0.33 ± 0.19 0.1 0.6 ± 0.26 0.44 ± 0.22 1.26 ± 0.44
n = 1 n = 4 n = 3 n = 1 n = 5 n = 4 n = 8
Growth Duration (s) 3327 692 1304 5797 3056 2751 2944
Shrinkage Duration (s) 382 356 537 594 512 540 380
MT number 32 14 16 41 22 25 20
Table 1. Folded Syn increases MT dynamics in vitro. Dynamic parameters were determined by VE-DIC 
light microscopy for MTs assembled from purified axonemes in the presence of tubulin (10 and 15 μ M) and 
increasing concentrations of Syn (0–15 μ M). In each condition, Syn was preincubated with tubulin prior the 
observation at 37 °C. Velocities are expressed as mean ± SEM. The total growth and shrinkage times analysed, 
as well as the number of MTs used for each condition, are given in the last three rows. Catastrophe and rescue 
frequencies were calculated by dividing the total number of events by the time spent in growth and shrinkage, 
respectively. The standard deviation is calculated by dividing Fcatastrophe or Frescue by √ n assuming a Poisson 
distribution55. (n) represents the total number of measurements for the growth and shrinkage rates, and the 
total number of observed events for the catastrophe and rescue frequencies. *p < 0.05 vs Syn 0 μ M, according to 
ANOVA, Dunnett post hoc test. Actual p are 0.005 (Syn 10 μ M) and 0.0051 (Syn 15 μ M).
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with the tubulin α 2β 2 tetramer, Syn acquires helical structure and becomes able to govern multiple steps of MT 
assembly and dynamics, such as nucleation, growth rate and catastrophe frequencies, in a purified system as well 
as in a neuronal cell model.
Syn displays sequence similarity to stathmin. Syn displays striking structural and functional similar-
ities with the tubulin-interacting protein stathmin. Both of them are about 14-15 kDa, intrinsically disordered 
proteins and capable of adopting α -helix conformation upon interaction with binding partners18,25 (Fig. 2a). It 
is noteworthy that Syn, like stathmin and RB3-SLD, interacts with the tubulin α 2β 2 tetramer and promotes MT 
catastrophes. Thus, we explored sequence similarities between Syn and the members of the stathmin family. 
Pairwise alignment of WT Syn to stathmin showed about 20% identical residues and over 50% conservative 
substitutions. Two possible tubulin-interacting domains have been proposed for Syn but the pathological point 
mutations, which impair the tubulin binding, are outside the suggested regions9,26. Therefore, searching for a 
tubulin-related physiological relevance for the region including the mutations, we decided to align two 21-residue 
stretches surrounding the residues 30 or 53 in the Syn polypeptide chain (Fig. 5). Interestingly, the fragment 
centered around Syn residue 53, in which four of the five PD-linked point mutations are clustered27, aligned to 
one of the functionally relevant regions of the stathmin family (Fig. 5, blue lines), namely the tubulin-binding 
domains28. This region displays multiple invariant residues (Fig. 5 asterisks), including the sites of the Syn patho-
logical mutations A53T and E46K (Fig. 5, red arrows), besides several other conservative or semi-conservative 
substitutions (Fig. 5, colons and dots, respectively). Furthermore, we completed the analysis in order to align the 
entire region 1–100 of Syn polypeptide chain to the stathmin-family (Supplementary Fig. S7), since we suggest 
that Syn acquires an α -helical structure (Fig. 2) and this is the domain of Syn that folds upon interaction with ves-
icle. As the two domains reported in Fig. 5 showed a good conservation, we anchored them and aligned the other 
stretches of Syn to the remaining regions of the stathmin-family. These regions display a very poor conservation 
and, thus, this result reinforces the idea that the region around the pathological mutations might be important 
for binding to tubulin and that its point mutations likely compromise Syn/tubulin interaction. All these data 
demonstrate that Syn and stathmin share physicochemical and functional properties, and the good alignment 
Figure 4. WT Syn increases MT dynamics in neuronal cells. (a) Representative western blot showing the 
levels of expression of human Syn (Syn) in 5 days NGF-differentiated control (GFP) and transfected (Syn) PC12 
cells. The antibody used (Sigma-Aldrich) recognized both human and rat Syn. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) is used as loading reference. (b) Representative micrographs of double transfected 
PC12 cells differentiated 3 days with NGF, showing the EB3 comets (EB3-mCherry, inverted contrast) and, 
in the inset, the GFP channel (GFP, grey line marks the cell boundary). The grey box indicates the area from 
which the frames of the time series were taken (elapsed time is shown). Scale bar, 5 μ m. Box plots of the 
number (c, *BASAL = 0.007, *RECOVERY = 0.005), speed (d, *BASAL = 0.02, *RECOVERY = 0.007) and lifetime 
(e, *BASAL = 0.02, *RECOVERY = 0.02) of MT growths, in each experimental condition. BASAL indicates 
cell cultures maintained at 37 °C whereas RECOVERY indicates registration during the rewarming phase after 
30 min at 4 °C. At least 30 cells were analysed per condition, for a total number of 2200 tracks, or more. *p < 0.05 
vs GFP, according to Student’s t-test. The analyses of the relative neurite’s area are reported in Supplementary 
Fig. S5.
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of the fragment 43–63 of Syn with a functionally relevant region of stathmins strongly indicates that Syn and 
proteins belonging to the stathmin-family may be involved in same biological processes, such as the regulation 
of MT cytoskeleton.
Pathological Syn mutations corrupt Syn/tubulin interaction. Having shown that four out of five 
PD-linked mutations map to the putative tubulin-binding domain of Syn (Fig. 5), these substitutions are expected 
to have a profound effect on Syn interaction with tubulin and, reasonably, on tubulin-induced folding of Syn. 
Indeed, CD analyses revealed that the A53T variant is much less sensitive than WT Syn to the structuring effect 
of tubulin (Fig. 6a, red lines) whereas the E46K mutant loses almost completely the ability to fold in the presence 
of tubulin (Fig. 6a, green lines). Although the pathological A30P mutation mapped far away from the putative 
tubulin-interacting domain we proposed (Fig. 5), this amino acid substitution has the potential to interfere with 
tubulin-induced folding of Syn, as confirmed by CD analyses (Fig. 6a, blue lines). In order to verify that mutated 
Syns used in the assays were not aggregated, thus to avoid unwanted effects on tubulin assembly, we analysed 
them by size exclusion chromatography. We observed a single peak for all the Syn corresponding to a molar mass 
of 14 kDa (Supplementary Fig. S8), which indicates the presence of monomeric Syn. Moreover, we observed that 
MTs assembled in the presence of Syn mutants (all pre-incubated with tubulin) are crowded and surrounded 
by abundant protein aggregates (Fig. 6b and Supplementary Fig. S2), which were not present at the beginning 
of the experiments (see size exclusion chromatography results, Supplementary Fig. S8) but rather are formed 
during the incubation. These aggregates should be composed of both tubulin and Syn; indeed, very few and 
small aggregates are observed both in control conditions, i.e. without adding Syn, meaning that they are made 
of tubulin, and in the presence of WT Syn (Supplementary Fig. S8). Since aggregates in the presence of mutated 
Syns (Supplementary Fig. S8) are also recognized by the Syn antibody (Supplementary Fig. S2), they should 
contain Syn. Interestingly, the aggregation propensity of the mutated Syns seems to be inversely proportional to 
their ability in folding in the presence of tubulin (Fig. 6a and Supplementary Fig. S8). Therefore, our data reveal 
that Syn mutants are much less sensitive than WT Syn to tubulin-induced folding and mainly promote tubulin 
aggregation. This could potentially impair the correct organization of the MT system impacting on the neuronal 
processes in which MTs and Syn are implicated.
Discussion
As stated by Feng and Walsh29 a decade ago: “Protein-protein interactions are a little like human relationships. 
Some are dedicated, faithful and lifelong, while other relationships are brief flings with a promiscuous variety 
of partners that may leave no lasting trace or may induce profound changes”. Here we show that the interplay 
between Syn and tubulin is a multifaceted protein-protein interaction. Indeed, their encounter triggers the struc-
tural rearrangement of Syn which, in turn, regulates the birth, the growth and the lifespan of individual MTs. 
Therefore, we set forth the hypothesis that Syn is a MT “dynamase”, a term introduced by Erent and colleagues30 
for Kinesin-8, which is able to regulate both MT nucleation and catastrophes in S. pombe, exactly what Syn does, 
regulating nucleation, growth rate and catastrophe frequency of MTs, in vitro and in cell.
MTs exhibit non-equilibrium dynamics, which depends on free-tubulin concentration. In cell systems, a con-
stant free tubulin concentration, and the presence of a multitude of MT-interacting proteins likely buffers and mit-
igates perturbations in MT dynamics, conferring a degree of robustness and homeostasis to the MT cytoskeleton31. 
Nevertheless, stressful conditions exist (i.e. neuronal aging) and under these conditions the free tubulin con-
tent may considerably change. When tubulin concentration is high, the initial response of a MT-associated 
protein will be potent and it would induce MT assembly, as we observe at the beginning of assembly kinetics 
in the presence of Syn (Fig. 3) or in VE-DIC experiments performed at high tubulin concentrations (Table 1). 
In the mechanistic model we propose, the ability of WT Syn to interact with the tubulin α 2β 2 tetramer ena-
bles Syn to fold (Fig. 7, STEP 1) and, possibly, to act as a tubulin carrier by delivering small tubulin oligomers 
(α 2β 2 tetramers), which have been recently proposed, although it is controversial, to promote MT nucleation 
and MT elongation32–34. Thus, Syn could either crosslink tubulin heterodimers, inducing nucleation (Fig.7, 
STEP 2-high [Tub]free), and/or stabilize them in a favourable orientation promoting supramolecular interactions 
involved in MT formation. As net polymerization is promoted, the free tubulin concentration drops down, mit-
igating the assembly-inducing activity of Syn, as observed at the steady state of assembly kinetics (Fig. 3) or with 
Figure 5. Syn displays sequence similarities with stathmin. Multiple alignment of Syn with four members 
of stathmin family was performed by ClustalW. Blue lines delimitate the domains of stathmin family involved 
in tubulin binding. Arrows mark the sites of Syn pathological mutations: Ala30 (green arrow), the conserved 
Glu46 and Ala53 (red arrows), His50 and Gly51 (blue arrows). Asterisks mark invariant positions, while dots 
and colons highlight semi-conservative and conservative substitutions, respectively.
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low tubulin concentrations in VE-DIC experiments (Table 1), when catastrophe stimulation prevails. How are 
these catastrophe events induced? Two possible mechanisms have been proposed for the catastrophe-promoting 
activity of stathmin35: (i) sequestering of soluble tubulin into assembly-incompetent tubulin/stathmin complexes, 
which has the same stoichiometry of Syn/tubulin complexes identified in the present study (Fig. 1), or (ii) direct 
binding of stathmin to MT ends, which would increase the frequency of switching from growth to shortening. It 
is unlikely that Syn acts by sequestering tubulin dimers, since such a phenomenon would reduce MT growth rate, 
in contrast to our observations (Table 1). We hypothesize that, once bound to the MT lattice, Syn could affect the 
whole stability of the polymer by inducing conformational changes in the intra- or inter-dimer angle and thus 
amplifying the intrinsic tendency of MTs to undergo catastrophes (Fig. 7, STEP 2-low [Tub]free). Nevertheless, 
further studies are needed to definitively solve the mechanism by which Syn promotes MT catastrophes.
Here, we also demonstrated that PD-linked Syn variants do not exhibit α -helical folding upon tubulin binding 
and induce tubulin aggregation. A30P mutation is located on the short helix of the lipid-folded Syn27, and the fact 
that the polypeptide region including this mutation is not part of the putative tubulin-interacting domain could 
explain why it is the most “benign” PD point mutation36. Conversely, the other 4 described point mutations of Syn 
(E46K, H50Q, G51D and A53T) fall inside a region corresponding to the tubulin-interacting domain of proteins 
belonging to the stathmin family. We are aware that this region maps outside the tubulin-binding regions previ-
ously proposed for the WT9,26., which seem to be unique for Syn and do not share homology with other known 
tubulin-interacting proteins. Nevertheless, the two previously reported binding domains are diverse, sharing only 
4 residues and completely excluding the region in which there are the pathological mutations. Alim and col-
leagues9, tried to justify the tubulin-aggregating effect of the A30P and A53T mutants saying that these mutations 
can alter the Syn folding, exactly what we showed here (Fig. 6). Our results propose an alternative tubulin-binding 
domain that well matches with the ones of the stathmin-like proteins, and which also includes most of the 
reported pathological mutations. Future work on pre-incubated Syn fragments will be necessary to validate this 
as tubulin-binding domain. Thus, our data provide mechanistic insights into the molecular pathology of PD, 
Figure 6. Pathological Syn mutations corrupt Syn/tubulin interaction. (a) Far UV CD spectra of 14 μ M 
mutated Syns, A30P (blue lines), A53T (red lines) and E46K (green lines), obtained with naïve proteins (dashed 
lines, alone) or by the difference between the spectrum of Syns in the presence of equimolar amount of tubulin 
minus the spectrum of tubulin alone (solid lines, differential spectrum). (b) Electron microscope images of MTs 
assembled in vitro (40 μ M tubulin) in the presence of 5 μ M of WT (WT) or mutated (A30P, A53T and E46K) 
Syns. Scale bars, 200 (top) and 100 nm (bottom).
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which would involve MT-dependent pathways. Indeed, tubulin aggregation induced by mutated Syns (Fig. 6, 
Supplementary Fig. S2, Supplementary Fig. S8 and Alim et al.9), could lead to excessive MT bundles, engulf-
ing axons and impairing intracellular transport, as previously described for other neurodegenerative disease37. 
Therefore, axonal transport disruption could be the missing link between Syn/tubulin interaction and PD. In 
accordance, a very recent paper showed that Syn oligomers, the most toxic Syn species, reduce MT stability, 
kinesin/MTs interplay and neuritic kinesin-dependent cargoes, promoting early neurite pathology5. Although 
alteration of axonal transport is considered as one of the earliest events in neurodegeneration38, we showed 
that it follows MT dysfunction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine-induced model of PD39,40. 
Hence, by affecting axonal transport, MT dysfunction may trigger the chain of events leading to PD. Accordingly, 
MT-targeted molecules have beneficial effects in both 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine-treated40 
and Syn-overexpressing41 mice and the correction of MT defects rescues control phenotype and cell homeostasis 
in PD patient derived cell lines42–44. Therefore, by providing insights into the interaction between Syn and MTs, 
our data would highlight some essential steps in neuronal function and degeneration.
Many controversial issues remain to be clarified, such as solving the puzzle of the actual naïve state of Syn: is 
it a folded tetramer45 or a labile unstructured monomer16? Nevertheless, here we have demonstrated that mon-
omeric WT Syn forms a specific complex with the tubulin α 2β 2 tetramer, acquiring a defined secondary struc-
ture. We could speculate that local accumulation (i.e. at the pre-synapse) of free tubulin dimers would change 
the equilibrium between unfolded and folded/tetrameric Syn, which may have evolved to act as a sensor of the 
tubulin dimers/MTs ratio. Thus, the increase in tubulin dimers concentration and the consequent folding of Syn 
molecules start the Syn-mediated regulation of both MT nucleation and dynamics, as we have demonstrated 
here. Therefore, we propose that Syn can be considered a MT dynamase, which potentially set MT mass at the 
pre-synapse.
Figure 7. Model for Syn/MTs interaction. Syn senses and binds free tubulin dimers forming a specific 
complex with tubulin α 2β 2 tetramer and acquiring α -helix conformation (STEP 1). Afterwards, Syn behaves 
like a tubulin deliverer promoting MT nucleation (STEP 2-High [Tub]free). When entrapped in the MT wall, Syn 
promotes MT catastrophes probably inducing changes in intra- or inter-dimer angles (STEP 2-Low [Tub]free).
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Methods
Protein purification. Tubulin was purified by two cycles of polymerization/depolymerization in high 
molar Pipes buffer13, suspended in BRB buffer (80 mM K-Pipes, pH 6.9, 2 mM EGTA, 1 mM MgCl2) and stored 
at − 80 °C. Recombinant Syn was produced and purified according to Martinez et al.46, and recombinant RB3-
SLD (kindly gifted by prof. Patrick A. Curmi, Evry University, France) was produced and purified according to 
Charbaut et al.47 (see also Supplementary information). Aliquots of Syn (in 20 mM Hepes, pH 7.4, 100 mM KCl) 
and RB3-SLD (in 10 mM Hepes, pH 7.2,150 mM NaCl) were kept at − 80 °C until needed. Each aliquot was clari-
fied by ultracentrifugation (230000× g at 4 °C for 30 min) immediately before use.
MT self-assembly. The kinetics of tubulin polymerization was followed turbidimetrically at 350 nm in a 
multimode plate reader (Infinite 200Pro, Tecan, Mannedorf, Switzerland) equipped with a temperature controller, 
as previously described48. Tubulin was diluted to different concentrations in standard assembly buffer and kept on 
ice; as WT or mutated Syns were added, the reaction was started by warming the solution at 37 °C. For the prein-
cubation, two solutions were prepared: T1, buffer with 2x glycerol and GTP and w/o proteins, and T2, with double 
of the final protein concentration but w/o glycerol and GTP. T2 was incubated 10 min at 20 °C, and the reaction 
was started mixing T1 and T2 1:1 and raising the temperature to 37 °C. Polymerization time-course was dissected 
and the kinetic parameters calculated according to Bonfils et al.20: P (number of successive steps during nucle-
ation) was determined by plotting log(A(t)/A∞ ) against log(t) and extrapolated as the pendency of the linear 
part of the resulting plot; initial velocity of polymerization (Vi) was calculated as the maximal variation of mass 
versus time (δ A/δ t); MT assembly was deduced from the extent of absorbance variation (Δ A) at the steady-state. 
The x-intercept of the linear dependence of Δ A from the initial tubulin concentration represents the tubulin 
critical concentration. To evaluate MT length and number, 2.7 μ M rhodamine-labelled tubulin (Cytoskeleton, 
Denver, CO) was included in the polymerization solutions and the reaction was stopped by addition of 0.5% 
glutaraldehyde. MTs were laid on slides and their length was measured using a digital image processing software 
(Axiovision, Carl Zeiss, Oberkochen, Germany) to analyse the images acquired with the Axiovert 200 M micro-
scope (Carl Zeiss). To assess the ultrastructure of assembled MTs, samples were fixed with 0.5% glutaraldehyde 
and then placed on Formvar-coated nickel grids, negative stained with uranyl acetate and observed with a Philips 
CM10 transmission electron microscope at 80 kV, equipped with a Morada Olympus digital camera.
Co-sedimentation assay. MTs were polymerized (from tubulin 40 μ M) 20 min at 37 °C, stabilized 10 min 
with paclitaxel (Sigma-Aldrich) and then diluted to 4 μ M. Syn (0.5–32 μ M) was incubated 20 min at 37 °C in 
the absence or in the presence of MTs and then centrifuged at 70000× g for 15 min at 25 °C. Supernatant and 
pellet were loaded on SDS-PAGE, proteins were transferred onto PVDF membranes and immunostained with 
anti-Syn rabbit IgG (Sigma-Aldrich) HRP goat anti-rabbit IgG (Sigma-Aldrich). Immunostaining was revealed 
by enhanced chemiluminescence (Super-Signal West Pico Chemiluminescent, Pierce). Quantification was per-
formed by Image J software (NIH) subtracting the background around bands. According to Ackmann et al.12, 
[Syn]bound was plotted versus [Syn]free and the data fitted by nonlinear regression to a standard binding equation 
(Equation 1) using SigmaPlot (Jandel, CA):
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Mass spectrometry. Nano-ESI-MS was performed on a hybrid quadrupole-time-of-flight instrument 
(QSTAR Elite, Applied Biosystems, Foster City, CA) with minor modifications to previously reported conditions49. 
Purified proteins were thawed and buffer exchanged by two cycles of desalting on Micro Bio-Spin™ P-6 Gel columns 
(Bio-Rad laboratories, Hercules, CA), immediately before use. All spectra were acquired in 10 mM ammonium 
acetate after incubation at room temperature for at least 10 min and no longer than 1 h.
Circular dichroism. Circular dichroism spectra were acquired using a Jasco J810 spectropolarimeter. 
Secondary structure of Syn (0.2 mg/ml) and RB3-SLD (0.1 mg/ml), either alone or in the presence of tubu-
lin (1.4 mg/ml), was investigated by recording far-UV circular dichroism spectra in 0.1 cm quartz cuvettes. 
All proteins were dissolved in BRB buffer. Spectra of pure Syn and RB3-SLD were baseline-corrected by sub-
tracting a buffer spectrum, while difference spectra of the Syn/tubulin and RB3-SLD/tubulin mixtures were 
“tubulin-corrected” by subtracting the spectrum of the pure tubulin from those of the mixtures. Syn spectra were 
normalized in terms of mean residual ellipticity by using a mean residue weight of 103 Da. Since BRB buffer does 
not allow to record spectra below 215 nm, the α -helical content was estimated from the mean residual ellipticity 
at 222 nm according to Chen and Yang50.
NMR spectroscopy. The NMR spectra were recorded on a Bruker AV600 spectrometer (Bruker 
Spectrospin AG, Rheinstetten, Germany), operating at 600.10 MHz for the 1H nucleus and equipped with a 
standard triple-resonance probe with z-axis gradients. Temperature control was achieved through the spec-
trometer BVT3000 temperature control unit, using nitrogen gas (flow 270 l/h) pre-cooled with a Bruker BCU20 
refrigeration unit. 1H-NMR chemical shifts (δ ) were measured in ppm, using as reference external sodium 
4,4-dimethyl-2-silapentane-1-sulfonate (DSS) set at 0.00 ppm. DOSY (Diffusion Oriented Spectroscopy) meas-
urements were performed at 25 °C on a freshly prepared 27 μ M solution of tubulin, dissolved in 0.6 ml H2O:D2O 
9:1 (v/v), pH 6.8 50 mM phosphate buffer, in the presence of various amounts of Syn (Syn/tubulin molar ratios 
varied between 0 and 10) after at least 0.5 h incubation. DSS, deuterium oxide (99.8% purity) and 5 mm O.D. NMR 
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tubes (Wilmad 535-PP type) were purchased from Sigma-Aldrich. Solvent suppression was achieved by including 
in the DOSY pulse-sequence a WATERGATE pulse-scheme51. A gradient-based stimulated echo bipolar pulse 
sequence was utilized52, with a 0.3 s diffusion delay (“big delta”) and a 1.5 ms gradient pulse length (“little delta”). 
32 one-dimensional spectra were collected with a gradient strength varying between 0.67 and 33.4 Gauss/cm. 
Values for “little delta” and “big delta” parameters were chosen by taking into account also the expected short 
transverse relaxation rates due to the formation of high molecular weight aggregates. Other relevant acquisition 
parameters: time-domain: 2 K; number of scans: 196; relaxation delay: 2 s. Raw data were Fourier-transformed 
after apodization with a 90°-shifted sine-bell-squared function and baseline corrected. Log(D) values were 
derived by a two-components non-linear fitting and displayed as pseudo-2D spectra.
Limiting values for the molar fraction of free Syn (α ) were estimated from the experimental diffusion coeffi-
cients (D, Equation 2) as:
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where Dsyn is the experimental value determined for free Syn. Dtub:syn and Dtub2:syn are the D values expected for 
complexes formed by Syn with α β tubulin dimer and α 2β 2 tubulin tetramer, respectively. These last values were 
estimated by applying the following correction factors to Dtub:
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The dissociation constant Kd of Syn-tubulin complex was derived by applying the following equation 5:
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where Dbound can be either Dtub:syn or Dtub2:syn as derived from equation 3 and 4.
Video-microscopy and data analysis. MTs were assembled from purified axonemes with tubulin (10–15 μ M) 
and increasing concentrations of preincubated Syn (5–15 μ M). Samples were prepared in perfusion chambers, 
previously saturated with 50 μ M Syn, and observed at 37 °C with an Olympus BX-51 microscope equipped with 
DIC prisms and a video camera coupled to an Argus 20 image processor (Hamamatsu, Hamamatsu City, Japan), 
as previously described53. Images were recorded every 2 s over periods of 5 min. The total recording time did not 
exceed 60 min for each chamber. Measurements of MT dynamics and data analysis were carried out using Image 
J (NIH, Bethesda, MD) and Kaleidagraph (Synergy Software Systems, Dubai, UAE), as previously described53.
Immunoblotting and live cell imaging. PC12 cells were maintained in cultures and differentiated as 
previously described39. PC12 cells were transiently transfected using Lipofectamine 2000 (Invitrogen), with 
C-terminal GFP-fused human WT Syn or with GFP-containing control vector (eGFP-N1). Whole cell extracts 
were loaded on SDS-PAGE, transferred onto PVDF membranes and immunostained with anti-Syn rabbit IgG 
and anti-GAPDH as loading control. For live cell imaging experiments, GFP-WT Syn and GFP-containing vec-
tors were co-transfected with EB3-mCherry construct24 (kindly provided by Dr Galjart, Medical Genetic Center, 
Erasmus University, Rotterdam, The Netherlands). As previously described39, cultures were transferred to a live 
cell imaging workstation; images were collected every 6 s with a cooled camera (Axiocam HRM Rev. 2; Zeiss) 
for periods of 3-4 min, and the total recording time did not exceed 60 min for each dish. MT growth dynamics 
was automatically analysed using plusTipTracker software54. The area of the analysed neurites was estimated by 
ImageJ software (Supplementary Fig. S6).
Protein alignment. Pairwise alignments between Syn and stathmin sequences were made using Pam250 or 
Bl50 matrix, whereas multiple protein alignment was performed with ClustalW software.
Statistical analyses. For multiple comparisons, the statistical significance of treatment was assessed by 
one-way ANOVA with Dunnett 2-sided or Fischer LSD post-hoc testing, whereas differences between WT Syn 
and controls were assessed using Student’s t-test. All analyses were performed using STATISTICA (StatSoft Inc., 
Tulsa, OK).
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